{"PMC7262257": [["INTRODUCTIONThe present world is experiencing a pandemic (coronavirus disease\u201019 or COVID\u201019) caused by a novel strain of coronavirus, called SARS\u2010CoV\u20102, previously called 2019\u2010CoV.", [["coronavirus disease", "DISEASE", 58, 77], ["coronavirus", "DISEASE", 122, 133], ["SARS", "DISEASE", 142, 146], ["coronavirus", "ORGANISM", 122, 133], ["2019\u2010CoV", "ORGANISM", 172, 180], ["coronavirus", "SPECIES", 122, 133], ["a pandemic (coronavirus disease", "PROBLEM", 46, 77], ["a novel strain of coronavirus", "PROBLEM", 104, 133]]], ["At the time of writing this article, 3 72 757 cases spanning over 195 countries and territories and 1 international conveyance have been reported.1This could be an underestimate due to the lower number of diagnostic tests and case identification partly due to poor health services in most countries.", [["diagnostic tests", "TEST", 205, 221]]], ["The mortality rate stands at 0.5\u20104.4%2; however, this could be an overestimate as the exact denominator of actual number of cases is underreported.", [["The mortality rate stands", "TEST", 0, 25]]], ["Diversion of all healthcare facilities toward the COVID\u201019 pandemic is likely to increase the morbidity and mortality due to other health problems.", [["the morbidity", "PROBLEM", 90, 103], ["other health problems", "PROBLEM", 125, 146], ["morbidity", "OBSERVATION", 94, 103]]], ["In such a scenario, understanding the impact on the economy is beyond the confines of a medical expert.INTRODUCTIONAnother conundrum faced is a high secondary infection rate among high\u2010risk healthcare workers annexing the already burdened healthcare system.3This would not only compound the impending shortage of healthcare facilities but would also mean more pervasive spread.", [["infection", "DISEASE", 159, 168], ["a high secondary infection rate", "PROBLEM", 142, 173], ["high", "OBSERVATION_MODIFIER", 144, 148], ["secondary", "OBSERVATION_MODIFIER", 149, 158], ["infection", "OBSERVATION", 159, 168], ["more pervasive", "OBSERVATION_MODIFIER", 355, 369], ["spread", "OBSERVATION_MODIFIER", 370, 376]]], ["Prevention is thus the best strategy to not only prevent more spread and deaths but also to unburden the healthcare system.", [["deaths", "DISEASE", 73, 79]]], ["Although methods like mitigation, quarantine, isolation, social distancing, and so on are being employed, these are not infallible.", [["quarantine", "TREATMENT", 34, 44]]], ["Contact tracing for the spread of infection from asymptomatic or mild undiagnosed cases, transition to community spread, and factors such as uncertainty regarding the survival of the virus in air or fomites are cumulatively adding to the mammoth task.4Hence, the focus has now been shifted toward evaluating and implementing other strategies like chemoprophylaxis and vaccination besides the continued use of the barrier system.", [["infection", "DISEASE", 34, 43], ["Contact tracing", "TEST", 0, 15], ["infection", "PROBLEM", 34, 43], ["asymptomatic or mild undiagnosed cases", "PROBLEM", 49, 87], ["the virus", "PROBLEM", 179, 188], ["chemoprophylaxis", "TREATMENT", 347, 363], ["vaccination", "TREATMENT", 368, 379], ["the barrier system", "TREATMENT", 409, 427], ["infection", "OBSERVATION", 34, 43], ["mild", "OBSERVATION_MODIFIER", 65, 69]]], ["Vaccine development will take time, between 12\u201018 months, as human trials are under way.", [["human", "ORGANISM", 61, 66], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["Vaccine", "TREATMENT", 0, 7]]], ["There is a lot of speculation on chemoprophylaxis stemming from the available data on the use of some antimalarial drugs, such as chloroquine (CQ) and hydroxychloroquine (HCQ), which have been tried for the treatment of this disease.5", [["chloroquine", "CHEMICAL", 130, 141], ["CQ", "CHEMICAL", 143, 145], ["hydroxychloroquine", "CHEMICAL", 151, 169], ["HCQ", "CHEMICAL", 171, 174], ["chloroquine", "CHEMICAL", 130, 141], ["CQ", "CHEMICAL", 143, 145], ["hydroxychloroquine", "CHEMICAL", 151, 169], ["HCQ", "CHEMICAL", 171, 174], ["chloroquine", "SIMPLE_CHEMICAL", 130, 141], ["CQ", "SIMPLE_CHEMICAL", 143, 145], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 151, 169], ["HCQ", "SIMPLE_CHEMICAL", 171, 174], ["chemoprophylaxis", "TREATMENT", 33, 49], ["some antimalarial drugs", "TREATMENT", 97, 120], ["chloroquine (CQ)", "TREATMENT", 130, 146], ["hydroxychloroquine (HCQ)", "TREATMENT", 151, 175], ["this disease", "PROBLEM", 220, 232], ["chemoprophylaxis", "OBSERVATION", 33, 49], ["disease", "OBSERVATION", 225, 232]]]], "PMC5778652": [["BackgroundBovine coronavirus (BCoV) and bovine respiratory syncytial virus (BRSV) are contagious pathogens detrimentally affecting production and animal welfare in the cattle industry.", [["respiratory syncytial virus", "DISEASE", 47, 74], ["BackgroundBovine coronavirus", "ORGANISM", 0, 28], ["BCoV", "ORGANISM", 30, 34], ["bovine respiratory syncytial virus", "ORGANISM", 40, 74], ["BRSV", "ORGANISM", 76, 80], ["BackgroundBovine coronavirus", "SPECIES", 0, 28], ["bovine", "SPECIES", 40, 46], ["respiratory syncytial virus", "SPECIES", 47, 74], ["BRSV", "SPECIES", 76, 80], ["cattle", "SPECIES", 168, 174], ["BackgroundBovine coronavirus", "SPECIES", 0, 28], ["BCoV", "SPECIES", 30, 34], ["bovine respiratory syncytial virus", "SPECIES", 40, 74], ["BRSV", "SPECIES", 76, 80], ["cattle", "SPECIES", 168, 174], ["BackgroundBovine coronavirus", "PROBLEM", 0, 28], ["BCoV", "TEST", 30, 34], ["bovine respiratory syncytial virus", "PROBLEM", 40, 74], ["contagious pathogens", "PROBLEM", 86, 106], ["respiratory syncytial virus", "OBSERVATION", 47, 74]]], ["The viruses are part of the bovine respiratory disease complex and are endemic worldwide.", [["respiratory disease", "DISEASE", 35, 54], ["bovine", "ORGANISM", 28, 34], ["bovine", "SPECIES", 28, 34], ["The viruses", "PROBLEM", 0, 11], ["the bovine respiratory disease complex", "PROBLEM", 24, 62], ["viruses", "OBSERVATION", 4, 11], ["bovine", "OBSERVATION_MODIFIER", 28, 34], ["respiratory disease", "OBSERVATION", 35, 54], ["endemic", "OBSERVATION_MODIFIER", 71, 78], ["worldwide", "OBSERVATION_MODIFIER", 79, 88]]], ["BRSV and BCoV can cause epidemics of respiratory disease and additionally BCoV cause diarrhea in calves and adult cattle (winter dysentery) [1\u20134].", [["respiratory", "ANATOMY", 37, 48], ["BCoV", "CHEMICAL", 9, 13], ["respiratory disease", "DISEASE", 37, 56], ["BCoV", "CHEMICAL", 74, 78], ["diarrhea", "DISEASE", 85, 93], ["dysentery", "DISEASE", 129, 138], ["BRSV", "ORGANISM", 0, 4], ["BCoV", "GENE_OR_GENE_PRODUCT", 9, 13], ["calves", "ORGANISM", 97, 103], ["BRSV", "SPECIES", 0, 4], ["calves", "SPECIES", 97, 103], ["cattle", "SPECIES", 114, 120], ["BRSV", "SPECIES", 0, 4], ["BCoV", "SPECIES", 9, 13], ["BCoV", "SPECIES", 74, 78], ["cattle", "SPECIES", 114, 120], ["BRSV", "PROBLEM", 0, 4], ["respiratory disease", "PROBLEM", 37, 56], ["diarrhea in calves", "PROBLEM", 85, 103], ["respiratory disease", "OBSERVATION", 37, 56]]], ["The traditional way of handling and preventing these diseases is through metaphylactic antibiotic treatment, use of vaccines, or changes in management to improve calf health in herds [5].", [["calf", "ORGANISM_SUBDIVISION", 162, 166], ["calf", "SPECIES", 162, 166], ["these diseases", "PROBLEM", 47, 61], ["metaphylactic antibiotic treatment", "TREATMENT", 73, 107], ["vaccines", "TREATMENT", 116, 124], ["changes in management", "TREATMENT", 129, 150]]], ["The within-herd prevalence and morbidity of BCoV and BRSV infections are high [6, 7] and once the virus enters a herd, circulation is difficult to mitigate.", [["BRSV infections", "DISEASE", 53, 68], ["BRSV", "ORGANISM", 53, 57], ["BRSV", "SPECIES", 53, 57], ["BCoV", "SPECIES", 44, 48], ["BRSV", "SPECIES", 53, 57], ["morbidity of BCoV", "PROBLEM", 31, 48], ["BRSV infections", "PROBLEM", 53, 68], ["the virus", "PROBLEM", 94, 103], ["BRSV infections", "OBSERVATION", 53, 68]]], ["An additional preventive strategy is therefore to reduce inter-herd transmission of virus.", [["An additional preventive strategy", "TREATMENT", 0, 33], ["inter-herd transmission of virus", "PROBLEM", 57, 89], ["virus", "OBSERVATION", 84, 89]]], ["If this risk is under control, the next question concerns the contribution of indirect spread of virus between herds.", [["indirect spread of virus", "PROBLEM", 78, 102]]], ["Indirect spread can occur via e.g. personnel travelling between herds, their clothes or equipment.BackgroundImportant risk factors for indirect spread are the level of virus contamination of relevant surfaces and the infectivity of the viruses.", [["Indirect spread", "PROBLEM", 0, 15], ["BackgroundImportant risk factors", "PROBLEM", 98, 130], ["indirect spread", "PROBLEM", 135, 150], ["virus contamination", "PROBLEM", 168, 187], ["the infectivity of the viruses", "PROBLEM", 213, 243], ["viruses", "OBSERVATION", 236, 243]]], ["Enveloped respiratory viruses like BCoV and BRSV are generally fragile outside the host [9].", [["Enveloped respiratory viruses", "ORGANISM", 0, 29], ["BCoV", "GENE_OR_GENE_PRODUCT", 35, 39], ["BRSV", "ORGANISM", 44, 48], ["BRSV", "SPECIES", 44, 48], ["BCoV", "SPECIES", 35, 39], ["BRSV", "SPECIES", 44, 48], ["Enveloped respiratory viruses", "PROBLEM", 0, 29], ["BCoV", "PROBLEM", 35, 39], ["BRSV", "PROBLEM", 44, 48], ["respiratory viruses", "OBSERVATION", 10, 29], ["BRSV", "ANATOMY", 44, 48]]], ["However, as related viruses like human respiratory syncytial virus (HRSV) and human coronavirus 229E remain infective for several hours on contaminated surfaces like countertops and surgical gloves [10, 11], there is a potential for indirect transmission.", [["respiratory syncytial virus", "DISEASE", 39, 66], ["human respiratory syncytial virus", "ORGANISM", 33, 66], ["HRSV", "ORGANISM", 68, 72], ["human coronavirus 229E", "ORGANISM", 78, 100], ["human", "SPECIES", 33, 38], ["respiratory syncytial virus", "SPECIES", 39, 66], ["HRSV", "SPECIES", 68, 72], ["human", "SPECIES", 78, 83], ["coronavirus", "SPECIES", 84, 95], ["human respiratory syncytial virus", "SPECIES", 33, 66], ["HRSV", "SPECIES", 68, 72], ["human coronavirus 229E", "SPECIES", 78, 100], ["viruses", "PROBLEM", 20, 27], ["human respiratory syncytial virus", "PROBLEM", 33, 66], ["human coronavirus", "PROBLEM", 78, 95], ["infective", "PROBLEM", 108, 117], ["surgical gloves", "TREATMENT", 182, 197], ["viruses", "OBSERVATION", 20, 27], ["respiratory syncytial virus", "OBSERVATION", 39, 66]]], ["Epidemiological studies also point out the importance of indirect transmission; Ohlson et al. found that lack of boot provision for visitors was a risk factor for infections with both viruses [12] and Toftaker et al. found that a herd\u2019s BCoV and BRSV antibody status was influenced by the status of its neighboring herds [8].BackgroundHuman nasal mucosa might also be a vector for inter-herd virus transmission, as traffic of personnel between herds is common.", [["nasal mucosa", "ANATOMY", 341, 353], ["infections", "DISEASE", 163, 173], ["BCoV", "CANCER", 237, 241], ["BRSV", "ORGANISM", 246, 250], ["Human", "ORGANISM", 335, 340], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 341, 353], ["inter-herd virus", "ORGANISM", 381, 397], ["BRSV antibody", "PROTEIN", 246, 259], ["BRSV", "SPECIES", 246, 250], ["Human", "SPECIES", 335, 340], ["BCoV", "SPECIES", 237, 241], ["BRSV", "SPECIES", 246, 250], ["Epidemiological studies", "TEST", 0, 23], ["boot provision", "TREATMENT", 113, 127], ["infections", "PROBLEM", 163, 173], ["a herd\u2019s BCoV", "TEST", 228, 241], ["BRSV antibody status", "PROBLEM", 246, 266], ["BackgroundHuman nasal mucosa", "PROBLEM", 325, 353], ["nasal mucosa", "ANATOMY", 341, 353]]], ["Carriage of BCoV and BRSV in human nostrils has not been studied.", [["nostrils", "ANATOMY", 35, 43], ["BCoV", "GENE_OR_GENE_PRODUCT", 12, 16], ["BRSV", "ORGANISM", 21, 25], ["human", "ORGANISM", 29, 34], ["nostrils", "ORGAN", 35, 43], ["BCoV", "PROTEIN", 12, 16], ["BRSV", "SPECIES", 21, 25], ["human", "SPECIES", 29, 34], ["BCoV", "SPECIES", 12, 16], ["BRSV", "SPECIES", 21, 25], ["human", "SPECIES", 29, 34], ["BRSV in human nostrils", "TREATMENT", 21, 43], ["BRSV", "OBSERVATION", 21, 25]]], ["Generally, there are few studies on indirect transmission of these viruses, and no experimental studies have been performed.", [["these viruses", "PROBLEM", 61, 74], ["experimental studies", "TEST", 83, 103], ["viruses", "OBSERVATION", 67, 74]]], ["Molecular methods and virus isolation in cell culture can be used to study the level of virus carriage and infectivity, which are determinants for virus transmission.", [["cell culture", "ANATOMY", 41, 53], ["cell culture", "CELL", 41, 53], ["Molecular methods", "PROBLEM", 0, 17], ["virus isolation", "TREATMENT", 22, 37], ["cell culture", "TEST", 41, 53], ["virus carriage", "PROBLEM", 88, 102], ["infectivity", "PROBLEM", 107, 118], ["virus transmission", "PROBLEM", 147, 165], ["virus isolation", "OBSERVATION", 22, 37], ["virus", "OBSERVATION", 88, 93]]], ["Combined, these methods provide sensitive quantification of viral genomes and assessment of virus infectivity.BackgroundConsequently, the aim of the present study was to investigate whether personnel (nostrils) and fomites carry viral RNA and infective viruses after exposure to BCoV or BRSV infected animals.Study design and animal experiments ::: MethodsThe present study was performed during two animal experiments, one with BCoV and one with BRSV, and during a field outbreak of winter dysentery.", [["nostrils", "ANATOMY", 201, 209], ["BCoV", "CHEMICAL", 279, 283], ["BRSV infected", "DISEASE", 287, 300], ["dysentery", "DISEASE", 490, 499], ["nostrils", "ORGANISM_SUBDIVISION", 201, 209], ["BCoV", "GENE_OR_GENE_PRODUCT", 279, 283], ["BRSV", "ORGANISM", 287, 291], ["BRSV", "ORGANISM", 446, 450], ["viral genomes", "DNA", 60, 73], ["viral RNA", "RNA", 229, 238], ["BRSV", "SPECIES", 287, 291], ["BRSV", "SPECIES", 446, 450], ["BCoV", "SPECIES", 279, 283], ["BRSV", "SPECIES", 287, 291], ["BRSV", "SPECIES", 446, 450], ["these methods", "TEST", 10, 23], ["viral genomes", "PROBLEM", 60, 73], ["virus infectivity", "PROBLEM", 92, 109], ["the present study", "TEST", 145, 162], ["personnel (nostrils)", "PROBLEM", 190, 210], ["viral RNA", "PROBLEM", 229, 238], ["infective viruses", "PROBLEM", 243, 260], ["BCoV", "TREATMENT", 279, 283], ["BRSV infected animals", "PROBLEM", 287, 308], ["Methods", "TREATMENT", 349, 356], ["The present study", "TEST", 356, 373], ["BCoV", "TREATMENT", 428, 432], ["BRSV", "PROBLEM", 446, 450], ["viral genomes", "OBSERVATION", 60, 73], ["virus infectivity", "OBSERVATION", 92, 109], ["infective viruses", "OBSERVATION", 243, 260]]], ["Swabs were rubbed in the nostrils of personnel and on their coats, boots, wristwatches and stethoscopes at different time points after animal contact, and examined for viral RNA and infective viruses.Study design and animal experiments ::: MethodsThe BCoV experiment was conducted in 2014 at the Swedish University of Agricultural Sciences (SLU) as described by Oma et al. [13].", [["Swabs", "ANATOMY", 0, 5], ["nostrils", "ANATOMY", 25, 33], ["coats", "ANATOMY", 60, 65], ["nostrils", "ORGANISM_SUBDIVISION", 25, 33], ["viral RNA", "RNA", 168, 177], ["Swabs", "TREATMENT", 0, 5], ["boots", "TREATMENT", 67, 72], ["wristwatches", "TREATMENT", 74, 86], ["stethoscopes", "TREATMENT", 91, 103], ["viral RNA and infective viruses", "PROBLEM", 168, 199], ["Methods", "TREATMENT", 240, 247], ["infective viruses", "OBSERVATION", 182, 199]]], ["A total of ten bull calves between six and twelve weeks of age were included, six were Swedish red and white, three were Swedish Holstein and one Swedish mountain breed.", [["calves", "ORGANISM", 20, 26], ["calves", "SPECIES", 20, 26], ["A total of ten bull calves", "TREATMENT", 0, 26], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Briefly, four calves at SLU were exposed to a group of six calves brought in from SLU\u2019s research farm that experienced an outbreak of winter dysentery.", [["dysentery", "DISEASE", 141, 150], ["calves", "ORGANISM", 14, 20], ["calves", "ORGANISM", 59, 65], ["calves", "SPECIES", 14, 20], ["calves", "SPECIES", 59, 65]]], ["The field outbreak was confirmed by RT-qPCR and serology to have been caused by BCoV.", [["BCoV", "SPECIES", 80, 84], ["RT-qPCR", "TEST", 36, 43], ["serology", "TEST", 48, 56]]], ["After comingling for 24 h, the calves were housed in the isolation unit within their original groups of four and six animals.", [["calves", "ORGANISM", 31, 37], ["calves", "SPECIES", 31, 37], ["calves", "ANATOMY", 31, 37]]], ["As six of the calves were naturally exposed to BCoV in the field, the dates of infection were unknown.", [["BCoV", "CHEMICAL", 47, 51], ["infection", "DISEASE", 79, 88], ["calves", "ORGANISM", 14, 20], ["calves", "SPECIES", 14, 20], ["infection", "PROBLEM", 79, 88], ["calves", "ANATOMY", 14, 20], ["infection", "OBSERVATION", 79, 88]]], ["The presented contamination study was conducted within a three week period while the calves showed signs of disease and shed virus as detected by RT-qPCR.", [["calves", "ORGANISM", 85, 91], ["calves", "SPECIES", 85, 91], ["The presented contamination study", "TEST", 0, 33], ["disease", "PROBLEM", 108, 115], ["shed virus", "PROBLEM", 120, 130], ["disease", "OBSERVATION", 108, 115]]], ["The number of BCoV RNA copies in nasal swabs from the ten calves varied between log10 2.9 and 10.4 (mean of log10 6.9) during the study period.Study design and animal experiments ::: MethodsThe BRSV experiment took place at the Norwegian Veterinary Institute in 2015 (to be published).", [["nasal swabs", "ANATOMY", 33, 44], ["BCoV", "GENE_OR_GENE_PRODUCT", 14, 18], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 33, 44], ["calves", "ORGANISM", 58, 64], ["BRSV", "ORGANISM", 194, 198], ["BCoV RNA", "RNA", 14, 22], ["calves", "SPECIES", 58, 64], ["BRSV", "SPECIES", 194, 198], ["BCoV RNA copies", "TEST", 14, 29], ["nasal swabs", "TEST", 33, 44], ["the ten calves", "TEST", 50, 64], ["the study", "TEST", 126, 135], ["Methods", "TREATMENT", 183, 190], ["nasal swabs", "ANATOMY", 33, 44], ["BRSV experiment", "OBSERVATION", 194, 209]]], ["A total of eight Norwegian Red calves between two and four months of age were included, six bulls and two heifers.", [["calves", "ORGANISM", 31, 37], ["calves", "SPECIES", 31, 37], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Briefly, six of the calves were infected after contact with two calves inoculated with a field isolate of BRSV, O4-4B/N-11 [14].", [["O4-4B/N-11", "CHEMICAL", 112, 122], ["calves", "ORGANISM", 20, 26], ["calves", "ORGANISM", 64, 70], ["BRSV", "ORGANISM", 106, 110], ["calves", "SPECIES", 20, 26], ["calves", "SPECIES", 64, 70], ["BRSV", "SPECIES", 106, 110], ["BRSV", "SPECIES", 106, 110], ["BRSV", "TEST", 106, 110], ["O4", "TEST", 112, 114], ["calves", "ANATOMY", 20, 26], ["infected", "OBSERVATION", 32, 40]]], ["The calves were housed in isolation units in groups of four including one inoculated calf.", [["calves", "ANATOMY", 4, 10], ["calves", "ORGANISM", 4, 10], ["calf", "ORGANISM_SUBDIVISION", 85, 89], ["calves", "SPECIES", 4, 10], ["calf", "SPECIES", 85, 89], ["isolation units", "TREATMENT", 26, 41], ["calves", "ANATOMY", 4, 10], ["inoculated", "OBSERVATION", 74, 84], ["calf", "ANATOMY", 85, 89]]], ["The contamination study was conducted on three different days within one week while the calves showed signs of respiratory disease and shed virus.", [["respiratory", "ANATOMY", 111, 122], ["respiratory disease", "DISEASE", 111, 130], ["calves", "ORGANISM", 88, 94], ["calves", "SPECIES", 88, 94], ["The contamination study", "TEST", 0, 23], ["respiratory disease", "PROBLEM", 111, 130], ["shed virus", "PROBLEM", 135, 145], ["calves", "ANATOMY", 88, 94], ["respiratory disease", "OBSERVATION", 111, 130]]], ["The number of BRSV RNA copies in nasal swabs from the calves varied between log10 2.7 and 8.1 (mean of log10 5.6) during the study period.Study design and animal experiments ::: MethodsBoth experiments were conducted in line with the ARRIVE guidelines for planning and reporting in vivo experiments and the concept of the 3R\u2019s (Reduction, Replacement and Refinement) [15, 16].", [["nasal swabs", "ANATOMY", 33, 44], ["BRSV", "ORGANISM", 14, 18], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 33, 44], ["calves", "ORGANISM", 54, 60], ["BRSV RNA copies", "RNA", 14, 29], ["BRSV", "SPECIES", 14, 18], ["calves", "SPECIES", 54, 60], ["BRSV", "SPECIES", 14, 18], ["BRSV RNA copies", "TEST", 14, 29], ["nasal swabs", "TEST", 33, 44], ["the calves", "TEST", 50, 60], ["the study", "TEST", 121, 130], ["MethodsBoth experiments", "TREATMENT", 178, 201], ["the 3R\u2019s (Reduction, Replacement", "TREATMENT", 318, 350], ["BRSV RNA", "OBSERVATION", 14, 22], ["nasal swabs", "ANATOMY", 33, 44], ["calves", "ANATOMY", 54, 60]]], ["In both experiments, efforts were made to minimize the stress and discomfort for the animals.", [["the stress and discomfort", "PROBLEM", 51, 76]]], ["The animals were closely monitored and medical treatment were administered in line with national Norwegian and Swedish recommendations for treatment of pneumonia and diarrhea in calves.Exposure procedure and sampling schemes ::: MethodsTable 1 presents an overview of exposed personnel and fomites.", [["pneumonia", "DISEASE", 152, 161], ["diarrhea", "DISEASE", 166, 174], ["animals", "ORGANISM", 4, 11], ["calves", "ORGANISM", 178, 184], ["calves", "SPECIES", 178, 184], ["medical treatment", "TREATMENT", 39, 56], ["treatment", "TREATMENT", 139, 148], ["pneumonia", "PROBLEM", 152, 161], ["diarrhea in calves", "PROBLEM", 166, 184], ["Exposure procedure", "TREATMENT", 185, 203], ["pneumonia", "OBSERVATION", 152, 161], ["diarrhea", "OBSERVATION", 166, 174]]], ["During ten minutes, the personnel handled and examined animals that showed clinical signs and shed either BCoV or BRSV.", [["BRSV", "ORGANISM", 114, 118], ["BRSV", "SPECIES", 114, 118], ["BRSV", "SPECIES", 114, 118], ["clinical signs", "PROBLEM", 75, 89], ["BRSV", "PROBLEM", 114, 118]]], ["In the BCoV experiment, swabs were collected from human nostrils prior to and 0.5, 2, 4 and 6 h after exposure to the animals.", [["swabs", "ANATOMY", 24, 29], ["nostrils", "ANATOMY", 56, 64], ["swabs", "ORGANISM_SUBSTANCE", 24, 29], ["human", "ORGANISM", 50, 55], ["nostrils", "ORGANISM_SUBDIVISION", 56, 64], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["swabs", "TEST", 24, 29]]], ["The BRSV experiment included only a single time point (0.5 h), as viral RNA was not detected in nasal swabs collected during a BRSV pilot study.Exposure procedure and sampling schemes ::: MethodsClean boots, coats, wristwatches and stethoscopes were used.", [["nasal swabs", "ANATOMY", 96, 107], ["coats", "ANATOMY", 208, 213], ["wristwatches", "ANATOMY", 215, 227], ["BRSV", "ORGANISM", 4, 8], ["nasal swabs", "ORGANISM_SUBSTANCE", 96, 107], ["coats", "ORGANISM_SUBSTANCE", 208, 213], ["viral RNA", "RNA", 66, 75], ["BRSV", "SPECIES", 4, 8], ["BRSV", "SPECIES", 127, 131], ["The BRSV experiment", "TEST", 0, 19], ["viral RNA", "PROBLEM", 66, 75], ["nasal swabs", "TEST", 96, 107], ["a BRSV pilot study", "TEST", 125, 143], ["Exposure procedure", "TREATMENT", 144, 162], ["MethodsClean boots", "TREATMENT", 188, 206], ["coats", "TREATMENT", 208, 213], ["wristwatches", "TREATMENT", 215, 227], ["stethoscopes", "TREATMENT", 232, 244], ["BRSV experiment", "OBSERVATION", 4, 19]]], ["After exposure to the animals, boots were rinsed in lukewarm water until visually clean and left to dry.", [["boots", "TREATMENT", 31, 36], ["boots", "ANATOMY", 31, 36], ["clean", "OBSERVATION", 82, 87], ["left", "ANATOMY_MODIFIER", 92, 96], ["dry", "OBSERVATION", 100, 103]]], ["All fomites were stored at 16\u201318 \u00b0C, in a room separate from the animals.Sampling procedure ::: MethodsA detailed protocol was developed for collection of material from fomites and human nostrils.", [["fomites", "ANATOMY", 4, 11], ["nostrils", "ANATOMY", 187, 195], ["human", "ORGANISM", 181, 186], ["nostrils", "ORGANISM_SUBDIVISION", 187, 195], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 181, 186], ["collection of material from fomites and human nostrils", "PROBLEM", 141, 195]]], ["The same person collected all the material from fomites in each experiment, and instructed the personnel that took part in the human mucosa trial.", [["mucosa", "ANATOMY", 133, 139], ["human", "ORGANISM", 127, 132], ["mucosa", "MULTI-TISSUE_STRUCTURE", 133, 139], ["person", "SPECIES", 9, 15], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["the human mucosa trial", "TREATMENT", 123, 145]]], ["Specimens were collected with ESwab\u2122 (Copan, Brescia, Italy) and stored in 1 ml of Liquid Amies medium.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9], ["Liquid Amies medium", "TREATMENT", 83, 102]]], ["Gloves were used throughout the experiments.Sampling procedure ::: MethodsSpecimens from human nasal mucosa were collected by rotating a swab inside one nostril for a couple of seconds.", [["nasal mucosa", "ANATOMY", 95, 107], ["nostril", "ANATOMY", 153, 160], ["human", "ORGANISM", 89, 94], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 95, 107], ["nostril", "ORGAN", 153, 160], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["Gloves", "TREATMENT", 0, 6], ["nasal mucosa", "ANATOMY", 95, 107]]], ["When a person was sampled more than once, the left and right nostrils were sampled alternately.", [["left", "ANATOMY", 46, 50], ["right nostrils", "ANATOMY", 55, 69], ["nostrils", "ORGAN", 61, 69], ["person", "SPECIES", 7, 13], ["left", "ANATOMY_MODIFIER", 46, 50], ["right nostrils", "ANATOMY", 55, 69]]], ["Sampling of fomites was performed by moistening the tip of the swab with Amies medium before lightly rubbing a defined area (5 cm \u00d7 10 cm of coats and boots) without visible contamination.", [["swab", "ANATOMY", 63, 67], ["coats", "ANATOMY", 141, 146], ["Sampling of fomites", "PROBLEM", 0, 19], ["the swab", "TREATMENT", 59, 67], ["Amies medium", "TREATMENT", 73, 85], ["boots", "TREATMENT", 151, 156], ["visible contamination", "PROBLEM", 166, 187], ["tip", "OBSERVATION_MODIFIER", 52, 55], ["5 cm", "OBSERVATION_MODIFIER", 125, 129], ["without", "UNCERTAINTY", 158, 165], ["visible", "OBSERVATION_MODIFIER", 166, 173], ["contamination", "OBSERVATION", 174, 187]]], ["For wristwatches and stethoscopes, the area was approximately 3 cm \u00d7 3 cm and 2 cm \u00d7 5 cm, respectively.", [["wristwatches and stethoscopes", "TREATMENT", 4, 33], ["area", "OBSERVATION_MODIFIER", 39, 43], ["approximately", "OBSERVATION_MODIFIER", 48, 61], ["3 cm \u00d7 3 cm", "OBSERVATION_MODIFIER", 62, 73], ["5 cm", "OBSERVATION_MODIFIER", 85, 89]]], ["At later time points, new areas were sampled.", [["new", "OBSERVATION_MODIFIER", 22, 25], ["areas", "OBSERVATION_MODIFIER", 26, 31]]], ["After sample collection, swabs were stored at 4 \u00b0C for no more than two hours and thereafter at \u221270 \u00b0C until use.BCoV ::: RNA extraction and quantification of viral genomes ::: MethodsRNA was extracted from 140 \u03bcl of the Amies medium by the QIAamp Viral RNA Mini QIAcube kit (Qiagen, Hilden, Germany) according to the manufacturer\u2019s instructions, eluted in 50 \u03bcl buffer and stored at \u221280 \u00b0C. RT-qPCR was performed, in duplicates for nasal swabs, using RNA UltraSense\u2122 One-Step Quantitative RT-PCR System (Invitrogen, MA, USA) and the target was an 85 bp fragment of the M protein gene [17].", [["sample", "ANATOMY", 6, 12], ["swabs", "ANATOMY", 25, 30], ["nasal swabs", "ANATOMY", 433, 444], ["BCoV", "DNA", 113, 117], ["viral genomes", "DNA", 159, 172], ["85 bp fragment", "DNA", 548, 562], ["M protein gene", "DNA", 570, 584], ["BCoV", "SPECIES", 113, 117], ["sample collection", "TEST", 6, 23], ["swabs", "TEST", 25, 30], ["RNA extraction", "TREATMENT", 122, 136], ["the Amies medium", "TREATMENT", 217, 233], ["RT-qPCR", "TEST", 392, 399], ["nasal swabs", "TREATMENT", 433, 444], ["viral genomes", "OBSERVATION", 159, 172], ["nasal", "ANATOMY", 433, 438]]], ["Two \u03bcl of RNA was used in a total volume of 20 ul containing 200 nM each of forward and reverse primer and 250 nM TaqMan probe.", [["RNA", "TREATMENT", 10, 13], ["a total volume", "TREATMENT", 26, 40], ["reverse primer", "TREATMENT", 88, 102], ["RNA", "OBSERVATION", 10, 13]]], ["The thermal profile included an RT step at 55 \u00b0C for 30 min followed by 95 \u00b0C for 2 min and thereafter 40 cycles of 15 s at 95 \u00b0C and 1 min at 60 \u00b0C. RT-qPCR was run in a Stratagene Mx3005p\u2122 (Agilent Technologies, CA, USA) and each run included a positive (RNA from the nostril of a BCoV positive trial calf) and negative control (water).BCoV ::: RNA extraction and quantification of viral genomes ::: MethodsPositive swabs from human nasal mucosa were subjected to Kaplan-Meier survival analysis in Stata (Stata SE/14, Stata Corp., College Station, TX, USA).", [["swabs", "ANATOMY", 418, 423], ["nasal mucosa", "ANATOMY", 435, 447], ["nostril", "ORGANISM_SUBDIVISION", 270, 277], ["calf", "ORGANISM", 303, 307], ["human", "ORGANISM", 429, 434], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 435, 447], ["BCoV", "DNA", 338, 342], ["viral genomes", "DNA", 384, 397], ["calf", "SPECIES", 303, 307], ["human", "SPECIES", 429, 434], ["BCoV", "SPECIES", 338, 342], ["human", "SPECIES", 429, 434], ["an RT step", "TREATMENT", 29, 39], ["RT-qPCR", "TEST", 150, 157], ["a positive (RNA", "PROBLEM", 245, 260], ["a BCoV positive trial calf", "TREATMENT", 281, 307], ["RNA extraction", "TREATMENT", 347, 361], ["MethodsPositive swabs from human nasal mucosa", "PROBLEM", 402, 447], ["positive", "OBSERVATION", 247, 255], ["viral genomes", "OBSERVATION", 384, 397], ["nasal mucosa", "ANATOMY", 435, 447]]], ["The function shows the cumulative survival, i.e. carriage of BCoV RNA over time, which descends as personnel turns BCoV RNA negative.", [["BCoV", "GENE_OR_GENE_PRODUCT", 61, 65], ["BCoV", "GENE_OR_GENE_PRODUCT", 115, 119], ["BCoV RNA", "RNA", 61, 69], ["BCoV RNA", "RNA", 115, 123], ["BCoV", "SPECIES", 61, 65], ["BCoV RNA", "PROBLEM", 61, 69]]], ["As the exact time-point a person turned negative was unknown, the mid-point between the last positive and the first negative sample was used in the analysis [18].BCoV ::: RNA extraction and quantification of viral genomes ::: MethodsIn order to estimate the number of BCoV RNA genome copies (GC), a standard curve was prepared using tenfold dilutions of a plasmid containing the BCoV target sequence.", [["plasmid", "ANATOMY", 356, 363], ["BCoV", "DNA", 162, 166], ["viral genomes", "DNA", 208, 221], ["BCoV RNA genome copies", "DNA", 268, 290], ["plasmid", "DNA", 356, 363], ["BCoV target sequence", "DNA", 379, 399], ["person", "SPECIES", 26, 32], ["BCoV", "SPECIES", 162, 166], ["BCoV", "SPECIES", 268, 272], ["the analysis", "TEST", 144, 156], ["RNA extraction", "TREATMENT", 171, 185], ["MethodsIn", "TREATMENT", 226, 235], ["a standard curve", "TEST", 297, 313], ["a plasmid", "TREATMENT", 354, 363], ["viral genomes", "OBSERVATION", 208, 221]]], ["The BCoV RNA positive control was aliquoted and included in every RT-qPCR plate as a calibrator to adjust for inter-plate variation.", [["BCoV", "GENE_OR_GENE_PRODUCT", 4, 8], ["BCoV RNA", "RNA", 4, 12], ["The BCoV RNA", "TEST", 0, 12], ["a calibrator", "TREATMENT", 83, 95], ["inter-plate variation", "TREATMENT", 110, 131], ["plate variation", "OBSERVATION", 116, 131]]], ["The number of GC in clinical samples was calculated using the formula from Livak and Schmittgen [19]:", [["samples", "ANATOMY", 29, 36]]]], "e4b977e389f9ceedc3a0cbae5b7b0df458cef0f7": [["IntroductionIn the UK, the first known case of influenza A(H1N1)pdm09 was reported in Scotland on 27 April 2009.", [["influenza A(H1N1)pdm09", "DISEASE", 47, 69], ["influenza A(H1N1)pdm09", "ORGANISM", 47, 69], ["influenza A(H1N1", "SPECIES", 47, 63], ["influenza", "PROBLEM", 47, 56], ["pdm09", "PROBLEM", 64, 69], ["influenza", "OBSERVATION", 47, 56]]], ["3 The public health response to control the spread of influenza A(H1N1)pdm09 was based on a number of phases described in pandemic preparedness plans.", [["influenza", "DISEASE", 54, 63], ["influenza A(H1N1)pdm09", "ORGANISM", 54, 76], ["influenza A(H1N1", "SPECIES", 54, 70], ["influenza A(H1N1)pdm09", "PROBLEM", 54, 76]]], ["4 The aim of the first phase (the 'containment phase') was to slow the spread of the virus, and to facilitate better understanding of the virus and the evolving pandemic.", [["the virus", "PROBLEM", 81, 90], ["the virus", "PROBLEM", 134, 143], ["pandemic", "PROBLEM", 161, 169], ["pandemic", "OBSERVATION", 161, 169]]], ["5 This included providing public health advice; gathering epidemiological data; and early identification, isolation, testing and treatment of possible cases.", [["testing", "TEST", 117, 124], ["treatment", "TREATMENT", 129, 138]]], ["4, 5 Multi-agency regional Flu Response Centres (FRCs) [coordinated by the Health Protection Agency (HPA)] were introduced to coordinate the operations of the containment phase, and to support the National Health Service (NHS) in England.", [["regional", "OBSERVATION_MODIFIER", 18, 26], ["Flu", "OBSERVATION", 27, 30], ["Response Centres", "OBSERVATION", 31, 47]]], ["3 These were telephone help and advice centres established at short notice to provide specialist advice on influenza A(H1N1) pdm09 to health professionals; and to liaise with general practitioners and the wider NHS on the diagnosis, testing and treatment of cases, and, where appropriate, follow-up of their contacts.", [["influenza A(H1N1) pdm09", "DISEASE", 107, 130], ["influenza A(H1N1) pdm09", "ORGANISM", 107, 130], ["testing", "TEST", 233, 240], ["treatment", "TREATMENT", 245, 254]]], ["In England, the West Midlands FRC was one of the first to be established and commenced operations on 18 May 2009, 3 weeks after identification of the first case.IntroductionAs the number of reported cases in the region accelerated and public concern increased, the remit of the FRC was widened to meet the increasing number of enquiries received from non-NHS organizations as well as members of the public.", [["non-NHS organizations", "TREATMENT", 351, 372], ["increased", "OBSERVATION_MODIFIER", 250, 259], ["increasing", "OBSERVATION_MODIFIER", 306, 316], ["number", "OBSERVATION_MODIFIER", 317, 323]]], ["HPA staff from across the region were recruited to work in the FRC, and staffing levels were augmented by sourcing personnel from other HPA regions, as well as NHS sources and non-NHS sources.", [["staffing levels", "TEST", 72, 87]]], ["Staff recruited to work in the FRC were trained for half a day, mainly in how to use the case management software and FRC operational arrangements.", [["the case management", "TREATMENT", 85, 104], ["FRC operational arrangements", "TREATMENT", 118, 146]]], ["Information on influenza A(H1N1)pdm09 was provided in FRC briefing packs.IntroductionWhen establishing helplines, it is recommended that staff should have a number of attributes including appropriate knowledge of the subject.", [["influenza A(H1N1)pdm09", "ORGANISM", 15, 37], ["influenza A(H1N1", "SPECIES", 15, 31], ["influenza", "PROBLEM", 15, 24], ["pdm09", "PROBLEM", 32, 37], ["FRC briefing packs", "TREATMENT", 54, 72]]], ["This study aims to provide an overview of West Midlands FRC staff, their disease-specific and precautionary behaviour knowledge, and their experience of FRC working arrangements in order to inform future planning for similar activities.RespondentsA retrospective cross-sectional survey of staff who had worked in the West Midlands FRC from 18 May 2009 to 10 July 2009 was conducted.", [["This study", "TEST", 0, 10]]], ["The questionnaire included questions on demographic attributes, experience of working arrangements, training received in the FRC, Fluzone (a casemanagement tool designed for FRCs to collect detailed epidemiological data using standardized algorithms), 3 sources of information on influenza A(H1N1)pdm09 (or 'swine flu' as it was then known), and an 11-item knowledge (true/false) section about influenza A(H1N1)pdm09 and the containment phase.", [["Fluzone", "CHEMICAL", 130, 137], ["influenza A(H1N1)pdm09", "ORGANISM", 280, 302], ["influenza A", "ORGANISM", 394, 405], ["swine", "SPECIES", 308, 313], ["influenza A(H1N1)pdm09", "SPECIES", 280, 302], ["swine", "SPECIES", 308, 313], ["Fluzone", "TREATMENT", 130, 137], ["standardized algorithms", "TREATMENT", 226, 249], ["influenza", "PROBLEM", 280, 289], ["pdm09", "PROBLEM", 297, 302], ["influenza", "PROBLEM", 394, 403], ["pdm09", "PROBLEM", 411, 416]]], ["1, 4, 5, 7, 8 A pilot study was conducted on a convenience sample of West Midlands HPA staff who had worked in the FRC.", [["A pilot study", "TEST", 14, 27]]], ["Data collection was closed on 30 November 2009.RespondentsFor the purposes of this study, FRC staff were divided into two categories based on their response to the question: 'Which of these best describes your occupation?'", [["Data collection", "TEST", 0, 15], ["this study", "TEST", 78, 88]]], ["Non-respondents to this question or those whose professional status was unknown and meant that they could have been either clinical or non-clinical staff (e.g. as public health trainees) were excluded from this analysis.Data analysisResponses were analysed based on the total number of respondents to each question, and non-responders to individual questions were excluded from the analysis of those questions.", [["this analysis", "TEST", 206, 219], ["Data analysisResponses", "TEST", 220, 242]]], ["Variables based on a four-point scale were collapsed into two categories to facilitate analysis.", [["analysis", "TEST", 87, 95]]], ["Results are presented as percentages with 95% confidence intervals (CI).", [["CI", "TEST", 68, 70]]], ["Yates's corrected Chi-squared statistic and (where appropriate) Fisher's exact test were employed for analysing 2 \u00c2 2 tables.", [["Fisher's exact test", "TEST", 64, 83]]], ["Microsoft Excel 2007 (Microsoft Corporation, Redmond, USA) was used for descriptive frequency analysis, and STATA Version 10 (StataCorp, College Station, TX, USA) was used for cross-tabulations.", [["descriptive frequency analysis", "TEST", 72, 102], ["STATA Version", "TEST", 108, 121]]], ["Answers to open-ended questions are not included in the data analysis due to the low number of responses.Characteristics of the sample and responseOverall, 190 former FRC staff were sent an e-mail inviting them to participate in the survey.", [["the data analysis", "TEST", 52, 69], ["the sample", "TEST", 124, 134]]], ["A response rate of 51% (89/ 176) was obtained, as 14 e-mails could not be delivered to the intended recipient.", [["A response rate", "TEST", 0, 15]]], ["A significantly greater proportion of staff were aged 25e44 years compared with other age groups (P < 0.0001), and staff were more likely to be from a White ethnic background (P < 0.003).", [["significantly", "OBSERVATION_MODIFIER", 2, 15], ["greater", "OBSERVATION_MODIFIER", 16, 23]]], ["The highest ranked factors contributing to this were availability of information technology support, clarity of the person's main role within the FRC, and availability of clinical support.", [["person", "SPECIES", 116, 122], ["technology support", "TREATMENT", 81, 99], ["clinical support", "TREATMENT", 171, 187]]], ["Although a significantly greater proportion of respondents would consider working in a call centre similar to the FRC in future compared with those who would not or were not sure (61% vs 39%), less than half of the respondents (48%) would recommend working in this type of call centre to colleagues.Experience of working arrangements in the FRCCompared with those who strongly-disagreed/disagreed, a significant proportion of respondents (66% vs 34%, n \u00bc 73) strongly-agreed/agreed that the FRC had made a positive contribution to the management of influenza A(H1N1)pdm09 during the containment phase.Knowledge of influenza A(H1N1)pdm09 and precautionary behaviourNearly all respondents indicated that they were familiar with the terms 'pandemic flu' or 'influenza pandemic' (99%, 72/73).", [["influenza", "DISEASE", 549, 558], ["flu", "DISEASE", 746, 749], ["influenza pandemic", "DISEASE", 755, 773], ["influenza A(H1N1)pdm09", "ORGANISM", 549, 571], ["influenza A(H1N1)pdm09", "ORGANISM", 614, 636], ["influenza A(H1N1", "SPECIES", 614, 630], ["influenza A(H1N1)pdm09", "SPECIES", 614, 636], ["influenza", "PROBLEM", 549, 558], ["pdm09", "PROBLEM", 566, 571], ["influenza", "PROBLEM", 614, 623], ["pdm09", "PROBLEM", 631, 636], ["influenza", "OBSERVATION", 549, 558]]], ["A significant proportion of respondents (91%) correctly identified the definition of an influenza pandemic, understood the aim of the containment phase (90%), and knew that the illness caused by the virus was mild in most cases (97%) ( Table 3) .Knowledge of influenza A(H1N1)pdm09 and precautionary behaviourHowever, respondents were less assured when it came to understanding management guidelines: 73% (48/66) stated that antiviral drugs could cure illness due to the pandemic virus, and 89% (59/66) believed that influenza A(H1N1)pdm09 could be treated successfully using antibiotics.Knowledge of influenza A(H1N1)pdm09 and precautionary behaviourCorrect knowledge of precautionary behaviour also varied.", [["influenza pandemic", "DISEASE", 88, 106], ["illness", "DISEASE", 177, 184], ["illness", "DISEASE", 452, 459], ["pandemic", "DISEASE", 471, 479], ["influenza A(H1N1)pdm09", "DISEASE", 517, 539], ["influenza A(H1N1)pdm09", "ORGANISM", 259, 281], ["influenza A(H1N1)pdm09", "ORGANISM", 517, 539], ["influenza A(H1N1)pdm09", "ORGANISM", 601, 623], ["influenza A(H1N1", "SPECIES", 601, 617], ["pandemic virus", "SPECIES", 471, 485], ["an influenza pandemic", "PROBLEM", 85, 106], ["the illness", "PROBLEM", 173, 184], ["the virus", "PROBLEM", 195, 204], ["influenza", "PROBLEM", 259, 268], ["pdm09", "PROBLEM", 276, 281], ["antiviral drugs", "TREATMENT", 425, 440], ["the pandemic virus", "PROBLEM", 467, 485], ["influenza A(H1N1)pdm09", "PROBLEM", 517, 539], ["antibiotics", "TREATMENT", 576, 587], ["influenza", "PROBLEM", 601, 610], ["pdm09", "PROBLEM", 618, 623], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["influenza", "OBSERVATION", 88, 97], ["mild", "OBSERVATION_MODIFIER", 209, 213], ["influenza", "OBSERVATION", 517, 526]]], ["All respondents knew that staying at home while ill would reduce the spread of influenza A(H1N1)pdm09, and a significant proportion correctly stated that frequent handwashing could be used to prevent the spread of virus (Table 3) .", [["influenza", "DISEASE", 79, 88], ["influenza A(H1N1)pdm09", "ORGANISM", 79, 101], ["influenza", "PROBLEM", 79, 88], ["pdm09", "PROBLEM", 96, 101]]], ["However, 77% (48/62) of respondents believed that the virus could be prevented from spreading by wearing face masks in public, while 56% (35/63) believed that spread could be prevented by not travelling abroad to areas already affected by influenza A(H1N1)pdm09.Association between professional status and responsesThe median knowledge score was 9 (range 6e11) out of a possible 11 for clinicians, and 10 (range 5e11) for nonclinicians.", [["influenza A(H1N1)pdm09", "ORGANISM", 239, 261], ["the virus", "PROBLEM", 50, 59], ["influenza", "PROBLEM", 239, 248], ["pdm09", "PROBLEM", 256, 261], ["The median knowledge score", "TEST", 315, 341], ["virus", "OBSERVATION", 54, 59]]], ["There were no significant differences in the proportion of clinicians and non-clinicians providing correct responses for 10 of the 11 items in this section.", [["this section", "TREATMENT", 143, 155], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["In comparison with non-clinicians, all clinicians agreed with the statement that spread of the virus can be prevented by frequent handwashing (100% vs 77%, P \u00bc 0.008).Association between professional status and responsesHowever, clinicians performed relatively poorly when responding to other questions: 59% (22/37) thought that avoiding international travel to areas already affected by influenza A(H1N1)pdm09 would be protective; 46% (17/37) thought that the virus mainly affected the young and the elderly; 33% (12/37) believed that antiviral drugs could cure illness caused by influenza A(H1N1)pdm09; and 27% (10/37) thought that wearing a face mask in public would prevent spread of the disease.DiscussionThis study shows that during the containment phase of the response to influenza A(H1N1)pdm09, staff of the West Midlands FRC had a positive attitude towards working in the FRC.", [["influenza", "DISEASE", 388, 397], ["illness", "DISEASE", 563, 570], ["influenza A(H1N1)pdm09", "DISEASE", 581, 603], ["influenza", "DISEASE", 780, 789], ["influenza A(H1N1)pdm09", "ORGANISM", 388, 410], ["influenza A(H1N1)pdm09", "ORGANISM", 581, 603], ["influenza A(H1N1)pdm09", "ORGANISM", 780, 802], ["influenza A(H1N1)pdm09", "SPECIES", 581, 603], ["the virus", "PROBLEM", 91, 100], ["influenza A(H1N1)pdm09", "PROBLEM", 388, 410], ["the virus", "PROBLEM", 457, 466], ["antiviral drugs", "TREATMENT", 536, 551], ["influenza A(H1N1)pdm09", "PROBLEM", 581, 603], ["a face mask", "TREATMENT", 642, 653], ["the disease", "PROBLEM", 688, 699], ["This study", "TEST", 710, 720], ["influenza", "PROBLEM", 780, 789], ["pdm09", "PROBLEM", 797, 802], ["virus", "OBSERVATION", 461, 466], ["disease", "OBSERVATION", 692, 699]]], ["Additionally, staff believed that the FRC had made a positive contribution to the management of influenza A(H1N1)pdm09 during the containment phase, and would work in similar call centres in future.", [["influenza", "DISEASE", 96, 105], ["influenza A(H1N1)pdm09", "ORGANISM", 96, 118], ["the FRC", "PROBLEM", 34, 41], ["influenza A", "PROBLEM", 96, 107], ["H1N1", "PROBLEM", 108, 112], ["pdm09", "PROBLEM", 113, 118], ["influenza", "OBSERVATION", 96, 105]]], ["These findings are consistent with a previous survey of clinical personnel in Taiwan staffing a telephone hotline for severe acute respiratory syndrome.", [["acute respiratory syndrome", "DISEASE", 125, 151], ["severe acute respiratory syndrome", "PROBLEM", 118, 151], ["consistent with", "UNCERTAINTY", 19, 34], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["respiratory syndrome", "OBSERVATION", 131, 151]]], ["10 Overall, the knowledge of FRC staff about influenza A(H1N1) pdm09 and the containment phase was generally good, and although there was no significant difference between the median overall knowledge scores for clinical and non-clinical staff, areas of potential concern were identified, particularly regarding the knowledge of clinicians.", [["influenza A(H1N1) pdm09", "ORGANISM", 45, 68], ["influenza", "PROBLEM", 45, 54], ["pdm09", "PROBLEM", 63, 68], ["the containment phase", "TEST", 73, 94], ["no", "UNCERTAINTY", 138, 140], ["significant", "OBSERVATION_MODIFIER", 141, 152]]], ["Clinicians clearly identified staying at home and frequent handwashing as preventive measures.", [["preventive measures", "TREATMENT", 74, 93]]], ["However, more than half would have advised not travelling abroad in order to avoid infection, approximately half did not know the main age group affected during the containment phase, nearly one-third thought that antiviral drugs could cure infection, and just over one-quarter thought that wearing face masks in public places was protective.", [["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 241, 250], ["infection", "PROBLEM", 83, 92], ["antiviral drugs", "TREATMENT", 214, 229], ["cure infection", "PROBLEM", 236, 250], ["face masks", "TREATMENT", 299, 309], ["infection", "OBSERVATION", 83, 92]]], ["There is no evidence supporting the effectiveness of these measures.", [["these measures", "TREATMENT", 53, 67], ["no evidence supporting", "UNCERTAINTY", 9, 31]]], ["10 One of the greatest challenges encountered when staffing the FRC was identifying and recruiting appropriate staff.", [["greatest", "OBSERVATION_MODIFIER", 14, 22]]], ["This is an area for potential future research.DiscussionE-mail surveys are known to have average response rates of 30e40% for online surveys; therefore, a relatively good response rate was achieved for this survey (51%).", [["this survey", "TEST", 202, 213]]], ["11, 12 However, inferences need to be interpreted cautiously given the relatively small number of respondents and potential bias due to varying levels of non-response to certain questions.", [["small", "OBSERVATION_MODIFIER", 82, 87]]], ["Another potential limitation is that the heterogeneous nature of the 'clinical' and 'non-clinical' groupings may have introduced error.", [["the 'clinical' and 'non-clinical' groupings", "PROBLEM", 65, 108], ["heterogeneous", "OBSERVATION_MODIFIER", 41, 54]]], ["Although the use of an electronic survey precluded detailed qualitative study, the method used allowed large-scale data collection in a timely, practical and costeffective manner.", [["an electronic survey", "TEST", 20, 40], ["detailed qualitative study", "TEST", 51, 77], ["the method", "TREATMENT", 79, 89]]], ["Surge capacity has been identified previously as an issue during pandemic preparedness, and securing sufficient and appropriate staff at short notice has been identified as challenging in this study and by others.", [["Surge capacity", "PROBLEM", 0, 14], ["this study", "TEST", 188, 198]]], ["5, 13 Time will need to be invested in training, and this study suggests that assumptions should not be made regarding the level of knowledge of clinicians, and that disease-specific training and education should be provided to all staff.", [["this study", "TEST", 53, 63]]]], "c9b74b08ea5da70d379995b796eba890cf3e7aea": [["IntroductionSARS-CoV-2 virus has caused the most significant pandemic (COVID-19) in recent history.", [["IntroductionSARS-CoV-2 virus", "ORGANISM", 0, 28], ["CoV-2 virus", "SPECIES", 17, 28], ["CoV-2 virus", "SPECIES", 17, 28], ["IntroductionSARS", "TEST", 0, 16], ["CoV-2 virus", "PROBLEM", 17, 28], ["COVID", "TEST", 71, 76]]], ["Within 5 months of its emergence in December 2019, the virus has spread to more than 210 countries, and has caused greater than 170,000 deaths and more than 2.5 million reported cases as of April 22, 2020.", [["deaths", "DISEASE", 136, 142], ["the virus", "PROBLEM", 51, 60]]], ["This virus is a positive strand RNA virus with a genomic length of about 30K (29,903 nucleotides in the reference genome), and is evolving rapidly.", [["30K", "DNA", 73, 76], ["This virus", "PROBLEM", 0, 10], ["a positive strand RNA virus", "PROBLEM", 14, 41], ["a genomic length", "TEST", 47, 63], ["positive", "OBSERVATION_MODIFIER", 16, 24], ["strand RNA virus", "OBSERVATION", 25, 41], ["genomic", "OBSERVATION_MODIFIER", 49, 56], ["length", "OBSERVATION_MODIFIER", 57, 63], ["evolving", "OBSERVATION_MODIFIER", 130, 138], ["rapidly", "OBSERVATION_MODIFIER", 139, 146]]], ["Aged mutations are persisting or diluted away and new mutations are arising.", [["Aged mutations", "PROBLEM", 0, 14]]], ["Mutations may increase the fitness of the virus to the environment, while elevating the risk of drug resistance, altering the case fatality rate, and reducing the efficacy of vaccines.", [["Mutations", "PROBLEM", 0, 9], ["drug resistance", "PROBLEM", 96, 111], ["vaccines", "TREATMENT", 175, 183], ["drug resistance", "OBSERVATION", 96, 111]]], ["Excluding the 5' leader and 3' terminal sequences, the genome contains 11 coding regions including S, E, M, N and several open reading frames (ORF1ab, ORF3a, ORF6, ORF7a, ORF7b, ORF8, and ORF10) with various lengths and biological implications.", [["3' terminal sequences", "CELLULAR_COMPONENT", 28, 49], ["genome", "CELLULAR_COMPONENT", 55, 61], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 143, 149], ["ORF3a", "GENE_OR_GENE_PRODUCT", 151, 156], ["ORF6", "GENE_OR_GENE_PRODUCT", 158, 162], ["ORF7a", "GENE_OR_GENE_PRODUCT", 164, 169], ["ORF7b", "GENE_OR_GENE_PRODUCT", 171, 176], ["ORF8", "GENE_OR_GENE_PRODUCT", 178, 182], ["ORF10", "GENE_OR_GENE_PRODUCT", 188, 193], ["5' leader and 3' terminal sequences", "DNA", 14, 49], ["E", "DNA", 102, 103], ["open reading frames", "DNA", 122, 141], ["ORF1ab", "DNA", 143, 149], ["ORF3a", "DNA", 151, 156], ["ORF6", "DNA", 158, 162], ["ORF7a", "DNA", 164, 169], ["ORF7b", "DNA", 171, 176], ["ORF8", "DNA", 178, 182], ["ORF10", "DNA", 188, 193], ["the 5' leader and 3' terminal sequences", "PROBLEM", 10, 49], ["ORF1ab", "TEST", 143, 149], ["ORF6", "TEST", 158, 162], ["ORF7b", "TEST", 171, 176], ["ORF8", "TEST", 178, 182]]], ["Based on the DNA sequence data of 1,932 SARS-CoV-2 strains from GISAID, NCBI Genbank, and CNCB (data release: March 31, 2020), we performed a phylogenetic analysis based on the full genomes, characterized the geographic and temporal patterns of aged and new mutations, examined genomic profile and identified frequent mutations, inferred linkage disequilibrium (LD) and haplotype structure, constructed the evolutionary paths, correlated phylogenetic clusters with mutations, and investigated how the mutation count influenced the case fatality.ResultsBased on the whole-genome sequence data, the phylogenetic tree of 1,932 SARS-CoV-2 strains showed there are six major groups (Figure 1) : (1) Europe-1 (76% of 810 strains are from Europe, with the majority from Iceland); (2) Oceania/Asia (38.6% and 38.6% of 57 strains are from Oceania (all of the Oceania strains are from Australia in this data set) and Asia, respectively, with the majority from Australia and China); (3) Americas (94.4% of 342 strains are from Americas, with the majority from the United States); (4) Europe-2 (80.8% of 104 strains are from Europe, with the majority from Great Britain and Iceland); (5) Asia-1 (72.2% of 133 strains are from Asia, with the majority from China); and (6) Asia-2 (55.5% of 364 strains are from Asia with the majorities from China and Japan).ResultsWe used the strain originally isolated in China (1) as the reference genome and defined variations from the reference as mutations.", [["SARS", "DISEASE", 624, 628], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["SARS-CoV-2", "ORGANISM", 624, 634], ["NCBI Genbank", "DNA", 72, 84], ["SARS-CoV", "SPECIES", 40, 48], ["Asia-1", "SPECIES", 1176, 1182], ["the DNA sequence data", "TEST", 9, 30], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["strains", "PROBLEM", 51, 58], ["GISAID", "PROBLEM", 64, 70], ["a phylogenetic analysis", "TEST", 140, 163], ["new mutations", "PROBLEM", 254, 267], ["frequent mutations", "PROBLEM", 309, 327], ["inferred linkage disequilibrium (LD) and haplotype structure", "PROBLEM", 329, 389], ["mutations", "PROBLEM", 465, 474], ["the mutation count", "TEST", 497, 515], ["the whole-genome sequence data", "TEST", 561, 591], ["the phylogenetic tree", "TEST", 593, 614], ["SARS", "TEST", 624, 628], ["CoV-2 strains", "TEST", 629, 642], ["Europe", "TEST", 694, 700], ["strains", "PROBLEM", 715, 722], ["Oceania/Asia", "TEST", 777, 789], ["57 strains", "PROBLEM", 810, 820], ["Oceania", "PROBLEM", 830, 837], ["the Oceania strains", "PROBLEM", 846, 865], ["the strain", "PROBLEM", 1359, 1369]]], ["Among 1,932 SARS-CoV-2 strains studied, the average mutation counts per sample in Europe and Americas were much higher than that in Asia (Figure 2A) .", [["SARS", "DISEASE", 12, 16], ["SARS-CoV-2", "ORGANISM", 12, 22], ["SARS-CoV", "SPECIES", 12, 20], ["SARS", "TEST", 12, 16], ["CoV", "TEST", 17, 20], ["the average mutation counts", "TEST", 40, 67]]], ["This phenomenon partially reflects the early occurrence of epidemic of COVID-19 in Asia.", [["This phenomenon", "PROBLEM", 0, 15], ["COVID", "TEST", 71, 76], ["early", "OBSERVATION_MODIFIER", 39, 44], ["epidemic", "OBSERVATION_MODIFIER", 59, 67]]], ["The six major clusters derived from the phylogenetic analysis (Figure 1 ) also showed more mutations in the European and American clusters compared to the two Asian clusters.", [["the phylogenetic analysis", "TEST", 36, 61], ["more mutations in the European and American clusters", "PROBLEM", 86, 138]]], ["The average mutation counts per sample in Europe-1, Oceania/Asia, Americas, Europe-2, Asia-1, and Asia-2 were 6.60, 6.46, 6.67, 6.21, 4.07, and 2.68, respectively.ResultsMutations were distributed across the genome in different patterns according to the geographic locations that the samples were isolated.", [["samples", "ANATOMY", 284, 291], ["samples", "CANCER", 284, 291], ["Asia-1", "SPECIES", 86, 92], ["The average mutation counts", "TEST", 0, 27], ["ResultsMutations", "TEST", 163, 179], ["the samples", "TEST", 280, 291]]], ["Mutation densities (i.e., the number of mutations per nucleotides in the gene region) were high in several gene regions including ORF3a (Luxembourg, France, and Singapore), ORF8 (the United States, Korea, and China), N (Switzerland, Ireland, and Portugal), and ORF10 (Japan and Spain) (Figure 2A) .", [["nucleotides", "CHEMICAL", 54, 65], ["Mutation densities", "PROBLEM", 0, 18], ["mutations per nucleotides", "PROBLEM", 40, 65], ["densities", "OBSERVATION", 9, 18], ["high", "OBSERVATION_MODIFIER", 91, 95]]], ["ORF1ab harbors a significant number of mutations, but because of its length the mutation density appears to be low.", [["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF1", "DNA", 0, 4], ["mutations", "PROBLEM", 39, 48], ["its length the mutation density", "PROBLEM", 65, 96], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["number", "OBSERVATION_MODIFIER", 29, 35], ["mutations", "OBSERVATION", 39, 48], ["density", "OBSERVATION", 89, 96], ["appears to be", "UNCERTAINTY", 97, 110], ["low", "OBSERVATION_MODIFIER", 111, 114]]], ["The United States had the largest sample size (N = 510) and the average mutation count was 6.42.", [["the average mutation count", "TEST", 60, 86], ["largest", "OBSERVATION_MODIFIER", 26, 33], ["size", "OBSERVATION_MODIFIER", 41, 45]]], ["The dominant mutation types in the east (NY) and the west (CA, WA, and UT) were different, with mutations in ORF3a dominating in the former, while mutations in ORF8 in the latter states.ResultsWe found a total of 169,060 mutation counts.", [["CA", "GENE_OR_GENE_PRODUCT", 59, 61], ["UT", "GENE_OR_GENE_PRODUCT", 71, 73], ["ORF3a", "GENE_OR_GENE_PRODUCT", 109, 114], ["ORF8", "GENE_OR_GENE_PRODUCT", 160, 164], ["ORF3a", "DNA", 109, 114], ["ORF8", "DNA", 160, 164], ["mutations in ORF3a", "PROBLEM", 96, 114], ["mutation counts", "TEST", 221, 236], ["dominant", "OBSERVATION_MODIFIER", 4, 12], ["mutation", "OBSERVATION", 13, 21], ["types", "OBSERVATION_MODIFIER", 22, 27]]], ["The average mutation count per locus was 169,060/29,903 = 5.654.", [["The average mutation count", "TEST", 0, 26]]], ["The average mutation count per sample was 169,060/1,931 = 87.55.", [["The average mutation count per sample", "TEST", 0, 37]]], ["The average mutation count per locus per sample was 0.298%.", [["The average mutation count", "TEST", 0, 26]]], ["After removing the mutations in 5' leader and 3' terminal sequences, the total mutation counts for all samples across genome reduced to 11,223.", [["samples", "ANATOMY", 103, 110], ["3' terminal sequences", "CELLULAR_COMPONENT", 46, 67], ["5' leader and 3' terminal sequences", "DNA", 32, 67], ["the mutations", "TREATMENT", 15, 28], ["5' leader", "TREATMENT", 32, 41], ["3' terminal sequences", "TREATMENT", 46, 67], ["the total mutation counts", "TEST", 69, 94], ["all samples across genome", "TEST", 99, 124]]], ["The average mutation count per locus was 11,223/29,409 = 0.3816.", [["The average mutation count", "TEST", 0, 26]]], ["The average mutation count per sample was 11,223/1931 = 5.812.", [["The average mutation count per sample", "TEST", 0, 37]]], ["The average mutation count per locus per sample was 0.0198%.ResultsGlobally, the average mutation count per sample was increasing with time (r = 0.65 in a linear regression) ( Figure 2B ).", [["The average mutation count", "TEST", 0, 26], ["the average mutation count", "TEST", 77, 103]]], ["This result indicates that the mutated strains persisted and were expanding.", [["the mutated strains", "PROBLEM", 27, 46]]], ["A large number of the mutations originated from China at the early stage have overwhelmed the samples collected from Americas and Europe after a few months.", [["samples", "ANATOMY", 94, 101], ["the mutations", "PROBLEM", 18, 31], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["In addition to the cumulated aged mutations, we also identified a significant number of new mutations occurring at each date.", [["new mutations", "PROBLEM", 88, 101], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["number", "OBSERVATION_MODIFIER", 78, 84], ["new", "OBSERVATION_MODIFIER", 88, 91], ["mutations", "OBSERVATION", 92, 101]]], ["Unlike the increasing trend of the cumulated aged mutations, the number of new mutations occurring globally at each date remained at a constant level.", [["the cumulated aged mutations", "PROBLEM", 31, 59], ["new mutations", "PROBLEM", 75, 88], ["increasing", "OBSERVATION_MODIFIER", 11, 21], ["trend", "OBSERVATION_MODIFIER", 22, 27], ["new", "OBSERVATION_MODIFIER", 75, 78], ["mutations", "OBSERVATION", 79, 88]]], ["The major contributor of the new mutations was China at the early stage but shifted to Americas and Europe after mid-February ( Figure 2C ).ResultsFourteen frequent mutations with a mutation frequency of >0.1 were identified (Table S1Resultsand Figure 3A ).", [["the new mutations", "PROBLEM", 25, 42], ["frequent mutations", "PROBLEM", 156, 174], ["a mutation frequency", "TEST", 180, 200], ["new", "OBSERVATION_MODIFIER", 29, 32], ["mutations", "OBSERVATION", 33, 42]]], ["These frequent mutations showed interesting patterns.", [["These frequent mutations", "PROBLEM", 0, 24]]], ["First, the mutations have a similar mutation rate if they were first observed at the same or close dates and in strong LD.", [["the mutations", "PROBLEM", 7, 20]]], ["For example, nt8782 (C to T) and nt28144 (T to C) that were used to define L type and S type of SARS-CoV-2 (2) first co-appeared on Jan 5th 2020 and the coefficient of LD is R2 = 0.983 ( Figure 3A) .", [["SARS", "DISEASE", 96, 100], ["SARS", "PROBLEM", 96, 100], ["CoV", "TEST", 101, 104], ["R2", "TEST", 174, 176]]], ["The reference strain used here is the L type, while the S type exhibits both mutations.", [["L type", "OBSERVATION_MODIFIER", 38, 44]]], ["This implies that the frequent mutations on the same haplotype were co-transmitted to the infected cases during infection.", [["infection", "DISEASE", 112, 121], ["the frequent mutations", "PROBLEM", 18, 40], ["infection", "PROBLEM", 112, 121], ["infection", "OBSERVATION", 112, 121]]], ["The haplotypes were located in the same or across different gene regions.", [["gene regions", "DNA", 60, 72], ["The haplotypes", "PROBLEM", 0, 14]]], ["Other cases first co-observed at the same date included nt1059 (C to T) and nt25563 (G to T) (Feb 21st 2020); nt28881 (G to A), nt28882 (G to A), and nt28883 (G to C) (Feb 25th 2020).", [["nt1059", "DNA", 56, 62], ["nt", "TEST", 56, 58]]], ["Nucleotides nt3037 (C to T), nt14408 (C to T), and nt23403 (A to G) having high pairwise LD are the most frequent nucleotides in the current data set.", [["nucleotides", "CHEMICAL", 114, 125], ["nt3037", "GENE_OR_GENE_PRODUCT", 12, 18], ["C to T", "GENE_OR_GENE_PRODUCT", 20, 26], ["nt14408 (C to T", "GENE_OR_GENE_PRODUCT", 29, 44], ["nt23403 (A to G", "GENE_OR_GENE_PRODUCT", 51, 66], ["nt23403", "DNA", 51, 58], ["Nucleotides", "TREATMENT", 0, 11], ["high pairwise LD", "PROBLEM", 75, 91]]], ["Nucleotides nt17747 (C to T), nt17858 (A to G), and nt18060 (C to T) having almost identical nucleotide frequency also showed high pairwise LD.", [["nucleotide", "CHEMICAL", 93, 103], ["nucleotide", "CHEMICAL", 93, 103], ["nt17747", "GENE_OR_GENE_PRODUCT", 12, 19], ["C to T", "GENE_OR_GENE_PRODUCT", 21, 27], ["A to G)", "GENE_OR_GENE_PRODUCT", 39, 46], ["nt18060 (C to T", "GENE_OR_GENE_PRODUCT", 52, 67], ["nt17858", "DNA", 30, 37], ["nt18060", "DNA", 52, 59], ["C to T", "DNA", 61, 67], ["Nucleotides", "TEST", 0, 11], ["nt", "TEST", 30, 32], ["nucleotide frequency", "TEST", 93, 113], ["high pairwise LD", "PROBLEM", 126, 142]]], ["Nucleotide nt11083 had two alternative nucleotides (G to T or C) and was not correlated to the other frequent mutations.ResultsSecond, the evolutionary path of the fourteen frequent mutations was constructed ( Figure 3B and 3C) based on their first observation time.", [["nucleotides", "CHEMICAL", 39, 50], ["G to T or C", "GENE_OR_GENE_PRODUCT", 52, 63], ["Nucleotide", "TREATMENT", 0, 10], ["alternative nucleotides", "TREATMENT", 27, 50], ["the other frequent mutations", "PROBLEM", 91, 119], ["the fourteen frequent mutations", "PROBLEM", 160, 191]]], ["Note that the real occurrence date of mutations should be earlier because of left censoring of mutation events.", [["mutations", "PROBLEM", 38, 47], ["mutation events", "PROBLEM", 95, 110], ["mutation", "OBSERVATION", 95, 103]]], ["The haplotype frequencies varied across continents and nations.", [["The haplotype frequencies", "PROBLEM", 0, 25]]], ["For example, the mutation haplotype 8782T-28144C was prevalent in the US but mutation 11083C/T and mutation haplotype 28881A-28882A-28883C were not), reflecting the different transmission paths of viral strains and their different ability to adapt to the local environment ( Figure 3D ).ResultsIt is also interesting to see the time trajectory of the average mutation count in the fourteen frequent mutations ( Figure 2D ).", [["the mutation haplotype", "TEST", 13, 35], ["mutation", "TEST", 77, 85], ["mutation haplotype", "TEST", 99, 117], ["viral strains", "PROBLEM", 197, 210], ["the average mutation count", "TEST", 347, 373], ["viral strains", "OBSERVATION", 197, 210]]], ["Nucleotides nt14408, nt23403 and nt3037 were in strong LD and have emerged to be the most prevalent mutations.", [["Nucleotides", "CHEMICAL", 0, 11], ["nt23403", "CHEMICAL", 21, 28], ["nt3037", "CHEMICAL", 33, 39], ["nt14408", "GENE_OR_GENE_PRODUCT", 12, 19], ["nt23403", "GENE_OR_GENE_PRODUCT", 21, 28], ["nt3037", "GENE_OR_GENE_PRODUCT", 33, 39], ["Nucleotides", "TEST", 0, 11]]], ["The raising patterns of the average mutation count may imply natural selection and adaptation to the different environment.", [["the average mutation count", "TEST", 24, 50], ["natural selection", "OBSERVATION", 61, 78]]], ["Unexpectedly, the earliest mutations reported were in nt8782 and nt28144 in this data set, also with strong LD, but their frequency has gradually declined.", [["nt8782", "DNA", 54, 60]]], ["Strains with the relatively new mutations in nt14408, nt23403 and nt3037 have emerged to become the most common strains identified in the world, particularly in subgroup Europe-1.ResultsThe major clusters of SARS-CoV-2 strains identified in the phylogenetic tree can be characterized by the key mutations (Figure 1) , most of which were also shown in Figure 2D .", [["SARS", "DISEASE", 208, 212], ["nt14408", "GENE_OR_GENE_PRODUCT", 45, 52], ["nt23403", "GENE_OR_GENE_PRODUCT", 54, 61], ["nt3037", "GENE_OR_GENE_PRODUCT", 66, 72], ["SARS-CoV-2", "ORGANISM", 208, 218], ["nt3037", "DNA", 66, 72], ["Europe-1", "SPECIES", 170, 178], ["SARS-CoV", "SPECIES", 208, 216], ["Strains", "PROBLEM", 0, 7], ["the relatively new mutations", "PROBLEM", 13, 41], ["the most common strains", "PROBLEM", 96, 119], ["SARS", "PROBLEM", 208, 212], ["CoV-2 strains", "PROBLEM", 213, 226], ["major", "OBSERVATION_MODIFIER", 190, 195], ["clusters", "OBSERVATION_MODIFIER", 196, 204], ["SARS", "OBSERVATION", 208, 212], ["phylogenetic", "ANATOMY_MODIFIER", 245, 257], ["tree", "ANATOMY_MODIFIER", 258, 262]]], ["The Europe-1 group carried the specific mutations nt3037T (ORF1ab), nt14408T (ORF1ab), and nt23403G (S), in addition to the nt241T mutation in 5' leader sequence.", [["nt3037T", "GENE_OR_GENE_PRODUCT", 50, 57], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 59, 65], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 78, 84], ["nt241T", "GENE_OR_GENE_PRODUCT", 124, 130], ["ORF1ab", "DNA", 59, 65], ["nt14408T", "DNA", 68, 76], ["nt241T", "DNA", 124, 130], ["5' leader sequence", "DNA", 143, 161], ["nt", "TEST", 68, 70], ["the nt241T mutation", "PROBLEM", 120, 139]]], ["These mutations were hardly observed in other groups.", [["These mutations", "PROBLEM", 0, 15]]], ["The Europe-2 group is characterized by mutations nt11083T (ORF1ab), nt14805T (ORF1ab), and nt26144T (ORF3a).", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 59, 65], ["nt14805T", "GENE_OR_GENE_PRODUCT", 68, 76], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 78, 84], ["nt26144T", "GENE_OR_GENE_PRODUCT", 91, 99], ["ORF3a", "GENE_OR_GENE_PRODUCT", 101, 106], ["ORF1ab", "DNA", 59, 65], ["ORF1ab", "DNA", 78, 84], ["nt26144T", "DNA", 91, 99], ["ORF3a", "DNA", 101, 106]]], ["The Oceania/Asia group carried mutations nt1397A (ORF1ab), nt11083T (ORF1ab) and nt28688C (N).", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 50, 56], ["ORF1ab", "DNA", 50, 56], ["nt11083T", "DNA", 59, 67], ["ORF1ab", "DNA", 69, 75], ["nt", "TEST", 59, 61]]], ["The Americas group carried mutations nt8782T (ORF1ab) and nt28144C (ORF8), which were used to define the S sub-type (2).", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 46, 52], ["ORF1ab", "DNA", 46, 52], ["ORF8", "DNA", 68, 72]]], ["These two mutations were also observed in the Asia-1 group, but not in the other groups.", [["Asia-1", "SPECIES", 46, 52], ["These two mutations", "PROBLEM", 0, 19]]], ["Additionally, the Americas group also carried mutations nt17747T (ORF1ab), nt17858G (ORF1ab), and nt18060T (ORF1ab).", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 66, 72], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 85, 91], ["ORF1ab", "DNA", 66, 72], ["nt17858G", "DNA", 75, 83], ["ORF1ab", "DNA", 85, 91], ["nt18060T", "DNA", 98, 106], ["ORF1ab", "DNA", 108, 114], ["nt", "TEST", 75, 77]]], ["The Asia-2 group is distinct from others because the strains in this group did not carry most of the frequent mutations.", [["the strains", "PROBLEM", 49, 60], ["the frequent mutations", "PROBLEM", 97, 119]]], ["On average, the dates of sample collection of the two Asian groups were closest to the first emergence of COVID-19 in December 2019 and their genomes were closest to the reference.", [["COVID-19", "DNA", 106, 114], ["sample collection", "TEST", 25, 42], ["average", "OBSERVATION_MODIFIER", 3, 10]]], ["They were characterized by multiple mutations with low frequencies.", [["multiple mutations with low frequencies", "PROBLEM", 27, 66], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["mutations", "OBSERVATION", 36, 45], ["low frequencies", "OBSERVATION_MODIFIER", 51, 66]]], ["Only about 6% of viral strains cannot be categorized into the six main phylogenetic clusters.ResultsFinally, a point worth noting is the strong linear correlation between the case fatality rate and the average mutation count per sample (r = 0.4258, p = 0.0482) as of April 9, 2020 ( Figure 4A ).", [["viral strains", "PROBLEM", 17, 30], ["the average mutation count", "TEST", 198, 224], ["p", "TEST", 249, 250]]], ["Among eleven gene regions, only ORF1ab showed a significant linear correlation (r = 0.407, p = 0.0542) (Figure 4B) , suggesting that ORF1ab mutation may contribute the most to the case fatality rate.", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 32, 38], ["ORF1", "GENE_OR_GENE_PRODUCT", 133, 137], ["ORF1ab", "DNA", 32, 38], ["ORF1", "DNA", 133, 137], ["p", "TEST", 91, 92], ["ORF1ab mutation", "PROBLEM", 133, 148]]], ["Surprisingly, by April 21, 2020 the correlation between case fatality and the average mutation count has become even more significant with p= 0.0348 (Figure 4C) , and its contribution from ORF1ab has a p value of 0.0291 ( Figure 4D ).", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 189, 195], ["ORF1ab", "PROTEIN", 189, 195], ["the average mutation count", "TEST", 74, 100], ["p", "TEST", 139, 140], ["a p value", "TEST", 200, 209]]], ["These results indicate that mutation has already impacted clinical outcome of COVID-19, not just a viral fitness evolution event.DiscussionIn summary, we report evidence for time and geographic variations of SARS-CoV-2 mutations, and identified six major subgroups of SARS-CoV-2 strains with strong geographic preferences based on the complete genomes of 1,932 SARS-CoV-2 strains.", [["SARS", "DISEASE", 208, 212], ["SARS", "DISEASE", 268, 272], ["SARS", "DISEASE", 361, 365], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 208, 218], ["SARS-CoV-2", "ORGANISM", 268, 278], ["SARS-CoV-2", "ORGANISM", 361, 371], ["SARS-CoV", "SPECIES", 208, 216], ["SARS-CoV", "SPECIES", 268, 276], ["mutation", "PROBLEM", 28, 36], ["COVID", "TEST", 78, 83], ["a viral fitness evolution event", "PROBLEM", 97, 128], ["SARS", "PROBLEM", 208, 212], ["SARS", "PROBLEM", 268, 272], ["CoV", "TEST", 273, 276], ["2 strains", "PROBLEM", 277, 286], ["the complete genomes", "TEST", 331, 351], ["SARS", "TEST", 361, 365], ["CoV", "TEST", 366, 369]]], ["These subgroups can be characterized by 14 common mutations, most of which occurred in ORF1ab, with notable exceptions in S, N, ORF3a and ORF8.", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 87, 93], ["ORF3a", "GENE_OR_GENE_PRODUCT", 128, 133], ["ORF8", "GENE_OR_GENE_PRODUCT", 138, 142], ["ORF1ab", "PROTEIN", 87, 93], ["ORF8", "PROTEIN", 138, 142], ["14 common mutations", "PROBLEM", 40, 59]]], ["This result suggests the importance of these genes in viral fitness and perhaps clinical relevance.", [["viral fitness", "PROBLEM", 54, 67], ["viral fitness", "OBSERVATION", 54, 67]]], ["The positive correlation was contributed mainly from gene region ORF1ab, which codes for polyproteins that are cleaved to become proteases, RNA-dependent RNA polymerase, helicase, and several nonstructural proteins (nsp).", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 65, 71], ["nsp", "GENE_OR_GENE_PRODUCT", 216, 219], ["gene region", "DNA", 53, 64], ["ORF1ab", "DNA", 65, 71], ["proteases", "PROTEIN", 129, 138], ["RNA-dependent RNA polymerase", "PROTEIN", 140, 168], ["helicase", "PROTEIN", 170, 178], ["nonstructural proteins", "PROTEIN", 192, 214], ["nsp", "PROTEIN", 216, 219], ["polyproteins", "PROBLEM", 89, 101], ["proteases", "TEST", 129, 138], ["RNA-dependent RNA polymerase", "PROBLEM", 140, 168], ["helicase", "PROBLEM", 170, 178]]], ["The significance of the correlation increased with time, suggesting that mutation may have impacted viral transmission, clinical manifestation, or treatment outcomes.DiscussionCompared to the L and S types originally reported (2) , and the A, B, C types reported recently (3), our classification of six subgroups provides a mutation-based taxonomy of viral strains and explains the heterogeneity of strains within each of L and S types and A, B, C types.", [["B", "GENE_OR_GENE_PRODUCT", 443, 444], ["mutation", "PROBLEM", 73, 81], ["impacted viral transmission", "PROBLEM", 91, 118], ["a mutation", "PROBLEM", 322, 332], ["viral strains", "PROBLEM", 351, 364], ["the heterogeneity of strains", "PROBLEM", 378, 406], ["viral strains", "OBSERVATION", 351, 364]]], ["Interestingly, 5 out of 6 subgroups are characterized by a few common mutations in each subgroup.", [["a few common mutations", "PROBLEM", 57, 79], ["few", "OBSERVATION_MODIFIER", 59, 62], ["common mutations", "OBSERVATION", 63, 79]]], ["This concept and method for classification and characterization of viral strains can be applied to other viruses of public health concerns.", [["viral strains", "PROBLEM", 67, 80], ["viral strains", "OBSERVATION", 67, 80]]], ["As more whole genome sequencing data of SARS-CoV-2 become available online, we will be better-posed to decipher and understand genomic, geographic and temporal distributions of viral mutations.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV", "SPECIES", 40, 48], ["SARS", "PROBLEM", 40, 44], ["viral mutations", "PROBLEM", 177, 192], ["viral mutations", "OBSERVATION", 177, 192]]], ["However, representativeness of the submitted genomic data should be considered carefully when explaining the results.DiscussionThe different protein reading frames exhibited different mutation frequencies depending on the geographic location.", [["protein reading frames", "DNA", 141, 163], ["the submitted genomic data", "PROBLEM", 31, 57], ["The different protein reading frames", "PROBLEM", 127, 163], ["different mutation frequencies", "PROBLEM", 174, 204]]], ["We dissected the prevalent mutations, investigated their LD structure, traced their evolutionary path, and found their importance in the characterization of phylogenetic clusters.", [["the prevalent mutations", "PROBLEM", 13, 36], ["phylogenetic clusters", "OBSERVATION", 157, 178]]], ["Interestingly, many frequent mutations occurred simultaneously, with LD close to 1.", [["many frequent mutations", "PROBLEM", 15, 38], ["many", "OBSERVATION_MODIFIER", 15, 19], ["frequent", "OBSERVATION_MODIFIER", 20, 28], ["mutations", "OBSERVATION", 29, 38]]], ["These mutations may occur simultaneously because of strong positive interactions.", [["These mutations", "PROBLEM", 0, 15], ["strong positive interactions", "PROBLEM", 52, 80]]], ["Alternatively, they might occur sequentially but appeared simultaneously due to insufficient sampling.", [["insufficient sampling", "PROBLEM", 80, 101]]], ["The biological implication of each mutation and their interactions remain an interesting topic to be explored.", [["each mutation", "PROBLEM", 30, 43]]], ["As aged mutations continued to accumulate in time and expand globally, new mutations emerged in the gene pool constantly to enrich the diversity of mutations.", [["new mutations", "PROBLEM", 71, 84]]], ["Since the fatality rate appears to correlate with the mutation count, the continued isolation and sequencing of the viral genome to monitor mutations become a crucially important component in the fight against this pandemic.Materials and MethodsWe downloaded the whole-genome sequence data from the Global Initiative on Sharing Avian Influenza Data (GISAID) database (https://www.gisaid.org/), National Center for Biotechnology Information (NCBI) Genbank (https://www.ncbi.nlm.nih.gov/genbank/), and China National Center for Bioinformation (CNCB) (https://bigd.big.ac.cn/ncov/release_genome) on Mar 31st 2020.", [["viral genome", "DNA", 116, 128], ["the mutation count", "TEST", 50, 68], ["the continued isolation", "TREATMENT", 70, 93], ["the viral genome to monitor mutations", "PROBLEM", 112, 149], ["this pandemic", "PROBLEM", 210, 223], ["Methods", "TREATMENT", 238, 245], ["viral genome", "OBSERVATION", 116, 128]]], ["After discarding the replicated sequences in the three databases and the sequences with a low quality indicator or no quality information, it remained the complete sequences of 1,938 SARS-CoV-2 genomes, including the Wuhan-Hu-1 reference genome with 29,903 nucleotides.", [["nucleotides", "CHEMICAL", 257, 268], ["1,938 SARS-CoV-2 genomes", "DNA", 177, 201], ["Wuhan-Hu-1 reference genome", "DNA", 217, 244], ["SARS-CoV", "SPECIES", 183, 191], ["Wuhan-Hu-1", "SPECIES", 217, 227], ["the sequences", "TEST", 69, 82], ["the complete sequences", "TEST", 151, 173], ["SARS", "TEST", 183, 187], ["CoV", "TEST", 188, 191]]], ["Multiple sequence alignment was performed by using MUSCLE (4) .", [["Multiple sequence alignment", "TEST", 0, 27], ["MUSCLE", "ANATOMY", 51, 57]]], ["Mutation was identified as variation from the reference.", [["Mutation", "PROBLEM", 0, 8]]], ["Generalized association plot (GAP) (5) was used to visualize the mutation patterns and identify the outliers in variations and samples ( Figure S2 ).", [["GAP", "PROTEIN", 30, 33], ["Generalized association plot (GAP)", "PROBLEM", 0, 34]]], ["We removed two ends (5' leader and 3' terminal sequences) of the SARS-CoV-2 genome because of a significant number of gaps.", [["SARS", "DISEASE", 65, 69], ["5' leader and 3' terminal sequences", "DNA", 21, 56], ["SARS-CoV-2 genome", "DNA", 65, 82], ["SARS-CoV", "SPECIES", 65, 73], ["5' leader", "TREATMENT", 21, 30], ["3' terminal sequences", "TREATMENT", 35, 56], ["the SARS", "TEST", 61, 69], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["number", "OBSERVATION_MODIFIER", 108, 114], ["gaps", "OBSERVATION", 118, 122]]], ["That is, we focused on nucleotides from positions 266 to 29,674.", [["nucleotides", "CHEMICAL", 23, 34]]], ["Before removing the two ends, we observed two nucleotides with a non-negligible mutation frequency relative to their neighboring regions: nt241 with a mutation frequency of 45.5% (and this nucleotide was in high LD with nt3037, nt14408, and nt23403) and nt29742 with a mutation frequency of 5.3%.", [["nucleotides", "CHEMICAL", 46, 57], ["nucleotide", "CHEMICAL", 189, 199], ["nt241", "GENE_OR_GENE_PRODUCT", 138, 143], ["nt241", "DNA", 138, 143], ["nt3037", "DNA", 220, 226], ["nt23403", "DNA", 241, 248], ["nt29742", "DNA", 254, 261], ["two nucleotides", "PROBLEM", 42, 57], ["a non-negligible mutation frequency", "PROBLEM", 63, 98], ["a mutation frequency", "TEST", 149, 169], ["this nucleotide", "TEST", 184, 199], ["a mutation frequency", "TEST", 267, 287]]], ["We also removed four samples with a large deletion in ORF8 (sample EPI_ISL_417518 from Taiwan with EPI_ISL_141378, EPI_ISL_141379, and EPI_ISL_141380 from Singapore), sample EPI_ISL_415435 from UK with a large deletion in ORF1ab, and sample EPI_ISL_413752 from China with a large number of deletions (>300 nucleotides).Materials and MethodsA new mutation at time t was defined as a mutation that has never been observed before t in this data set.", [["samples", "ANATOMY", 21, 28], ["nucleotides", "CHEMICAL", 306, 317], ["UK", "GENE_OR_GENE_PRODUCT", 194, 196], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 222, 228], ["ORF8", "DNA", 54, 58], ["ORF1ab", "DNA", 222, 228], ["EPI_ISL_413752", "SPECIES", 241, 255], ["a large deletion", "PROBLEM", 34, 50], ["EPI", "TEST", 99, 102], ["a large deletion in ORF1ab", "PROBLEM", 202, 228], ["A new mutation", "PROBLEM", 340, 354], ["a mutation", "PROBLEM", 380, 390], ["large", "OBSERVATION_MODIFIER", 36, 41], ["deletion", "OBSERVATION", 42, 50], ["large", "OBSERVATION_MODIFIER", 204, 209], ["deletion", "OBSERVATION", 210, 218], ["large", "OBSERVATION_MODIFIER", 274, 279]]], ["Average mutation count per sample and/or per locus were calculated for nations and for the data collection time points to study geographic and temporal distributions of mutations.", [["Average mutation count", "TEST", 0, 22], ["the data collection", "TEST", 87, 106], ["mutations", "PROBLEM", 169, 178], ["temporal", "OBSERVATION_MODIFIER", 143, 151]]], ["Mutation frequencies in gene regions were illustrated and coefficient of LD (R2) between pairs of nucleotides was calculated by using PLINK (6) .", [["nucleotides", "CHEMICAL", 98, 109], ["gene regions", "DNA", 24, 36], ["Mutation frequencies in gene regions", "PROBLEM", 0, 36]]], ["Frequent mutations were defined as mutations with a frequency of >0.1 in this paper.", [["Frequent mutations", "PROBLEM", 0, 18]]], ["Annotation of the frequent mutations was collected from China National Center for Bioinformation.", [["the frequent mutations", "PROBLEM", 14, 36]]], ["Nucleotide frequency and haplotype frequency were calculated by using a direct counting method.", [["Nucleotide frequency and haplotype frequency", "TREATMENT", 0, 44]]], ["Phylogenetic tree analysis was performed by using MEGA X (7) .", [["Phylogenetic tree analysis", "TEST", 0, 26], ["tree", "OBSERVATION_MODIFIER", 13, 17]]], ["GAP was applied to present the relationship between phylogenetic cluster and mutations.", [["GAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["GAP", "PROTEIN", 0, 3]]], ["Finally, the data of case fatality rate was collected the website of Coronavirus Resource Center, Johns Hopkins University on Apr 9th 2020 and Apr 21st 2020.", [["case fatality rate", "TEST", 21, 39]]], ["A linear regression model was built to correlate the average mutation count per sample and case fatality rate.", [["A linear regression model", "PROBLEM", 0, 25], ["case fatality rate", "TEST", 91, 109], ["linear", "OBSERVATION_MODIFIER", 2, 8]]], ["Other statistical graphs were generated using our self-developed R programs.", [["Other statistical graphs", "TEST", 0, 24]]], ["Table S1 .", [["S1", "ANATOMY", 6, 8]]], ["Geographic distributions of the average mutation counts in the entire genome and the standardized mutation densities in the eleven gene regions in the United States.", [["eleven gene regions", "DNA", 124, 143], ["the average mutation counts", "PROBLEM", 28, 55], ["the standardized mutation densities", "PROBLEM", 81, 116], ["distributions", "OBSERVATION_MODIFIER", 11, 24], ["average", "OBSERVATION_MODIFIER", 32, 39], ["mutation counts", "OBSERVATION", 40, 55], ["mutation densities", "OBSERVATION", 98, 116]]], ["A mutation is defined by a nucleotide change from the original nucleotide in the reference genome to the alternative nucleotide in the studied viral genomes.", [["nucleotide", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 117, 127], ["nucleotide", "CHEMICAL", 27, 37], ["nucleotide", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 117, 127], ["reference genome", "DNA", 81, 97], ["viral genomes", "DNA", 143, 156], ["A mutation", "PROBLEM", 0, 10], ["a nucleotide change", "PROBLEM", 25, 44], ["mutation", "OBSERVATION", 2, 10], ["viral genomes", "OBSERVATION", 143, 156]]], ["In each nation, the average mutation count per sample (i.e., the number of mutations in the genomes of all virus strains divided by the number of strains) is displayed in a color spectrum from blue (low average mutation count) to red (high average mutation count).", [["the average mutation count", "TEST", 16, 42], ["mutations", "PROBLEM", 75, 84], ["all virus strains", "PROBLEM", 103, 120], ["blue (low average mutation count", "PROBLEM", 193, 225]]], ["The statistics of the average mutation count per sample are provided.", [["the average mutation count", "TEST", 18, 44]]], ["Mutation density in each of the eleven gene regions (i.e., the number of mutations divided by the number of nucleotides in a gene region for all virus strains) is standardized (i.e., the mutation density in each gene divided by the sum of mutation densities in the eleven gene regions) and shown in a pie chart.", [["nucleotides", "CHEMICAL", 108, 119], ["eleven gene regions", "DNA", 32, 51], ["eleven gene regions", "DNA", 265, 284], ["Mutation density", "PROBLEM", 0, 16], ["mutations", "PROBLEM", 73, 82], ["nucleotides", "TREATMENT", 108, 119], ["all virus strains", "PROBLEM", 141, 158], ["the mutation density", "PROBLEM", 183, 203], ["mutation densities", "PROBLEM", 239, 257], ["density", "OBSERVATION", 9, 16], ["eleven gene", "ANATOMY_MODIFIER", 32, 43], ["regions", "ANATOMY_MODIFIER", 44, 51]]], ["A table of the average mutation count per sample for the states having at least 10 cases reported in this dataset is listed.", [["the average mutation count", "TEST", 11, 37]]], ["23 26 30 01 02 05 07 08 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 20 21 22 23 24 25 26 27 28 29 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Dec Jan Feb Mar 2020 2019 q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q qSupplemental Information(B) ( ) Proportion \u3002 T\"\"\" 8 \u00b7 0 9 \u00b7 0 \u5bf8 \u00b7 0 z \u00b7 0 0 \u00b7 0 nt14408 (ORF1ab) nt23403 (S) nt3037 (ORF1ab) nt28883 (N) nt28882 (N) nt28881 (N) nt25563 (ORF3a) nt1059 (ORF1ab) \ufffd(ORF1at nt28144 (ORF8) nt8782 (ORF1ab) nt18060 (ORF1ab) \u8f9c\u7434\u5b5a\ufffd\u7f55\u7afa\u7afa(B) q CT q TC q CC q CGT q TCC q TGC q CGC q CTT q TTC q CGCT q CTCT q TCCC q TGCC q TGTC q TTCC q CGCC q CCGCAT q TCGCGT q CCTCAT q CTCCAC q CTGCAC q CTGTAC q CTTCAC q CCGCAC q CTGCGC q CCGCCACAT q TCGCCACGT q TCGTCACGT q CCTCCACAT q CTCCCACAC q CTGCCACAC q CTGCCACGC q CTGCCATAC q CTGCTGTAC q CTTCCACAC q CCGCCACAC q CCCGCCACAGT q CTCGCCACGGT q CTCGTCACGGT q TTCGTCACGTT q CCCTCCACAGT q CCTCCCACAGC q CCTGCCACAGC q CCTGCCACGGC q CCTGCCATAGC q CCTGCTGTAGC q CCTTCCACAGC q CCCGCCACAGC q CCCGCCACAGTGGG q CTCGCCACGGTGGG q CTCGTCACGGTAAC q CTCGTCACGGTGGG q TTCGTCACGTTGGG q CCCTCCACAGTGGG q CCTCCCACAGCGGG q CCTGCCACAGCGGG q CCTGCCACGGCGGG q CCTGCCATAGCGGG q CCTGCTGTAGCGGG q CCTTCCACAGCGGG q CCCGCCACAGCGGG q CTTGTCACGGTGGG q CTCGTCACGTTGGG q TCCTCCACAGTGGG q CTCTTCACGGTGGG q CTCTTCACGGTAAC q CCTGCCGTAGCGGG q CCTGCCACAGTGGG q CCTTCTGTAGCGGG q TTCGTCACGGTGGG q CCCTTCACAGTGGG q CCTGCTGCAGCGGG q CCCGTCACGGTGGG q CCCTCCATAGTGGG q TTCTTCACGTTGGG q TCCGTCACAGTGGG q CCCGCCACAGTGGGGene RegionVirus strains to be excluded from further analyses Figure S2", [["ORF1ab", "DNA", 1220, 1226], ["ORF3a", "DNA", 1301, 1306], ["ORF1ab", "DNA", 1316, 1322], ["ORF1at nt28144", "DNA", 1326, 1340], ["ORF8", "DNA", 1342, 1346], ["ORF1ab", "DNA", 1356, 1362], ["ORF1ab", "TEST", 1220, 1226], ["ORF1ab", "TEST", 1248, 1254], ["ORF3a", "TEST", 1301, 1306], ["ORF1ab", "TEST", 1316, 1322], ["ORF1at", "TEST", 1326, 1332], ["ORF1ab", "TEST", 1356, 1362], ["nt", "TEST", 1364, 1366], ["ORF1ab", "TEST", 1373, 1379], ["B", "TEST", 1389, 1390], ["CT", "TEST", 1394, 1396], ["TC", "TEST", 1399, 1401], ["CC", "TEST", 1404, 1406], ["CGT", "TEST", 1409, 1412], ["TCC", "TEST", 1415, 1418], ["TGC", "TEST", 1421, 1424], ["CGC", "TEST", 1427, 1430], ["CTT", "TEST", 1433, 1436], ["TTC", "TEST", 1439, 1442], ["CGCT", "TEST", 1445, 1449], ["CTCT", "TEST", 1452, 1456], ["TCCC", "TEST", 1459, 1463], ["TGCC", "TEST", 1466, 1470], ["TGTC", "TEST", 1473, 1477], ["TTCC", "TEST", 1480, 1484], ["CGCC", "TEST", 1487, 1491], ["CCGCAT", "TEST", 1494, 1500], ["TCGCGT", "TEST", 1503, 1509], ["CCTCAT", "TEST", 1512, 1518], ["CTCCAC", "TEST", 1521, 1527], ["CTGCAC", "TEST", 1530, 1536], ["CTGTAC", "TEST", 1539, 1545], ["CTTCAC", "TEST", 1548, 1554], ["CCGCAC", "TEST", 1557, 1563], ["CTGCGC", "TEST", 1566, 1572], ["CCGCCACAT", "TEST", 1575, 1584], ["TCGCCACGT", "TEST", 1587, 1596], ["TCGTCACGT", "TEST", 1599, 1608], ["CCTCCACAT", "TEST", 1611, 1620], ["CTCCCACAC", "TEST", 1623, 1632], ["CTGCCACAC", "TEST", 1635, 1644], ["CTGCCACGC", "TEST", 1647, 1656], ["CTGCCATAC", "TEST", 1659, 1668], ["CTGCTGTAC", "TEST", 1671, 1680], ["CTTCCACAC", "TEST", 1683, 1692], ["CCGCCACAC", "TEST", 1695, 1704], ["CCCGCCACAGT", "TEST", 1707, 1718], ["CTCGCCACGGT", "TEST", 1721, 1732], ["CTCGTCACGGT", "TEST", 1735, 1746], ["TTCGTCACGTT", "TEST", 1749, 1760], ["CCCTCCACAGT", "TEST", 1763, 1774], ["CCTCCCACAGC", "TEST", 1777, 1788], ["CCTGCCACAGC", "TEST", 1791, 1802], ["CCTGCCACGGC", "TEST", 1805, 1816], ["CCTGCCATAGC", "TEST", 1819, 1830], ["CCTGCTGTAGC", "TEST", 1833, 1844], ["CCTTCCACAGC", "TEST", 1847, 1858], ["CCCGCCACAGC", "TEST", 1861, 1872], ["CCCGCCACAGTGGG", "TEST", 1875, 1889], ["CTCGCCACGGTGGG", "TEST", 1892, 1906], ["CTCGTCACGGTAAC", "TEST", 1909, 1923], ["CTCGTCACGGTGGG", "TEST", 1926, 1940], ["TTCGTCACGTTGGG", "TEST", 1943, 1957], ["CCCTCCACAGTGGG", "TEST", 1960, 1974], ["CCTCCCACAGCGGG", "TEST", 1977, 1991], ["CCTGCCACAGCGGG", "TEST", 1994, 2008], ["CCTGCCACGGCGGG", "TEST", 2011, 2025], ["CCTGCCATAGCGGG", "TEST", 2028, 2042], ["CCTGCTGTAGCGGG", "TEST", 2045, 2059], ["CCTTCCACAGCGGG", "TEST", 2062, 2076], ["CCCGCCACAGCGGG", "TEST", 2079, 2093], ["CTTGTCACGGTGGG", "TEST", 2096, 2110], ["CTCGTCACGTTGGG", "TEST", 2113, 2127], ["TCCTCCACAGTGGG", "TEST", 2130, 2144], ["CTCTTCACGGTGGG", "TEST", 2147, 2161], ["CTCTTCACGGTAAC", "TEST", 2164, 2178], ["CCTGCCGTAGCGGG", "TEST", 2181, 2195], ["CCTGCCACAGTGGG", "TEST", 2198, 2212], ["CCTTCTGTAGCGGG", "TEST", 2215, 2229], ["TTCGTCACGGTGGG", "TEST", 2232, 2246], ["CCCTTCACAGTGGG", "TEST", 2249, 2263], ["CCTGCTGCAGCGGG", "TEST", 2266, 2280], ["CCCGTCACGGTGGG", "TEST", 2283, 2297], ["CCCTCCATAGTGGG", "TEST", 2300, 2314], ["TTCTTCACGTTGGG", "TEST", 2317, 2331], ["TCCGTCACAGTGGG q CCCGCCACAGTGGGGene RegionVirus strains", "TREATMENT", 2334, 2389]]]], "d9c8df0cd9723cb145803915ea3adad6a500702c": [["munsystem -sowie die T-Helferzellen und die cytotoxischen T-Lymphocyten, welche gemeinsam das zellul\u00e4re Abwehrsystem repr\u00e4sentieren.", [["munsystem -sowie die T-Helferzellen und die cytotoxischen T-Lymphocyten, welche gemeinsam das zellul\u00e4re Abwehrsystem repr\u00e4sentieren", "SPECIES", 0, 131], ["T", "TEST", 58, 59]]], ["Die Systeme der spezifischen und unspezifischen Immunantwort stehen vor allem \u00fcber die Cytokine, Chemokine und Interferone in engem Kontakt miteinander.", [["Interferone", "CHEMICAL", 111, 122], ["Cytokine", "TREATMENT", 87, 95], ["Chemokine und Interferone", "TREATMENT", 97, 122]]], ["Man wei\u00df, dass Molek\u00fcle mit einer Molekularmasse von weniger als 3-4 kD hierzu meist nicht in der Lage sind.", [["Man", "SPECIES", 0, 3]]], ["Hier nehmen sie als antigenpr\u00e4sentierende Zellen Kontakt mit B-und T-Lymphocyten auf und sind somit entscheidend an der Einleitung der spezifischen Immunantwort beteiligt: Sie aktivieren T-Helfer-Lymphocyten und Makrophagen, steuern das Cytokinmuster der entstehenden T-Helfer-Lymphocyten zu IFN-\u03b3 produzierenden T H 1-Zellen beziehungsweise IL-4 produzierenden T H 2-Zellen, sie leiten die Bildung von cytotoxischen T-Lymphocyten ein und induzieren mittels der T-Zellhilfe die Differenzierung der Plasmazellen zu Antik\u00f6rper-produzierenden B-Lymphocyten.", [["produzierenden B-Lymphocyten", "CELL", 525, 553], ["IFN", "PROTEIN", 292, 295], ["Hier nehmen sie als antigenpr\u00e4sentierende Zellen Kontakt mit B-und T-Lymphocyten auf und sind somit entscheidend an der Einleitung der spezifischen Immunantwort beteiligt: Sie aktivieren T-Helfer-Lymphocyten und Makrophagen, steuern das Cytokinmuster der entstehenden T-Helfer-Lymphocyten zu IFN-\u03b3 produzierenden T H 1-Zellen beziehungsweise IL-4 produzierenden T H 2-Zellen, sie leiten die Bildung von cytotoxischen T-Lymphocyten ein und induzieren mittels der T-Zellhilfe die Differenzierung der Plasmazellen zu Antik\u00f6rper-produzierenden B-Lymphocyten", "SPECIES", 0, 553], ["T", "TEST", 268, 269], ["Helfer", "TEST", 270, 276], ["Lymphocyten", "TEST", 277, 288], ["IFN", "TEST", 292, 295], ["H", "TEST", 315, 316], ["Zellen", "TEST", 319, 325], ["IL", "TEST", 342, 344], ["Zellen", "PROBLEM", 368, 374], ["Lymphocyten", "TREATMENT", 542, 553]]], ["Plasmacytoide und myeloide dendritische Zellen sind damit hoch spezialisiert zur Stimulation der spezifischen Immunantworten und ein wichtiges Bindeglied zwischen der unspezifischen und der spezifischen Abwehr.", [["Zellen sind damit hoch spezialisiert zur Stimulation der spezifischen Immunantworten und ein wichtiges Bindeglied zwischen der unspezifischen und der spezifischen Abwehr", "SPECIES", 40, 209], ["Plasmacytoide", "TREATMENT", 0, 13], ["zur Stimulation", "TREATMENT", 77, 92]]]], "PMC7354007": [["IntroductionCoronavirus disease 2019 (COVID-19) is a respiratory syndrome, amongst a larger family of ribonucleic acid (RNA) viruses, that has infected humans, causing unprecedented numbers of deaths and substantial psychological distress across the globe.1\u20133 COVID-19 emerged in Wuhan, China at the end of 2019 and spread to other countries, leading the World Health Organisation (WHO) to declare COVID-19 a global health emergency of international concern.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["respiratory syndrome", "DISEASE", 53, 73], ["ribonucleic acid", "CHEMICAL", 102, 118], ["deaths", "DISEASE", 193, 199], ["1\u20133 COVID-19", "CHEMICAL", 256, 268], ["ribonucleic acid", "GENE_OR_GENE_PRODUCT", 102, 118], ["humans", "ORGANISM", 152, 158], ["humans", "SPECIES", 152, 158], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["humans", "SPECIES", 152, 158], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["a respiratory syndrome", "PROBLEM", 51, 73], ["ribonucleic acid (RNA) viruses", "PROBLEM", 102, 132], ["substantial psychological distress across the globe", "PROBLEM", 204, 255], ["COVID", "TEST", 260, 265], ["respiratory syndrome", "OBSERVATION", 53, 73], ["infected", "OBSERVATION", 143, 151], ["substantial", "OBSERVATION_MODIFIER", 204, 215], ["psychological distress", "OBSERVATION", 216, 238], ["globe", "ANATOMY", 250, 255]]], ["The WHO emphasised the importance of compliance with infection control standards.4 Not only were the obvious practices of hygiene and use of hygiene equipment, such as facemasks, important but, also, limiting personal contact through social distancing became the gold standard.5,6IntroductionIn response, several countries have implemented decisive measures to contain the spread of the disease, which include the imposition of nationwide lockdowns.", [["infection", "DISEASE", 53, 62], ["infection control standards", "TREATMENT", 53, 80], ["hygiene equipment", "TREATMENT", 141, 158], ["the disease", "PROBLEM", 383, 394], ["nationwide lockdowns", "TREATMENT", 428, 448], ["infection", "OBSERVATION", 53, 62], ["disease", "OBSERVATION", 387, 394]]], ["China was the first country to implement a successful lockdown to prevent the further spread of COVID-19.7 Notwithstanding the resultant mitigation of the pandemic in China, there has been a deterioration in most Chinese residents\u2019 psychological wellbeing under the lockdown.8\u201310 The adverse psychological impact includes acute stress disorder, insomnia, post-traumatic symptoms and depression.11 Moreover, recent evidence reveals that 35% of the Chinese population were psychologically distressed.12IntroductionThe distress caused by COVID-19 is arguably not limited to China because the factors that could lead to this psychological state are common.", [["COVID", "DISEASE", 96, 101], ["acute stress disorder", "DISEASE", 322, 343], ["insomnia", "DISEASE", 345, 353], ["post-traumatic symptoms", "DISEASE", 355, 378], ["depression", "DISEASE", 383, 393], ["distress", "DISEASE", 516, 524], ["COVID-19", "CHEMICAL", 535, 543], ["COVID-19", "CHEMICAL", 535, 543], ["a successful lockdown", "TREATMENT", 41, 62], ["COVID", "TEST", 96, 101], ["a deterioration", "PROBLEM", 189, 204], ["acute stress disorder", "PROBLEM", 322, 343], ["insomnia", "PROBLEM", 345, 353], ["post-traumatic symptoms", "PROBLEM", 355, 378], ["depression", "PROBLEM", 383, 393], ["psychologically distressed", "PROBLEM", 471, 497], ["The distress", "PROBLEM", 512, 524], ["deterioration", "OBSERVATION_MODIFIER", 191, 204], ["acute stress disorder", "OBSERVATION", 322, 343], ["distress", "OBSERVATION", 516, 524]]], ["For instance, the knowledge of coronavirus biology and transmission is still limited, which increases panic due to the uncertainty of its spread.7 In addition, there is a global absence of a vaccine to control COVID-19, leading to unrest about its containment.13 Moreover, globalisation and increased access to information in the current era make such worrying insights relating to uncertainty easily transferable, causing increased psychological distress, including fear and anxiety, amongst the general public.14\u201316IntroductionThe WHO issued a COVID-19 guideline on mental health and psychological distress in an effort to support people\u2019s mental and psychological wellbeing during this outbreak.2 Nevertheless, empirical evidence on the distribution of psychological distress across the public due to COVID-19 remains sparse.", [["panic", "DISEASE", 102, 107], ["anxiety", "DISEASE", 476, 483], ["psychological distress", "DISEASE", 586, 608], ["psychological distress", "DISEASE", 756, 778], ["coronavirus", "ORGANISM", 31, 42], ["people", "ORGANISM", 633, 639], ["people", "SPECIES", 633, 639], ["coronavirus biology", "TEST", 31, 50], ["panic", "PROBLEM", 102, 107], ["a vaccine", "TREATMENT", 189, 198], ["COVID", "TEST", 210, 215], ["increased psychological distress", "PROBLEM", 423, 455], ["fear", "PROBLEM", 467, 471], ["anxiety", "PROBLEM", 476, 483], ["psychological distress", "PROBLEM", 586, 608], ["mental and psychological wellbeing", "PROBLEM", 642, 676], ["psychological distress", "PROBLEM", 756, 778], ["COVID", "TEST", 804, 809], ["increased", "OBSERVATION_MODIFIER", 291, 300]]], ["Therefore, this study aims to investigate the impact of COVID-19 on the psychological wellbeing among Saudi adults amid the unprecedented lockdown.", [["COVID-19", "CHEMICAL", 56, 64], ["this study", "TEST", 11, 21], ["COVID", "TEST", 56, 61]]], ["Preventive measures, such as lockdown, disrupt normal life activities, which could generate boredom and stress.", [["boredom", "DISEASE", 92, 99], ["Preventive measures", "TREATMENT", 0, 19]]], ["Moreover, the limited access to outdoor leisure, combined with the uncertainty of an effective remedy to contain the pandemic, could increase distress.", [["increase distress", "PROBLEM", 133, 150], ["increase", "OBSERVATION_MODIFIER", 133, 141], ["distress", "OBSERVATION", 142, 150]]], ["However, these potential negative effects could generate different levels of distress conditional on people\u2019s sociodemographic characteristics.", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["distress", "PROBLEM", 77, 85], ["negative", "OBSERVATION", 25, 33]]], ["For instance, the demand for outdoor activities could be different between older people and the young, while fears relating to the lack of available treatment for the pandemic could also differ depending on whether one works in healthcare services or not.", [["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["available treatment", "TREATMENT", 139, 158]]], ["These issues demand adequate attention and, therefore, the study also examines the association between different sociodemographic characteristics and psychological distress due to COVID-19 using data from the Kingdom of Saudi Arabia (KSA).IntroductionKSA has become a compelling case in understanding how COVID-19 has caused psychological distress amongst health workers and the general public for the following reasons.", [["psychological distress", "DISEASE", 150, 172], ["psychological distress", "DISEASE", 325, 347], ["the study", "TEST", 55, 64], ["psychological distress", "PROBLEM", 150, 172], ["COVID", "TEST", 180, 185], ["psychological distress", "PROBLEM", 325, 347]]], ["First, KSA currently has the largest confirmed number of cases in the Arabian Gulf countries, which means that the likelihood of pressure on the health system and fear of infection, which could cause distress, remain high.", [["infection", "DISEASE", 171, 180], ["pressure on the health system", "PROBLEM", 129, 158], ["infection", "PROBLEM", 171, 180], ["distress", "PROBLEM", 200, 208], ["largest", "OBSERVATION_MODIFIER", 29, 36], ["pressure", "OBSERVATION_MODIFIER", 129, 137], ["infection", "OBSERVATION", 171, 180], ["high", "OBSERVATION_MODIFIER", 217, 221]]], ["Second, despite the potential for increased psychological distress in KSA, no study has been conducted to identify the groups that might be suffering the most in terms of distress due to the pandemic.", [["psychological distress", "DISEASE", 44, 66], ["increased psychological distress", "PROBLEM", 34, 66], ["study", "TEST", 78, 83], ["distress", "PROBLEM", 171, 179], ["the pandemic", "PROBLEM", 187, 199]]], ["Third, the Arabian Gulf region has specific unique characteristics, such as a natural resource-financed health system,17 that would necessitate that the public health response to COVID-19 be different from the rest of the world, hence the demand for special academic attention.", [["COVID", "TEST", 179, 184], ["special academic attention", "TREATMENT", 250, 276]]], ["Finally, as the Arabian Gulf countries have similar backgrounds, culture and religion and are facing similar challenges, this study on KSA could inform policy design to mitigate COVID-19 related distress in the entire region.Study Design and Sample ::: Materials and MethodsThis study uses data from a cross-sectional survey that was conducted in Saudi Arabia from 3 May to 8 May 2020, using a validated self-reported survey.", [["culture", "TEST", 65, 72], ["this study", "TEST", 121, 131], ["COVID", "TEST", 178, 183], ["distress in the entire region", "PROBLEM", 195, 224], ["Methods", "TREATMENT", 267, 274], ["This study", "TEST", 274, 284], ["a cross-sectional survey", "TEST", 300, 324]]], ["The survey used the COVID-19 Peritraumatic Distress Index (CPDI) self-reported questionnaire that was originally employed by a study in China to survey peritraumatic psychological distress during the epidemic.12 The Shanghai Mental Health Centre verified the content validity of the CPDI as fit to be used in collecting the COVID-19 distress information.", [["psychological distress", "DISEASE", 166, 188], ["The survey", "TEST", 0, 10], ["the COVID", "TEST", 16, 25], ["Peritraumatic Distress Index", "PROBLEM", 29, 57], ["peritraumatic psychological distress", "PROBLEM", 152, 188]]], ["The survey then used the Arabic text to administer the study.Study Design and Sample ::: Materials and MethodsData were collected online, using SurveyMonkey, targeting individuals living in KSA.", [["the study", "TEST", 51, 60], ["MethodsData", "TEST", 103, 114], ["SurveyMonkey", "TREATMENT", 144, 156]]], ["The respondents were clearly informed about the study\u2019s aim and objectives and that they were free to withdraw at any time, without giving a reason, and that all information and opinions provided would be anonymous and confidential.Measurement Tool and Data Analysis ::: Materials and MethodsThe questionnaire consisted of two main sections.", [["sections", "ANATOMY", 332, 340], ["the study", "TEST", 44, 53], ["Methods", "TREATMENT", 285, 292]]], ["The first section gathered information on the respondents\u2019 sociodemographic characteristics, including age, gender, marital status, education level, nationality, work status, whether the participants are health workers and, if so, whether they were working on the frontline to face the new coronavirus pandemic.", [["coronavirus", "DISEASE", 290, 301], ["coronavirus", "ORGANISM", 290, 301], ["participants", "SPECIES", 187, 199]]], ["The second section collected information on self-perceived psychological distress in relation to the COVID outbreak.Dependent Variable (Psychological Distress Assessment) ::: Materials and MethodsIn this paper, psychological distress is defined as an unpleasant feeling or emotion that affects a human being\u2019s general functioning and could induce negative feelings of self, others and the environment.18 Participants were asked to respond to 24 questions that had five scaled responses to assess their psychological distress and the responses were used to construct a CPDI.", [["psychological distress", "DISEASE", 59, 81], ["psychological distress", "DISEASE", 211, 233], ["CPDI", "DISEASE", 568, 572], ["human", "ORGANISM", 296, 301], ["human", "SPECIES", 296, 301], ["Participants", "SPECIES", 404, 416], ["human", "SPECIES", 296, 301], ["self-perceived psychological distress", "PROBLEM", 44, 81], ["the COVID outbreak", "PROBLEM", 97, 115], ["Dependent Variable (Psychological Distress", "PROBLEM", 116, 158], ["Methods", "TREATMENT", 189, 196], ["psychological distress", "PROBLEM", 211, 233], ["their psychological distress", "PROBLEM", 496, 524], ["Variable", "OBSERVATION_MODIFIER", 126, 134]]], ["The questions included those on the frequency of anxiety, depression, specific phobias, cognitive change, avoidance and compulsive behaviour, physical symptoms and loss of social functioning since the appearance of the COVID-19 pandemic.", [["anxiety", "DISEASE", 49, 56], ["depression", "DISEASE", 58, 68], ["phobias", "DISEASE", 79, 86], ["avoidance and compulsive behaviour", "DISEASE", 106, 140], ["loss of social functioning", "DISEASE", 164, 190], ["anxiety", "PROBLEM", 49, 56], ["depression", "PROBLEM", 58, 68], ["specific phobias", "PROBLEM", 70, 86], ["cognitive change", "PROBLEM", 88, 104], ["compulsive behaviour", "PROBLEM", 120, 140], ["physical symptoms", "PROBLEM", 142, 159], ["loss of social functioning", "PROBLEM", 164, 190], ["the COVID", "TEST", 215, 224], ["pandemic", "PROBLEM", 228, 236]]], ["These questions encompass the diagnostic guidelines for stress disorders and phobias specified in the International Classification of Diseases, 11th Revision.12Dependent Variable (Psychological Distress Assessment) ::: Materials and MethodsTo construct the CPDI, we summed the codes of the responses of the 24 questions, meaning that the respondents\u2019 scores could range from 0 to 96.", [["stress disorders", "DISEASE", 56, 72], ["phobias", "DISEASE", 77, 84], ["stress disorders", "PROBLEM", 56, 72], ["phobias", "PROBLEM", 77, 84], ["11th Revision", "TREATMENT", 144, 157]]], ["A base count of 4 was added to all respondents to enable the maximum of the standard 100 for a CPDI.", [["CPDI", "DISEASE", 95, 99], ["A base count", "TEST", 0, 12], ["a CPDI", "TREATMENT", 93, 99]]], ["The addition of the base, which was also done in a recent study on the effects of COVID-19 on distress in China,12 allows our results to be compared to previous studies that used 100 by increasing the base without changing the gradient of the effects.", [["COVID-19", "CHEMICAL", 82, 90], ["COVID-19", "CHEMICAL", 82, 90], ["a recent study", "TEST", 49, 63], ["COVID", "TEST", 82, 87], ["distress", "PROBLEM", 94, 102], ["previous studies", "TEST", 152, 168], ["base", "ANATOMY_MODIFIER", 20, 24], ["base", "ANATOMY_MODIFIER", 201, 205]]], ["The CPDI was then classified to obtain the levels of distress, as follows: a CPDI score between 0 and 28 indicates normal levels, a CPDI score between 29 and 52 indicates that the participant is mildly distressed and a CPDI score between 53 and 100 means that the respondent is severely distressed.", [["participant", "SPECIES", 180, 191], ["distress", "PROBLEM", 53, 61], ["a CPDI score", "TEST", 75, 87], ["a CPDI score", "TEST", 130, 142], ["mildly distressed", "PROBLEM", 195, 212], ["a CPDI score", "TEST", 217, 229], ["severely distressed", "PROBLEM", 278, 297], ["normal", "OBSERVATION", 115, 121], ["mildly", "OBSERVATION_MODIFIER", 195, 201], ["distressed", "OBSERVATION", 202, 212], ["severely", "OBSERVATION_MODIFIER", 278, 286], ["distressed", "OBSERVATION", 287, 297]]], ["Items were evaluated for internal reliability, using Cronbach\u2019s \u03b1.", [["internal reliability", "TEST", 25, 45]]], ["The Cronbach\u2019s alpha coefficient was 0.91 (p<0.001), indicating internal reliability.19Independent Variables ::: Materials and MethodsFor the sociodemographic variables, the age variable was divided into categories: 18 to 29 (reference category), 30 to 39, 40 to 49, 50 to 59 and 60 or above.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 4, 20], ["The Cronbach\u2019s alpha coefficient", "TEST", 0, 32], ["internal reliability", "OBSERVATION", 64, 84]]], ["Nationality was coded as a dummy variable, with 1 for Saudi national and 0 for non-Saudi.", [["non-Saudi", "PROBLEM", 79, 88]]], ["Frontline health worker against COVID-19 was also coded as 1 for participants who were frontline health workers and 0 for otherwise.Statistical Analysis ::: Materials and MethodsDescriptive statistics were used to analyse the general data.", [["participants", "SPECIES", 65, 77]]], ["The respondents\u2019 characteristics were classified by their psychological distress through the three distress categories and their mean and percentage composition presented per distress group.", [["their psychological distress", "PROBLEM", 52, 80], ["the three distress categories", "PROBLEM", 89, 118]]], ["The study used a statistical model corrected for multiple comparisons by the Bonferroni procedure, which divides the 0.05 p-value by the number of comparisons to minimise type 1 errors.20 The method allows us to present the statistically significant differences across the three distress categories with respective p-values depicted.Statistical Analysis ::: Materials and MethodsMultinomial logistic regressions were used with CPDI as the dependent variable to examine the factors associated with normal, mild and severe distress due to COVID-19, while the sociodemographic characteristics are the independent variables.", [["The study", "TEST", 0, 9], ["the Bonferroni procedure", "TREATMENT", 73, 97], ["type 1 errors", "PROBLEM", 171, 184], ["respective p-values", "TEST", 304, 323], ["Materials", "TREATMENT", 358, 367], ["MethodsMultinomial logistic regressions", "TREATMENT", 372, 411], ["CPDI", "TREATMENT", 427, 431], ["mild and severe distress", "PROBLEM", 505, 529], ["COVID", "TEST", 537, 542], ["normal", "OBSERVATION", 497, 503], ["mild", "OBSERVATION_MODIFIER", 505, 509], ["severe", "OBSERVATION_MODIFIER", 514, 520], ["distress", "OBSERVATION", 521, 529]]], ["The CPDI is coded with three groups \u20131 for normal distress (reference category), 2 for mild distress and 3 for severe distress.", [["mild distress", "PROBLEM", 87, 100], ["severe distress", "PROBLEM", 111, 126], ["mild", "OBSERVATION_MODIFIER", 87, 91], ["distress", "OBSERVATION", 92, 100], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["distress", "OBSERVATION", 118, 126]]], ["Since the logistic coefficients are composite numbers, we obtained the marginal effects using the first derivative method and all the results presented in the paper are the actual probabilities.", [["the first derivative method", "TREATMENT", 94, 121]]], ["Knowing that the degree of exposure to COVID-19 could generate variations in the distress levels, the study, besides presenting the full sample probabilities, includes a subsample analysis that looks only at health workers.", [["COVID-19", "CHEMICAL", 39, 47], ["COVID-19", "CHEMICAL", 39, 47], ["COVID", "TEST", 39, 44], ["the distress levels", "PROBLEM", 77, 96], ["the study", "TEST", 98, 107], ["a subsample analysis", "TEST", 168, 188]]], ["All analyses were conducted using STATA 15.1 software (StataCorp LP, Texas, USA).Ethical Approval ::: Materials and MethodsAll procedures performed in this study involving human participants complied with the institutional and/or national research committee ethical standards and the 1964 Helsinki declaration, and subsequent amendments, or equivalent ethical standards.", [["human", "ORGANISM", 172, 177], ["human", "SPECIES", 172, 177], ["participants", "SPECIES", 178, 190], ["human", "SPECIES", 172, 177], ["All analyses", "TEST", 0, 12], ["STATA", "TEST", 34, 39], ["All procedures", "TEST", 123, 137], ["this study", "TEST", 151, 161]]], ["The study was designed and conducted in accordance with the ethical principles established by King Abdulaziz University and, therefore, ethical approval was obtained from the Biomedical Ethics Research Committee, Faculty of Medicine, King Abdulaziz University (Ref-228-20).Sociodemographic Characteristics and Distress Level ::: ResultsTable 1 shows the results of the descriptive analysis.", [["The study", "TEST", 0, 9], ["the descriptive analysis", "TEST", 365, 389]]], ["In total, 3036 participants, including 950 (31.35%) health workers, of which 449 (14.8%) were frontline health workers, with the remaining 2086 (68.7%) being the general public, participated in the study from the 13 administrative regions in KSA.", [["participants", "SPECIES", 15, 27], ["the study", "TEST", 194, 203]]], ["Of the participants, 30.9% were aged between 18 and 29 years, 50.1% were males and 62.7% were married.", [["participants", "SPECIES", 7, 19]]], ["In terms of education, 26% of the participants were educated at the high school level or below, while 54.3% had completed college or university degrees and 19.6% had completed a postgraduate degree.", [["participants", "ORGANISM", 34, 46], ["participants", "SPECIES", 34, 46]]]], "0cb18e05f18c2e8c65b88afa2da2e7886c6c9089": [["INTRODUCTIONCurrently, the world is facing an ongoing pandemic of coronavirus disease 2019 (COVID- 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["coronavirus disease", "DISEASE", 66, 85], ["COVID- 19", "CHEMICAL", 92, 101], ["acute respiratory syndrome coronavirus", "DISEASE", 120, 158], ["coronavirus", "ORGANISM", 66, 77], ["SARS-CoV-2", "ORGANISM", 162, 172], ["severe acute respiratory syndrome coronavirus", "SPECIES", 113, 158], ["SARS-CoV-2", "SPECIES", 162, 172], ["coronavirus disease", "PROBLEM", 66, 85], ["COVID", "TEST", 92, 97], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 113, 158], ["CoV", "TEST", 167, 170], ["coronavirus disease", "OBSERVATION", 66, 85], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["respiratory syndrome", "OBSERVATION", 126, 146]]], ["As of May 1, 2020, in Italy, the rapid spread of the virus had caused 204,576 confirmed cases (including 21,338 health care workers) and 26,049 deaths; the median age was 62 years (1) .", [["deaths", "DISEASE", 144, 150], ["the virus", "PROBLEM", 49, 58]]], ["Very limited data are available for patients with cancer during the COVID-19 pandemic.", [["cancer", "ANATOMY", 50, 56], ["cancer", "DISEASE", 50, 56], ["patients", "ORGANISM", 36, 44], ["cancer", "CANCER", 50, 56], ["patients", "SPECIES", 36, 44], ["cancer", "PROBLEM", 50, 56], ["the COVID", "TEST", 64, 73], ["pandemic", "PROBLEM", 77, 85]]], ["Data on comorbidities from the Istituto Superiore di Sanit\u00e0 on April 23, 2020, described the characteristics of 2,041 patients with COVID-19 dying in the hospital for whom it was possible to analyze the clinical charts.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126]]], ["Overall, only 3.6% of the sample presented with no comorbidities, 14.4% with a single comorbidity, 21.1% with two, and 60.9% with three or more comorbidities.", [["the sample", "TEST", 22, 32], ["comorbidities", "PROBLEM", 51, 64], ["a single comorbidity", "TEST", 77, 97], ["no", "UNCERTAINTY", 48, 50]]], ["In this series of fatal COVID-19 cases, 328 patients (16.1%) had been diagnosed with active cancer (1) .", [["cancer", "ANATOMY", 92, 98], ["COVID", "DISEASE", 24, 29], ["cancer", "DISEASE", 92, 98], ["patients", "ORGANISM", 44, 52], ["cancer", "CANCER", 92, 98], ["patients", "SPECIES", 44, 52], ["fatal COVID", "TEST", 18, 29], ["active cancer", "PROBLEM", 85, 98], ["active", "OBSERVATION_MODIFIER", 85, 91], ["cancer", "OBSERVATION", 92, 98]]], ["This suggests bolstering telemedicine services, reducing clinic visits, and switching to subcutaneous or oral therapies, rather than intravenous ones, when possible (2) .", [["subcutaneous", "ANATOMY", 89, 101], ["oral", "ANATOMY", 105, 109], ["intravenous", "ANATOMY", 133, 144], ["oral", "ORGANISM_SUBDIVISION", 105, 109], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 144], ["subcutaneous", "TREATMENT", 89, 101], ["oral therapies", "TREATMENT", 105, 119], ["intravenous ones", "TREATMENT", 133, 149]]], ["There is also advice on supporting patients and infection control.", [["infection", "DISEASE", 48, 57], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["infection control", "TREATMENT", 48, 65], ["infection", "OBSERVATION", 48, 57]]], ["Here, we report how several Italian and American cancer centers have reorganized their health care systems and updated their recommendations for testing patients with cancer, also identifying and discussing future research strategies.CORONAVIRUS DISEASE 19 TRIAGE TESTS FOR PATIENTS WITH CANCER: THE MOLECULAR BIOLOGIST PERSPECTIVEAt University Federico II in Naples, the triage of an asymptomatic patient with cancer initially included a lateral flow chromatographic immunoassay (LFIA) for the qualitative detection of immunoglobulin (Ig)G and IgM antibodies against SARS-CoV-2 in fingerstick whole-blood specimens.", [["cancer", "ANATOMY", 49, 55], ["cancer", "ANATOMY", 167, 173], ["cancer", "ANATOMY", 411, 417], ["whole-blood specimens", "ANATOMY", 594, 615], ["cancer", "DISEASE", 49, 55], ["cancer", "DISEASE", 167, 173], ["cancer", "DISEASE", 411, 417], ["cancer", "CANCER", 49, 55], ["patients", "ORGANISM", 153, 161], ["cancer", "CANCER", 167, 173], ["patient", "ORGANISM", 398, 405], ["cancer", "CANCER", 411, 417], ["immunoglobulin (Ig)G", "GENE_OR_GENE_PRODUCT", 520, 540], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 568, 578], ["fingerstick", "ORGANISM", 582, 593], ["blood specimens", "ORGANISM_SUBSTANCE", 600, 615], ["immunoglobulin (Ig)G", "PROTEIN", 520, 540], ["IgM antibodies", "PROTEIN", 545, 559], ["patients", "SPECIES", 153, 161], ["patient", "SPECIES", 398, 405], ["SARS-CoV", "SPECIES", 568, 576], ["cancer", "PROBLEM", 167, 173], ["research strategies", "TREATMENT", 214, 233], ["CORONAVIRUS DISEASE", "PROBLEM", 234, 253], ["cancer", "PROBLEM", 411, 417], ["a lateral flow chromatographic immunoassay", "TEST", 437, 479], ["immunoglobulin", "TEST", 520, 534], ["Ig", "TEST", 536, 538], ["G", "TEST", 539, 540], ["IgM antibodies", "TEST", 545, 559], ["SARS", "TEST", 568, 572], ["CoV", "TEST", 573, 576], ["fingerstick", "TEST", 582, 593], ["blood specimens", "TEST", 600, 615], ["cancer", "OBSERVATION", 411, 417]]], ["LFIA positivity for IgM or IgG in symptomatic patients was further assessed via nasopharyngeal swabs and tested by realtime polymerase chain reaction (RT-PCR) for SARS-CoV-2 (Figure 1) .", [["nasopharyngeal swabs", "ANATOMY", 80, 100], ["LFIA", "GENE_OR_GENE_PRODUCT", 0, 4], ["IgM", "GENE_OR_GENE_PRODUCT", 20, 23], ["IgG", "GENE_OR_GENE_PRODUCT", 27, 30], ["patients", "ORGANISM", 46, 54], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 80, 100], ["LFIA", "PROTEIN", 0, 4], ["IgM", "PROTEIN", 20, 23], ["IgG", "PROTEIN", 27, 30], ["patients", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 163, 171], ["LFIA positivity", "TEST", 0, 15], ["IgM", "TEST", 20, 23], ["IgG in symptomatic patients", "PROBLEM", 27, 54], ["nasopharyngeal swabs", "TEST", 80, 100], ["realtime polymerase chain reaction", "TEST", 115, 149], ["RT-PCR", "TEST", 151, 157], ["SARS", "PROBLEM", 163, 167], ["CoV", "TEST", 168, 171]]], ["The rapid LFIA test for IgM and IgG can complement the RT-PCR test and can be helpful, especially during the early phase of infection (3) .", [["infection", "DISEASE", 124, 133], ["IgM", "GENE_OR_GENE_PRODUCT", 24, 27], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["LFIA", "PROTEIN", 10, 14], ["IgM", "PROTEIN", 24, 27], ["IgG", "PROTEIN", 32, 35], ["The rapid LFIA test", "TEST", 0, 19], ["IgM", "TEST", 24, 27], ["IgG", "TEST", 32, 35], ["the RT-PCR test", "TEST", 51, 66], ["infection", "PROBLEM", 124, 133], ["infection", "OBSERVATION", 124, 133]]], ["Rapid antigen tests can theoretically provide the advantage of quicker time to results and low-cost detection but are likely to suffer from poor sensitivity (4-6).", [["Rapid antigen tests", "TEST", 0, 19], ["low-cost detection", "PROBLEM", 91, 109], ["poor sensitivity", "PROBLEM", 140, 156]]], ["Recent reports from many European countries suggest that most of the rapid tests for COVID-19 did not show good sensitivity and did not detect over 70% of COVID-19 cases (7, 8) .", [["the rapid tests", "TEST", 65, 80], ["COVID", "TEST", 85, 90], ["COVID", "TEST", 155, 160]]], ["Collectively, data from the literature indicate that the COVID-19 IgM/IgG LFIA rapid test is not recommended for the triage of patients with suspected COVID-19.", [["COVID-19", "CHEMICAL", 151, 159], ["COVID-19", "GENE_OR_GENE_PRODUCT", 57, 65], ["IgM", "GENE_OR_GENE_PRODUCT", 66, 69], ["IgG", "GENE_OR_GENE_PRODUCT", 70, 73], ["patients", "ORGANISM", 127, 135], ["COVID", "PROTEIN", 57, 62], ["IgM", "PROTEIN", 66, 69], ["IgG", "PROTEIN", 70, 73], ["patients", "SPECIES", 127, 135], ["the COVID", "TEST", 53, 62], ["IgM/IgG LFIA rapid test", "TEST", 66, 89], ["COVID", "TEST", 151, 156]]], ["Nevertheless, Long et al. (9) recently demonstrated that IgG antibodies were detected in 100% of COVID-19 patients and that both IgM and IgG reached a plateau simultaneously or closely within 6 days after seroconversion.", [["IgG antibodies", "GENE_OR_GENE_PRODUCT", 57, 71], ["patients", "ORGANISM", 106, 114], ["IgM", "GENE_OR_GENE_PRODUCT", 129, 132], ["IgG", "GENE_OR_GENE_PRODUCT", 137, 140], ["IgG antibodies", "PROTEIN", 57, 71], ["IgM", "PROTEIN", 129, 132], ["IgG", "PROTEIN", 137, 140], ["patients", "SPECIES", 106, 114], ["IgG antibodies", "TEST", 57, 71], ["COVID", "TEST", 97, 102], ["IgM", "TEST", 129, 132], ["IgG", "TEST", 137, 140], ["seroconversion", "PROBLEM", 205, 219]]], ["On this basis, serological tests may facilitate the identification of asymptomatic individuals infected with SARS-CoV-2.", [["SARS", "DISEASE", 109, 113], ["SARS-CoV-2", "ORGANISM", 109, 119], ["SARS-CoV", "SPECIES", 109, 117], ["serological tests", "TEST", 15, 32], ["asymptomatic individuals", "PROBLEM", 70, 94], ["CoV", "TEST", 114, 117]]], ["Therefore, a good serological test could be considered a very precious tool in COVID-19 triage in patients with cancer requiring active treatment.", [["cancer", "ANATOMY", 112, 118], ["cancer", "DISEASE", 112, 118], ["patients", "ORGANISM", 98, 106], ["cancer", "CANCER", 112, 118], ["patients", "SPECIES", 98, 106], ["a good serological test", "TEST", 11, 34], ["COVID", "TEST", 79, 84], ["cancer", "PROBLEM", 112, 118], ["active treatment", "TREATMENT", 129, 145], ["cancer", "OBSERVATION", 112, 118]]], ["Chemiluminescence immunoassay (CLIA) has an exciting potential, running on an automated chemiluminescence analyzer with a throughput of about 50 tests/h for the detection of IgG and IgM in about 30 min (10, 11) .", [["IgG", "GENE_OR_GENE_PRODUCT", 174, 177], ["IgM", "GENE_OR_GENE_PRODUCT", 182, 185], ["IgG", "PROTEIN", 174, 177], ["IgM", "PROTEIN", 182, 185], ["Chemiluminescence immunoassay", "TEST", 0, 29], ["an automated chemiluminescence analyzer", "TEST", 75, 114], ["the detection", "TEST", 157, 170], ["IgG", "TEST", 174, 177], ["IgM", "TEST", 182, 185]]], ["Compared with rapid LFIA tests, the advantages of automated CLIA analyzers-based COVID-19 assays include not only the very high throughput of samples that can be analyzed but also the ability to perform tests for other biomarkers, such as C-reactive protein (CRP), which also needs to be monitored in COVID-19 suspects (12) .", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 239, 257], ["CRP", "GENE_OR_GENE_PRODUCT", 259, 262], ["C-reactive protein", "PROTEIN", 239, 257], ["CRP", "PROTEIN", 259, 262], ["rapid LFIA tests", "TEST", 14, 30], ["automated CLIA analyzers", "TEST", 50, 74], ["based COVID", "TEST", 75, 86], ["tests", "TEST", 203, 208], ["other biomarkers", "TEST", 213, 229], ["CRP", "TEST", 259, 262], ["COVID", "TEST", 301, 306]]], ["Since CLIAs for IgM and IgG in venous blood were available at Federico II University, the approach changed as follows: (a) asymptomatic individuals underwent serological testing for IgG and/or IgM anti-SARS-CoV-2; and in case of positivity, RT-PCR for SARS-CoV-2 would be performed in respiratory tract specimens collected by nasopharyngeal swabs and (b) symptomatic individuals underwent nasopharyngeal swab collection and rapid RT-PCR for SARS-CoV-2 detection (13, 14) available at our university hospital.ETHICAL DILEMMAS AND CLINICAL CHALLENGES: THE ONCOLOGIST'S PERSPECTIVECancer patients are more likely to develop COVID-19, and cancer is associated with a more severe course of the disease (15); therefore, novel strategies to contain SARS-CoV-2 spreading among patients with cancer represent a compelling need in the current pandemic scenario.ETHICAL DILEMMAS AND CLINICAL CHALLENGES: THE ONCOLOGIST'S PERSPECTIVEOne approach is to assess the feasibility, on a case-by-case basis, to postpone scheduled office visits of patients who are neither on active therapy nor on oral antineoplastic medication.", [["venous blood", "ANATOMY", 31, 43], ["respiratory tract specimens", "ANATOMY", 285, 312], ["nasopharyngeal swabs", "ANATOMY", 326, 346], ["nasopharyngeal swab", "ANATOMY", 389, 408], ["cancer", "ANATOMY", 635, 641], ["cancer", "ANATOMY", 783, 789], ["oral", "ANATOMY", 1078, 1082], ["COVID", "DISEASE", 621, 626], ["cancer", "DISEASE", 635, 641], ["SARS", "DISEASE", 742, 746], ["cancer", "DISEASE", 783, 789], ["CLIAs", "GENE_OR_GENE_PRODUCT", 6, 11], ["IgM", "GENE_OR_GENE_PRODUCT", 16, 19], ["IgG", "GENE_OR_GENE_PRODUCT", 24, 27], ["venous blood", "ORGANISM_SUBSTANCE", 31, 43], ["individuals", "ORGANISM", 136, 147], ["IgG", "GENE_OR_GENE_PRODUCT", 182, 185], ["SARS-CoV-2", "ORGANISM", 252, 262], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 326, 346], ["individuals", "ORGANISM", 367, 378], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 389, 408], ["patients", "ORGANISM", 585, 593], ["cancer", "CANCER", 635, 641], ["SARS-CoV-2", "ORGANISM", 742, 752], ["patients", "ORGANISM", 769, 777], ["cancer", "CANCER", 783, 789], ["patients", "ORGANISM", 1028, 1036], ["oral", "ORGANISM_SUBDIVISION", 1078, 1082], ["CLIAs", "PROTEIN", 6, 11], ["IgM", "PROTEIN", 16, 19], ["IgG", "PROTEIN", 24, 27], ["IgG", "PROTEIN", 182, 185], ["IgM", "PROTEIN", 193, 196], ["patients", "SPECIES", 585, 593], ["patients", "SPECIES", 769, 777], ["patients", "SPECIES", 1028, 1036], ["SARS-CoV", "SPECIES", 252, 260], ["SARS-CoV", "SPECIES", 441, 449], ["CLIAs", "TEST", 6, 11], ["IgM", "TEST", 16, 19], ["IgG in venous blood", "TEST", 24, 43], ["serological testing", "TEST", 158, 177], ["IgG", "TEST", 182, 185], ["IgM anti-SARS", "TEST", 193, 206], ["CoV", "TEST", 207, 210], ["positivity", "PROBLEM", 229, 239], ["RT", "TEST", 241, 243], ["PCR", "TEST", 244, 247], ["SARS", "PROBLEM", 252, 256], ["CoV", "TEST", 257, 260], ["respiratory tract specimens", "TEST", 285, 312], ["nasopharyngeal swabs", "TEST", 326, 346], ["symptomatic individuals", "PROBLEM", 355, 378], ["nasopharyngeal swab collection", "TEST", 389, 419], ["rapid RT-PCR", "TEST", 424, 436], ["SARS", "PROBLEM", 441, 445], ["CoV", "TEST", 446, 449], ["COVID", "TEST", 621, 626], ["cancer", "PROBLEM", 635, 641], ["the disease", "PROBLEM", 685, 696], ["SARS", "PROBLEM", 742, 746], ["cancer", "PROBLEM", 783, 789], ["active therapy", "TREATMENT", 1056, 1070], ["oral antineoplastic medication", "TREATMENT", 1078, 1108], ["venous", "ANATOMY", 31, 37], ["respiratory tract", "ANATOMY", 285, 302], ["nasopharyngeal", "ANATOMY", 326, 340], ["nasopharyngeal", "ANATOMY", 389, 403], ["cancer", "OBSERVATION", 635, 641], ["more severe", "OBSERVATION_MODIFIER", 663, 674]]], ["The use of telephone, e-mail, or commercially available instant messaging applications may allow the treating oncologist to assess the reliability of referred symptoms and evaluate the results of prescribed tests on the grounds of the patient's cancer history.", [["cancer", "ANATOMY", 245, 251], ["cancer", "DISEASE", 245, 251], ["patient", "ORGANISM", 235, 242], ["cancer", "CANCER", 245, 251], ["patient", "SPECIES", 235, 242], ["referred symptoms", "PROBLEM", 150, 167], ["prescribed tests", "TEST", 196, 212], ["cancer", "OBSERVATION", 245, 251]]], ["Although digital technology has evolved to enable the transfer of hundreds of megabytes of data, as it is the case for computed tomography or magnetic resonance images using freely available online services, it would be more appropriate if dedicated digital platforms could be provided by health care providers along with standardized procedures in order to facilitate the process, protect privacy, and preserve data integrity.", [["computed tomography", "TEST", 119, 138], ["magnetic resonance images", "TEST", 142, 167], ["standardized procedures", "TREATMENT", 322, 345]]], ["The initial evaluation of patients before they are admitted to the medical oncology ward is mandatory to identify those with a strong suspicion of being infected with SARS-CoV-2, who should first undergo nasal swab collection and can only be admitted after COVID-19 has been ruled out.", [["nasal swab", "ANATOMY", 204, 214], ["SARS", "DISEASE", 167, 171], ["COVID-19", "CHEMICAL", 257, 265], ["COVID-19", "CHEMICAL", 257, 265], ["patients", "ORGANISM", 26, 34], ["SARS-CoV-2", "ORGANISM", 167, 177], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 204, 214], ["patients", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 167, 175], ["The initial evaluation", "TEST", 0, 22], ["nasal swab collection", "PROBLEM", 204, 225], ["COVID", "TEST", 257, 262], ["infected", "OBSERVATION", 153, 161], ["nasal", "ANATOMY", 204, 209], ["swab", "OBSERVATION", 210, 214]]], ["The benefits associated with the use of rapid screening tests are hampered by their low accuracy, which carries potential harm associated with the performance of unnecessary tests and a potential delay in the delivery of antineoplastic therapy in false-positive patients, who have to wait for RT-PCR testing before they can be admitted.ETHICAL DILEMMAS AND CLINICAL CHALLENGES: THE ONCOLOGIST'S PERSPECTIVESince most patients infected with SARS-CoV-2 are asymptomatic, the diagnosis of asymptomatic disease poses unresolved clinical challenges.", [["antineoplastic", "ANATOMY", 221, 235], ["SARS", "DISEASE", 440, 444], ["antineoplastic", "CANCER", 221, 235], ["patients", "ORGANISM", 262, 270], ["patients", "ORGANISM", 417, 425], ["SARS-CoV-2", "ORGANISM", 440, 450], ["patients", "SPECIES", 262, 270], ["patients", "SPECIES", 417, 425], ["SARS-CoV", "SPECIES", 440, 448], ["rapid screening tests", "TEST", 40, 61], ["unnecessary tests", "TEST", 162, 179], ["antineoplastic therapy", "TREATMENT", 221, 243], ["RT-PCR testing", "TEST", 293, 307], ["SARS", "PROBLEM", 440, 444], ["asymptomatic", "PROBLEM", 455, 467], ["asymptomatic disease", "PROBLEM", 486, 506], ["asymptomatic", "OBSERVATION_MODIFIER", 486, 498], ["disease", "OBSERVATION", 499, 506]]], ["Although most patients with severe COVID-19 are not eligible to receive antineoplastic therapy, the optimal management of cancer patients with asymptomatic or mild COVID-19 is debatable.", [["cancer", "ANATOMY", 122, 128], ["cancer", "DISEASE", 122, 128], ["patients", "ORGANISM", 14, 22], ["cancer", "CANCER", 122, 128], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 129, 137], ["severe COVID", "PROBLEM", 28, 40], ["antineoplastic therapy", "TREATMENT", 72, 94], ["cancer", "PROBLEM", 122, 128], ["asymptomatic or mild COVID", "PROBLEM", 143, 169], ["cancer", "OBSERVATION", 122, 128], ["mild", "OBSERVATION_MODIFIER", 159, 163]]], ["Immunotherapy with anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PDL-1) agents may facilitate the progression to severe COVID-19 in asymptomatic SARS-CoV-2 patients according to the so-called \"cytokine storm\" theory (16) .", [["COVID", "DISEASE", 150, 155], ["SARS", "DISEASE", 175, 179], ["COVID-19", "CHEMICAL", 150, 158], ["anti-programmed cell death protein 1", "GENE_OR_GENE_PRODUCT", 19, 55], ["PD-1", "GENE_OR_GENE_PRODUCT", 57, 61], ["programmed cell death ligand 1", "GENE_OR_GENE_PRODUCT", 63, 93], ["PDL-1", "GENE_OR_GENE_PRODUCT", 95, 100], ["SARS-CoV", "ORGANISM", 175, 183], ["patients", "ORGANISM", 186, 194], ["cytokine", "PROTEIN", 223, 231], ["patients", "SPECIES", 186, 194], ["Immunotherapy", "TREATMENT", 0, 13], ["anti-programmed cell death protein", "TEST", 19, 53], ["PD", "TEST", 57, 59], ["programmed cell death ligand", "TEST", 63, 91], ["PDL", "TEST", 95, 98], ["agents", "TREATMENT", 102, 108], ["severe COVID", "PROBLEM", 143, 155], ["asymptomatic SARS", "PROBLEM", 162, 179]]], ["However, clinical data seem to show that COVID-19 patients are not at a greater risk of serious adverse events or a more aggressive course of the disease upon treatment with anti-PD-1/PDL-1 monoclonal antibodies (17) .", [["patients", "ORGANISM", 50, 58], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 174, 183], ["PDL-1", "GENE_OR_GENE_PRODUCT", 184, 189], ["anti-PD", "PROTEIN", 174, 181], ["PDL-1 monoclonal antibodies", "PROTEIN", 184, 211], ["patients", "SPECIES", 50, 58], ["clinical data", "TEST", 9, 22], ["COVID", "TEST", 41, 46], ["serious adverse events", "PROBLEM", 88, 110], ["the disease", "PROBLEM", 142, 153], ["anti-PD", "TEST", 174, 181], ["PDL", "TEST", 184, 187], ["monoclonal antibodies", "TEST", 190, 211]]], ["The clinical course of asymptomatic disease in patients with cancer is currently unknown; therefore, the risk of delaying antineoplastic therapy until the patient becomes SARS-CoV-2 negative cannot be accurately estimated, and a decision must be made on a case-by-case basis with the patient's informed consent.ETHICAL DILEMMAS AND CLINICAL CHALLENGES: THE ONCOLOGIST'S PERSPECTIVECompared with outpatients, inpatients must be informed of the additional risk associated with intra-hospital exposure to the virus and accept all procedures required by hospital policies (e.g., nasal swab).", [["cancer", "ANATOMY", 61, 67], ["antineoplastic", "ANATOMY", 122, 136], ["nasal swab", "ANATOMY", 575, 585], ["cancer", "DISEASE", 61, 67], ["SARS", "DISEASE", 171, 175], ["patients", "ORGANISM", 47, 55], ["cancer", "CANCER", 61, 67], ["antineoplastic", "CANCER", 122, 136], ["patient", "ORGANISM", 155, 162], ["SARS-CoV-2", "ORGANISM", 171, 181], ["patient", "ORGANISM", 284, 291], ["outpatients", "ORGANISM", 395, 406], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 575, 585], ["patients", "SPECIES", 47, 55], ["patient", "SPECIES", 155, 162], ["patient", "SPECIES", 284, 291], ["asymptomatic disease", "PROBLEM", 23, 43], ["cancer", "PROBLEM", 61, 67], ["antineoplastic therapy", "TREATMENT", 122, 144], ["SARS", "PROBLEM", 171, 175], ["CoV", "TEST", 176, 179], ["the virus", "TREATMENT", 502, 511], ["all procedures", "TREATMENT", 523, 537], ["nasal swab", "TEST", 575, 585], ["asymptomatic", "OBSERVATION_MODIFIER", 23, 35], ["disease", "OBSERVATION", 36, 43], ["cancer", "OBSERVATION", 61, 67]]], ["During the pandemic, patients with symptoms that may be associated with COVID-19 should undergo testing even if a more likely cause is identified (e.g., fever in neutropenic patients should prompt nasal swab collection, as well as cough in patients with interstitial pneumonia possibly associated with antineoplastic medication).", [["nasal swab", "ANATOMY", 197, 207], ["interstitial", "ANATOMY", 254, 266], ["antineoplastic", "ANATOMY", 302, 316], ["fever", "DISEASE", 153, 158], ["neutropenic", "DISEASE", 162, 173], ["cough", "DISEASE", 231, 236], ["interstitial pneumonia", "DISEASE", 254, 276], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 174, 182], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 197, 207], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 240, 248], ["symptoms", "PROBLEM", 35, 43], ["COVID", "TEST", 72, 77], ["testing", "TEST", 96, 103], ["fever", "PROBLEM", 153, 158], ["prompt nasal swab collection", "PROBLEM", 190, 218], ["cough", "PROBLEM", 231, 236], ["interstitial pneumonia", "PROBLEM", 254, 276], ["antineoplastic medication", "TREATMENT", 302, 327], ["interstitial", "ANATOMY_MODIFIER", 254, 266], ["pneumonia", "OBSERVATION", 267, 276]]], ["At admission, patients should consent that any refusal to undergo SARS-CoV-2 testing, if deemed necessary by the hospital staff, would prompt immediate discharge or transfer to another ward.ETHICAL DILEMMAS AND CLINICAL CHALLENGES: THE ONCOLOGIST'S PERSPECTIVEFinally, one important aspect in clinical practice is the implications of physical distancing in the patient-physician relationship.", [["SARS", "DISEASE", 66, 70], ["patients", "ORGANISM", 14, 22], ["patient", "ORGANISM", 361, 368], ["patients", "SPECIES", 14, 22], ["patient", "SPECIES", 361, 368], ["CoV-2 testing", "TEST", 71, 84]]], ["Trust, which is the basis of a successful relationship, can easily be gained in some patients, while it is hard to achieve in others, especially with the current restrictions imposed due to the COVID-19 pandemic.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["the COVID", "TEST", 190, 199], ["pandemic", "PROBLEM", 203, 211]]], ["Furthermore, the use of surgical masks during office visits may make it more difficult to interpret patients' emotions, perplexities, and questions.RESPONSE TO THE CORONAVIRUS DISEASE 2019 PANDEMIC AT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTONStarting in February 2020, several nations implemented various measures to reduce the spread of COVID-19.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["surgical masks", "TREATMENT", 24, 38], ["various measures", "TREATMENT", 314, 330], ["COVID", "TEST", 355, 360], ["CORONAVIRUS DISEASE", "OBSERVATION", 164, 183]]], ["The medical community found itself in a \"state of emergency\" due to the rapid spreading of a pandemic infection caused by a novel coronavirus, SARS-CoV-2.", [["infection", "DISEASE", 102, 111], ["coronavirus", "DISEASE", 130, 141], ["SARS", "DISEASE", 143, 147], ["coronavirus", "ORGANISM", 130, 141], ["SARS-CoV-2", "ORGANISM", 143, 153], ["coronavirus", "SPECIES", 130, 141], ["SARS-CoV", "SPECIES", 143, 151], ["a pandemic infection", "PROBLEM", 91, 111], ["a novel coronavirus", "PROBLEM", 122, 141], ["infection", "OBSERVATION", 102, 111]]], ["With limited prior experience in the management of a pandemic, very limited testing options, and rudimental knowledge of this new viral disease, hospitals around the world designed isolation, testing, and treatment strategies to best protect their patient populations.RESPONSE TO THE CORONAVIRUS DISEASE 2019 PANDEMIC AT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTONAt our tertiary cancer center, current strategies focus on preventing exposure, expanding testing, and implementing hospital-wide algorithms for the supportive care and treatment of affected patients.", [["cancer", "ANATOMY", 395, 401], ["viral disease", "DISEASE", 130, 143], ["cancer", "DISEASE", 395, 401], ["patient", "ORGANISM", 248, 255], ["cancer", "CANCER", 395, 401], ["patients", "ORGANISM", 570, 578], ["patient", "SPECIES", 248, 255], ["patients", "SPECIES", 570, 578], ["the management", "TREATMENT", 33, 47], ["a pandemic", "PROBLEM", 51, 61], ["this new viral disease", "PROBLEM", 121, 143], ["testing", "TEST", 192, 199], ["treatment strategies", "TREATMENT", 205, 225], ["THE CORONAVIRUS DISEASE", "PROBLEM", 280, 303], ["expanding testing", "TEST", 459, 476], ["the supportive care", "TREATMENT", 524, 543], ["treatment", "TREATMENT", 548, 557], ["affected patients", "PROBLEM", 561, 578], ["new", "OBSERVATION_MODIFIER", 126, 129], ["viral disease", "OBSERVATION", 130, 143], ["CORONAVIRUS DISEASE", "OBSERVATION", 284, 303]]], ["These changes have a significant impact on daily clinical activities and the choice of treatments for patients with cancer.Clinical ActivitiesIn order to prevent the spread of the infection, hospital admissions and visits to the clinic are limited to patients in need of emergent and urgent treatments.", [["cancer", "ANATOMY", 116, 122], ["cancer", "DISEASE", 116, 122], ["infection", "DISEASE", 180, 189], ["patients", "ORGANISM", 102, 110], ["cancer", "CANCER", 116, 122], ["patients", "ORGANISM", 251, 259], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 251, 259], ["treatments", "TREATMENT", 87, 97], ["cancer", "PROBLEM", 116, 122], ["the infection", "PROBLEM", 176, 189], ["emergent and urgent treatments", "TREATMENT", 271, 301], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["impact", "OBSERVATION_MODIFIER", 33, 39], ["cancer", "OBSERVATION", 116, 122], ["infection", "OBSERVATION", 180, 189]]], ["Clinical areas are made accessible only to essential clinical personnel; in-person appointments are confirmed only for patients who require initial evaluation for an urgent or emergent cancer diagnosis and for patients who need to continue life-saving ongoing cancer therapies.", [["cancer", "ANATOMY", 185, 191], ["cancer", "ANATOMY", 260, 266], ["cancer", "DISEASE", 185, 191], ["cancer", "DISEASE", 260, 266], ["patients", "ORGANISM", 119, 127], ["cancer", "CANCER", 185, 191], ["patients", "ORGANISM", 210, 218], ["cancer", "CANCER", 260, 266], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 210, 218], ["initial evaluation", "TEST", 140, 158], ["ongoing cancer therapies", "TREATMENT", 252, 276], ["cancer", "OBSERVATION", 185, 191], ["cancer", "OBSERVATION", 260, 266]]], ["The remaining patients are assisted by a variety of strategies that include telephone appointments, virtual care visits, and close partnership with oncologists and primary care physicians in the community.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Our center is a research institution, and many patients are receiving treatments within clinical trials.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["treatments", "TREATMENT", 70, 80]]], ["In compliance with the regulatory authorities, each clinical study implemented a plan to monitor enrolled participants to ensure safety and to obtain the clinical information to be able to continue to evaluate the investigated intervention activity.Clinical ActivitiesWe invested a significant effort in educating our patients regarding the risk of contracting the SARS-CoV-2 infection.", [["SARS", "DISEASE", 365, 369], ["infection", "DISEASE", 376, 385], ["patients", "ORGANISM", 318, 326], ["SARS-CoV-2", "ORGANISM", 365, 375], ["participants", "SPECIES", 106, 118], ["patients", "SPECIES", 318, 326], ["SARS-CoV-2", "SPECIES", 365, 375], ["each clinical study", "TEST", 47, 66], ["the SARS", "PROBLEM", 361, 369], ["CoV-2 infection", "PROBLEM", 370, 385], ["infection", "OBSERVATION", 376, 385]]], ["All patients received education materials digitally, and additional information was provided in person at the time of clinic visits.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["person", "SPECIES", 96, 102], ["education materials", "TREATMENT", 22, 41]]], ["Patients with cancer are aware of being susceptible to infections and are accustomed to taking precautions; therefore, we have seen excellent adherence to our recommendations and a low rate of SARS-CoV-2 positivity in our patient population.Clinical ActivitiesPrior to entering the clinic, all patients (as well as staff) go through an interview process that assesses the presence of symptoms and history of exposure, have a body temperature check, perform hand sanitation, and are provided with a mask.", [["cancer", "ANATOMY", 14, 20], ["body", "ANATOMY", 425, 429], ["hand", "ANATOMY", 457, 461], ["cancer", "DISEASE", 14, 20], ["infections", "DISEASE", 55, 65], ["SARS", "DISEASE", 193, 197], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 14, 20], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 193, 203], ["patient", "ORGANISM", 222, 229], ["patients", "ORGANISM", 294, 302], ["body", "ORGANISM_SUBDIVISION", 425, 429], ["hand", "ORGANISM_SUBDIVISION", 457, 461], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 222, 229], ["patients", "SPECIES", 294, 302], ["cancer", "PROBLEM", 14, 20], ["infections", "PROBLEM", 55, 65], ["SARS", "TEST", 193, 197], ["CoV", "TEST", 198, 201], ["symptoms", "PROBLEM", 384, 392], ["a body temperature check", "TEST", 423, 447], ["hand sanitation", "TREATMENT", 457, 472], ["a mask", "TREATMENT", 496, 502], ["cancer", "OBSERVATION", 14, 20], ["infections", "OBSERVATION", 55, 65]]], ["Patients suspected of having the infection are screened, triaged, evaluated, and treated by dedicated medical teams equipped with appropriate protective gear and kept physically separated from the rest of the patients until their testing results become available.", [["infection", "DISEASE", 33, 42], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 209, 217], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 209, 217], ["the infection", "PROBLEM", 29, 42], ["their testing", "TEST", 224, 237], ["infection", "OBSERVATION", 33, 42]]], ["Patients with positive COVID-19 tests are transferred to a specialized multidisciplinary team.Clinical ActivitiesThe most widely used testing tool at our center has so far been RT-PCR testing for the presence of SARS-CoV-2 in samples obtained through a posterior pharynx nasal swab.", [["samples", "ANATOMY", 226, 233], ["pharynx nasal swab", "ANATOMY", 263, 281], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 212, 222], ["samples", "CANCER", 226, 233], ["pharynx", "ORGAN", 263, 270], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 271, 281], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 212, 220], ["testing tool", "TEST", 134, 146], ["PCR testing", "TEST", 180, 191], ["SARS", "PROBLEM", 212, 216], ["CoV", "TEST", 217, 220], ["a posterior pharynx nasal swab", "TEST", 251, 281], ["posterior", "ANATOMY_MODIFIER", 253, 262], ["pharynx", "ANATOMY", 263, 270], ["nasal swab", "ANATOMY", 271, 281]]], ["Simultaneous testing for SARS-CoV-2 and other common respiratory viruses is routinely performed.", [["respiratory viruses", "DISEASE", 53, 72], ["SARS-CoV-2", "ORGANISM", 25, 35], ["SARS-CoV", "SPECIES", 25, 33], ["Simultaneous testing", "TEST", 0, 20], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["other common respiratory viruses", "PROBLEM", 40, 72], ["common respiratory", "ANATOMY", 46, 64], ["viruses", "OBSERVATION", 65, 72]]], ["Our institution has recently expanded RT-PCR testing to all patients immediately prior to undergoing surgery or other invasive procedures or receiving intensive chemotherapy regimens and cellular therapies.", [["cellular", "ANATOMY", 187, 195], ["patients", "ORGANISM", 60, 68], ["cellular", "CELL", 187, 195], ["patients", "SPECIES", 60, 68], ["PCR testing", "TEST", 41, 52], ["surgery", "TREATMENT", 101, 108], ["other invasive procedures", "TREATMENT", 112, 137], ["intensive chemotherapy regimens", "TREATMENT", 151, 182], ["cellular therapies", "TREATMENT", 187, 205]]], ["Two additional testing modalities are key to a timely and complete patient assessment: a rapid antigen assay and IgG and IgM antibody titers evaluation to follow the development of SARS-CoV-2 antibody response.", [["SARS", "DISEASE", 181, 185], ["patient", "ORGANISM", 67, 74], ["IgG", "GENE_OR_GENE_PRODUCT", 113, 116], ["CoV-2", "ORGANISM", 186, 191], ["IgG", "PROTEIN", 113, 116], ["IgM antibody", "PROTEIN", 121, 133], ["patient", "SPECIES", 67, 74], ["SARS-CoV", "SPECIES", 181, 189], ["Two additional testing modalities", "TEST", 0, 33], ["complete patient assessment", "TEST", 58, 85], ["a rapid antigen assay", "TEST", 87, 108], ["IgG", "TEST", 113, 116], ["IgM antibody titers evaluation", "TEST", 121, 151], ["SARS", "TEST", 181, 185], ["CoV", "TEST", 186, 189]]], ["We anticipate that a rapid antigen assay should be available in the near future and will be used as a screening tool.", [["a rapid antigen assay", "TEST", 19, 40], ["a screening tool", "TEST", 100, 116]]], ["Antibody testing has recently become available in our institution for selected patients, and it is likely to be used to screen health care workers once supply is in sufficient amount and the test has been validated for its accuracy.Treatment PlanningThe ongoing COVID-19 pandemic and the individual patient risk of developing severe disease are additional elements that need to be considered during the development of an oncology treatment plan.", [["patients", "ORGANISM", 79, 87], ["patient", "ORGANISM", 299, 306], ["patients", "SPECIES", 79, 87], ["patient", "SPECIES", 299, 306], ["Antibody testing", "TEST", 0, 16], ["the test", "TEST", 187, 195], ["The ongoing COVID", "TEST", 250, 267], ["pandemic", "PROBLEM", 271, 279], ["developing severe disease", "PROBLEM", 315, 340], ["an oncology treatment plan", "TREATMENT", 418, 444], ["severe", "OBSERVATION_MODIFIER", 326, 332], ["disease", "OBSERVATION", 333, 340]]], ["Several reports have described a higher mortality in patients with cancer who contracted COVID-19; however, the majority of the reports have small sample sizes, and the population described is heterogeneous in terms of cancer stage, treatment, and the presence of other contributing factors such as comorbidities.", [["cancer", "ANATOMY", 67, 73], ["cancer", "ANATOMY", 219, 225], ["cancer", "DISEASE", 67, 73], ["cancer", "DISEASE", 219, 225], ["patients", "ORGANISM", 53, 61], ["cancer", "CANCER", 67, 73], ["cancer", "CANCER", 219, 225], ["patients", "SPECIES", 53, 61], ["cancer", "PROBLEM", 67, 73], ["small sample sizes", "PROBLEM", 141, 159], ["cancer stage", "PROBLEM", 219, 231], ["treatment", "TREATMENT", 233, 242], ["comorbidities", "PROBLEM", 299, 312], ["cancer", "OBSERVATION", 67, 73], ["small", "OBSERVATION_MODIFIER", 141, 146], ["sample", "OBSERVATION_MODIFIER", 147, 153], ["sizes", "OBSERVATION_MODIFIER", 154, 159], ["heterogeneous", "OBSERVATION_MODIFIER", 193, 206], ["cancer", "OBSERVATION", 219, 225]]], ["The recommendations implemented at our center are based on the consensus opinion of disease experts and focus on reducing the number of days with myelosuppression by preferring less myelosuppressive regimens (when an alternative treatment is available), administering growth factors, temporarily discontinuing treatments for patients in remission with low risk for relapse, and optimizing antimicrobial prophylaxis and supportive care.", [["myelosuppression", "DISEASE", 146, 162], ["patients", "ORGANISM", 325, 333], ["patients", "SPECIES", 325, 333], ["myelosuppression", "PROBLEM", 146, 162], ["less myelosuppressive regimens", "TREATMENT", 177, 207], ["an alternative treatment", "TREATMENT", 214, 238], ["temporarily discontinuing treatments", "TREATMENT", 284, 320], ["relapse", "PROBLEM", 365, 372], ["optimizing antimicrobial prophylaxis", "TREATMENT", 378, 414], ["supportive care", "TREATMENT", 419, 434]]], ["An open discussion on the risks and benefits, individual patient goals, and where each patient is in their cancer disease journey, combined with disease-specific metrics, is very important not only to help patients and their families in making an educated decision but also to the institution in its effort to provide high-quality, appropriate, and compassionate cancer treatment at a time of need to prioritize available resources.Treatment PlanningThere is a possibility that certain cancer treatments may have beneficial effects in patients who have contracted COVID-19 and have respiratory complications.", [["cancer", "ANATOMY", 107, 113], ["cancer", "ANATOMY", 363, 369], ["cancer", "ANATOMY", 486, 492], ["respiratory", "ANATOMY", 582, 593], ["cancer", "DISEASE", 107, 113], ["cancer", "DISEASE", 363, 369], ["cancer", "DISEASE", 486, 492], ["respiratory complications", "DISEASE", 582, 607], ["patient", "ORGANISM", 57, 64], ["patient", "ORGANISM", 87, 94], ["cancer", "CANCER", 107, 113], ["patients", "ORGANISM", 206, 214], ["cancer", "CANCER", 363, 369], ["cancer", "CANCER", 486, 492], ["patients", "ORGANISM", 535, 543], ["patient", "SPECIES", 57, 64], ["patient", "SPECIES", 87, 94], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 535, 543], ["compassionate cancer treatment", "TREATMENT", 349, 379], ["certain cancer treatments", "TREATMENT", 478, 503], ["respiratory complications", "PROBLEM", 582, 607], ["cancer", "OBSERVATION", 107, 113], ["cancer", "OBSERVATION", 486, 492]]], ["In a recently published letter, Treon et al. (18) reported a beneficial effect of treatment with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib on lung inflammation and hypoxia in five patients with Waldenstr\u00f6m macroglobulinemia.", [["lung", "ANATOMY", 155, 159], ["tyrosine", "CHEMICAL", 110, 118], ["ibrutinib", "CHEMICAL", 142, 151], ["lung inflammation", "DISEASE", 155, 172], ["hypoxia", "DISEASE", 177, 184], ["Waldenstr\u00f6m macroglobulinemia", "DISEASE", 207, 236], ["tyrosine", "CHEMICAL", 110, 118], ["ibrutinib", "CHEMICAL", 142, 151], ["Bruton's tyrosine kinase", "GENE_OR_GENE_PRODUCT", 101, 125], ["BTK", "GENE_OR_GENE_PRODUCT", 127, 130], ["ibrutinib", "SIMPLE_CHEMICAL", 142, 151], ["lung", "ORGAN", 155, 159], ["patients", "ORGANISM", 193, 201], ["Waldenstr\u00f6m macroglobulinemia", "CANCER", 207, 236], ["Bruton's tyrosine kinase", "PROTEIN", 101, 125], ["BTK", "PROTEIN", 127, 130], ["patients", "SPECIES", 193, 201], ["treatment", "TREATMENT", 82, 91], ["the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib", "TREATMENT", 97, 151], ["lung inflammation", "PROBLEM", 155, 172], ["hypoxia", "PROBLEM", 177, 184], ["Waldenstr\u00f6m macroglobulinemia", "PROBLEM", 207, 236], ["lung", "ANATOMY", 155, 159], ["inflammation", "OBSERVATION", 160, 172], ["hypoxia", "OBSERVATION", 177, 184], ["macroglobulinemia", "OBSERVATION", 219, 236]]], ["This lead has been followed by other groups that have reported the potential protective effect of acalabrutinib in patients with lymphoproliferative disorders affected by severe forms of COVID-19 (19) and by the initiation of clinical trials with BTK inhibitors in patients with severe COVID-19.", [["acalabrutinib", "CHEMICAL", 98, 111], ["lymphoproliferative disorders", "DISEASE", 129, 158], ["COVID-19", "CHEMICAL", 187, 195], ["acalabrutinib", "CHEMICAL", 98, 111], ["COVID-19", "CHEMICAL", 187, 195], ["acalabrutinib", "SIMPLE_CHEMICAL", 98, 111], ["patients", "ORGANISM", 115, 123], ["BTK", "GENE_OR_GENE_PRODUCT", 247, 250], ["patients", "ORGANISM", 265, 273], ["BTK", "PROTEIN", 247, 250], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 265, 273], ["acalabrutinib", "TREATMENT", 98, 111], ["lymphoproliferative disorders", "PROBLEM", 129, 158], ["COVID", "TEST", 187, 192], ["BTK inhibitors", "TREATMENT", 247, 261], ["severe COVID", "PROBLEM", 279, 291], ["severe", "OBSERVATION_MODIFIER", 171, 177]]], ["The mechanisms underlying the activity of BTK inhibitors in improving hypoxia in patients with severe COVID-19 seem to be mediated by an inhibition of exaggerated monocyte autophosphorylation and reduction in interleukin (IL)-6 production.Treatment PlanningCancer centers like ours have also developed tools to assist in the care of patients affected by COVID-19.", [["monocyte", "ANATOMY", 163, 171], ["hypoxia", "DISEASE", 70, 77], ["COVID-19", "CHEMICAL", 102, 110], ["Cancer", "DISEASE", 257, 263], ["COVID-19", "CHEMICAL", 102, 110], ["COVID-19", "CHEMICAL", 354, 362], ["BTK", "GENE_OR_GENE_PRODUCT", 42, 45], ["patients", "ORGANISM", 81, 89], ["monocyte", "CELL", 163, 171], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 209, 227], ["patients", "ORGANISM", 333, 341], ["BTK", "PROTEIN", 42, 45], ["interleukin (IL)-6", "PROTEIN", 209, 227], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 333, 341], ["BTK inhibitors", "TREATMENT", 42, 56], ["improving hypoxia", "PROBLEM", 60, 77], ["severe COVID", "PROBLEM", 95, 107], ["exaggerated monocyte autophosphorylation", "PROBLEM", 151, 191], ["interleukin (IL)", "TREATMENT", 209, 225], ["COVID", "TEST", 354, 359], ["improving", "OBSERVATION_MODIFIER", 60, 69], ["hypoxia", "OBSERVATION", 70, 77], ["exaggerated", "OBSERVATION_MODIFIER", 151, 162], ["monocyte autophosphorylation", "OBSERVATION", 163, 191], ["reduction", "OBSERVATION_MODIFIER", 196, 205]]], ["The first step is deciding which patients need to be treated in the inpatient setting and which can safely remain outpatients.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41]]], ["Cancer diagnosis, current treatment, age, gender, and comorbidities are key elements in this initial decision.", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["Cancer", "CANCER", 0, 6], ["current treatment", "TREATMENT", 18, 35], ["comorbidities", "PROBLEM", 54, 67]]], ["Symptomatic patients who require in-hospital care are risk-stratified based on the severity of illness and managed according to an internal COVID-19 clinical management algorithm compiled by a multidisciplinary task force.", [["illness", "DISEASE", 95, 102], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["illness", "PROBLEM", 95, 102], ["an internal COVID", "TEST", 128, 145], ["clinical management algorithm", "TREATMENT", 149, 178]]], ["This algorithm has been revised and updated multiple times to incorporate the most recent information available on COVID-19 features and treatment in patients with cancer and relevant publications and consensus statements from the Centers for Disease Control and Prevention (CDC), various medical societies, and task forces.", [["cancer", "ANATOMY", 164, 170], ["cancer", "DISEASE", 164, 170], ["patients", "ORGANISM", 150, 158], ["cancer", "CANCER", 164, 170], ["patients", "SPECIES", 150, 158], ["treatment", "TREATMENT", 137, 146], ["cancer", "PROBLEM", 164, 170], ["Disease Control", "TREATMENT", 243, 258], ["cancer", "OBSERVATION", 164, 170]]], ["The goal of the algorithm is to provide both guidance and uniformity in diagnostic workup, supportive care, and treatment of patients affected by COVID-19, given the unprecedented challenges that this disease poses and the absence of consensus guidelines.CHANGES IN CANCER CARE IN THE CORONAVIRUS DISEASE 2019 ERA: ILLUSTRATIVE CLINICAL SCENARIOS AND POTENTIAL DIFFERENCES BETWEEN ITALIAN AND UNITED STATES-BASED CENTERSIn some clinical settings, both oral and intravenous agents are indicated.", [["oral", "ANATOMY", 452, 456], ["intravenous", "ANATOMY", 461, 472], ["patients", "ORGANISM", 125, 133], ["oral", "ORGANISM_SUBDIVISION", 452, 456], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 461, 472], ["patients", "SPECIES", 125, 133], ["diagnostic workup", "TEST", 72, 89], ["supportive care", "TREATMENT", 91, 106], ["treatment", "TREATMENT", 112, 121], ["COVID", "TEST", 146, 151], ["this disease poses", "PROBLEM", 196, 214], ["both oral and intravenous agents", "TREATMENT", 447, 479], ["CANCER", "OBSERVATION", 266, 272]]], ["For example, in prostate cancer patients with metastatic castration-sensitive disease, both novel hormonal agents including abiraterone, apalutamide, and enzalutamide and chemotherapy-based docetaxel have been shown to provide a survival advantage (20) .", [["prostate cancer", "ANATOMY", 16, 31], ["prostate cancer", "DISEASE", 16, 31], ["castration-sensitive disease", "DISEASE", 57, 85], ["abiraterone", "CHEMICAL", 124, 135], ["apalutamide", "CHEMICAL", 137, 148], ["enzalutamide", "CHEMICAL", 154, 166], ["docetaxel", "CHEMICAL", 190, 199], ["abiraterone", "CHEMICAL", 124, 135], ["apalutamide", "CHEMICAL", 137, 148], ["enzalutamide", "CHEMICAL", 154, 166], ["docetaxel", "CHEMICAL", 190, 199], ["prostate cancer", "CANCER", 16, 31], ["patients", "ORGANISM", 32, 40], ["abiraterone", "SIMPLE_CHEMICAL", 124, 135], ["apalutamide", "SIMPLE_CHEMICAL", 137, 148], ["enzalutamide", "SIMPLE_CHEMICAL", 154, 166], ["docetaxel", "SIMPLE_CHEMICAL", 190, 199], ["patients", "SPECIES", 32, 40], ["prostate cancer", "PROBLEM", 16, 31], ["metastatic castration", "PROBLEM", 46, 67], ["sensitive disease", "PROBLEM", 68, 85], ["novel hormonal agents", "TREATMENT", 92, 113], ["abiraterone", "TREATMENT", 124, 135], ["apalutamide", "TREATMENT", 137, 148], ["enzalutamide", "TREATMENT", 154, 166], ["chemotherapy", "TREATMENT", 171, 183], ["based docetaxel", "TREATMENT", 184, 199], ["prostate", "ANATOMY", 16, 24], ["cancer", "OBSERVATION", 25, 31], ["metastatic", "OBSERVATION_MODIFIER", 46, 56], ["sensitive", "OBSERVATION_MODIFIER", 68, 77], ["disease", "OBSERVATION", 78, 85]]], ["While in the universal Italian health care system, an oral hormonal agent is more likely to be preferred over docetaxel in view of a more favorable safety profile as well as reduced risk of hospitalization and need for in-person visits, some patients in the US may not afford such an expensive and prolonged treatment and prefer a short course of docetaxel.", [["oral", "ANATOMY", 54, 58], ["docetaxel", "CHEMICAL", 110, 119], ["docetaxel", "CHEMICAL", 347, 356], ["docetaxel", "CHEMICAL", 110, 119], ["docetaxel", "CHEMICAL", 347, 356], ["oral", "ORGANISM_SUBDIVISION", 54, 58], ["docetaxel", "SIMPLE_CHEMICAL", 110, 119], ["patients", "ORGANISM", 242, 250], ["docetaxel", "SIMPLE_CHEMICAL", 347, 356], ["patients", "SPECIES", 242, 250], ["an oral hormonal agent", "TREATMENT", 51, 73], ["docetaxel", "TREATMENT", 110, 119], ["prolonged treatment", "TREATMENT", 298, 317], ["docetaxel", "TREATMENT", 347, 356]]], ["Similarly, in kidney cancer, oral agents including cabozantinib, sunitinib, and pazopanib may be preferred over nivolumab/ipilimumab (21) .", [["kidney cancer", "ANATOMY", 14, 27], ["oral", "ANATOMY", 29, 33], ["kidney cancer", "DISEASE", 14, 27], ["cabozantinib", "CHEMICAL", 51, 63], ["sunitinib", "CHEMICAL", 65, 74], ["pazopanib", "CHEMICAL", 80, 89], ["nivolumab", "CHEMICAL", 112, 121], ["ipilimumab", "CHEMICAL", 122, 132], ["cabozantinib", "CHEMICAL", 51, 63], ["sunitinib", "CHEMICAL", 65, 74], ["pazopanib", "CHEMICAL", 80, 89], ["nivolumab", "CHEMICAL", 112, 121], ["ipilimumab", "CHEMICAL", 122, 132], ["kidney cancer", "CANCER", 14, 27], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["cabozantinib", "SIMPLE_CHEMICAL", 51, 63], ["sunitinib", "SIMPLE_CHEMICAL", 65, 74], ["pazopanib", "SIMPLE_CHEMICAL", 80, 89], ["nivolumab", "SIMPLE_CHEMICAL", 112, 121], ["ipilimumab", "SIMPLE_CHEMICAL", 122, 132], ["kidney cancer", "PROBLEM", 14, 27], ["oral agents", "TREATMENT", 29, 40], ["cabozantinib", "TREATMENT", 51, 63], ["sunitinib", "TREATMENT", 65, 74], ["pazopanib", "TREATMENT", 80, 89], ["nivolumab/ipilimumab", "TREATMENT", 112, 132], ["kidney", "ANATOMY", 14, 20], ["cancer", "OBSERVATION", 21, 27]]], ["In clinical scenarios in which adjuvant treatment benefit is uncertain, such as muscle-invasive bladder cancer after radical cystectomy, the COVID-19 emergency may discourage the use of cisplatin-based chemotherapy (22) .CHANGES IN CANCER CARE IN THE CORONAVIRUS DISEASE 2019 ERA: ILLUSTRATIVE CLINICAL SCENARIOS AND POTENTIAL DIFFERENCES BETWEEN ITALIAN AND UNITED STATES-BASED CENTERSWhile there are multiple clinical situations in which an oral treatment may be preferred over intravenous therapy, accessibility, reimbursement policies, and overall costs may cause differences in Italian vs. United States-based clinical practices.CANCER IMMUNOLOGISTS COMBATING BIOLOGICAL MECHANISMS IN CORONAVIRUS DISEASE 2019Since November 2019, we have been exposed to a global outbreak recalling the 1918 Spanish flu and facing similar challenges and solutions, such as wearing safety devices and observing physical distancing.", [["muscle-invasive bladder cancer", "ANATOMY", 80, 110], ["oral", "ANATOMY", 443, 447], ["intravenous", "ANATOMY", 480, 491], ["muscle-invasive bladder cancer", "DISEASE", 80, 110], ["cisplatin", "CHEMICAL", 186, 195], ["cisplatin", "CHEMICAL", 186, 195], ["muscle-invasive bladder cancer", "CANCER", 80, 110], ["cisplatin", "SIMPLE_CHEMICAL", 186, 195], ["oral", "ORGANISM_SUBDIVISION", 443, 447], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 480, 491], ["adjuvant treatment benefit", "TREATMENT", 31, 57], ["muscle-invasive bladder cancer", "PROBLEM", 80, 110], ["radical cystectomy", "TREATMENT", 117, 135], ["cisplatin-based chemotherapy", "TREATMENT", 186, 214], ["multiple clinical situations", "PROBLEM", 402, 430], ["an oral treatment", "TREATMENT", 440, 457], ["intravenous therapy", "TREATMENT", 480, 499], ["safety devices", "TREATMENT", 869, 883], ["muscle", "ANATOMY", 80, 86], ["invasive", "OBSERVATION_MODIFIER", 87, 95], ["bladder", "ANATOMY", 96, 103], ["cancer", "OBSERVATION", 104, 110], ["radical cystectomy", "OBSERVATION", 117, 135], ["CANCER", "OBSERVATION", 232, 238], ["multiple", "OBSERVATION_MODIFIER", 402, 410], ["CORONAVIRUS DISEASE", "OBSERVATION", 690, 709]]], ["However, we have an important advantage, as we have a much deeper knowledge of the immune system, thanks to years of studies and research achievements in the context of infections, autoimmune diseases, and cancer.", [["immune system", "ANATOMY", 83, 96], ["cancer", "ANATOMY", 206, 212], ["infections", "DISEASE", 169, 179], ["autoimmune diseases", "DISEASE", 181, 200], ["cancer", "DISEASE", 206, 212], ["cancer", "CANCER", 206, 212], ["studies", "TEST", 117, 124], ["infections", "PROBLEM", 169, 179], ["autoimmune diseases", "PROBLEM", 181, 200], ["cancer", "PROBLEM", 206, 212], ["infections", "OBSERVATION", 169, 179], ["autoimmune diseases", "OBSERVATION", 181, 200], ["cancer", "OBSERVATION", 206, 212]]], ["Particularly in the last two decades, we have experienced the flourishing and rapid evolution of immunotherapeutic strategies of high impact in oncology.", [["immunotherapeutic strategies", "TREATMENT", 97, 125]]], ["Knowing that the immune response plays a central role in the pathogenetic mechanisms of COVID-19, we can thus exploit all the experience accumulated in recent years to better understand the constellation of symptoms of a disease that attacks almost any organ with devastating consequences in roughly 5% of patients.CANCER IMMUNOLOGISTS COMBATING BIOLOGICAL MECHANISMS IN CORONAVIRUS DISEASE 2019As an example, we recently learned that a rare disorder named secondary hemophagocytic lymphohistiocytosis, previously associated with viral infections and T-cell immunotherapybased cancer treatments, was identified in some COVID-19 patients (23) .CANCER IMMUNOLOGISTS COMBATING BIOLOGICAL MECHANISMS IN CORONAVIRUS DISEASE 2019The varied symptoms observed in COVID-19 patients often appear as a consequence of an overzealous immune response.", [["organ", "ANATOMY", 253, 258], ["T-cell", "ANATOMY", 551, 557], ["cancer", "ANATOMY", 577, 583], ["hemophagocytic lymphohistiocytosis", "DISEASE", 467, 501], ["viral infections", "DISEASE", 530, 546], ["cancer", "DISEASE", 577, 583], ["COVID-19", "CELL", 88, 96], ["organ", "ORGAN", 253, 258], ["patients", "ORGANISM", 306, 314], ["T-cell immunotherapybased cancer", "CANCER", 551, 583], ["patients", "ORGANISM", 628, 636], ["patients", "ORGANISM", 764, 772], ["patients", "SPECIES", 306, 314], ["patients", "SPECIES", 628, 636], ["patients", "SPECIES", 764, 772], ["COVID", "TEST", 88, 93], ["symptoms", "PROBLEM", 207, 215], ["a disease that attacks", "PROBLEM", 219, 241], ["a rare disorder", "PROBLEM", 435, 450], ["hemophagocytic lymphohistiocytosis", "PROBLEM", 467, 501], ["viral infections", "PROBLEM", 530, 546], ["T-cell immunotherapybased cancer treatments", "TREATMENT", 551, 594], ["The varied symptoms", "PROBLEM", 723, 742], ["an overzealous immune response", "PROBLEM", 806, 836], ["CORONAVIRUS DISEASE", "OBSERVATION", 371, 390], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 467, 501], ["viral", "OBSERVATION_MODIFIER", 530, 535], ["infections", "OBSERVATION", 536, 546], ["cancer", "OBSERVATION", 577, 583], ["CORONAVIRUS DISEASE", "OBSERVATION", 699, 718], ["varied", "OBSERVATION_MODIFIER", 727, 733], ["immune response", "OBSERVATION", 821, 836]]], ["The high cytokine serum levels, such as IL-6 and IL-1, reflect the \"cytokine storm, \" a familiar event to oncologists, seen in patients with cancer who receive chimeric antigen receptor (CAR) T-cell immunotherapy and, thanks to this knowledge, efficacious treatments with anti-IL-6 monoclonal antibodies have been developed.", [["serum", "ANATOMY", 18, 23], ["cancer", "ANATOMY", 141, 147], ["T-cell", "ANATOMY", 192, 198], ["cancer", "DISEASE", 141, 147], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 40, 44], ["IL-1", "GENE_OR_GENE_PRODUCT", 49, 53], ["patients", "ORGANISM", 127, 135], ["cancer", "CANCER", 141, 147], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 160, 185], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 272, 281], ["cytokine", "PROTEIN", 9, 17], ["IL", "PROTEIN", 49, 51], ["cytokine", "PROTEIN", 68, 76], ["chimeric antigen receptor", "PROTEIN", 160, 185], ["CAR", "PROTEIN", 187, 190], ["anti-IL-6 monoclonal antibodies", "PROTEIN", 272, 303], ["patients", "SPECIES", 127, 135], ["The high cytokine serum levels", "TEST", 0, 30], ["IL", "TEST", 40, 42], ["cancer", "PROBLEM", 141, 147], ["chimeric antigen receptor (CAR) T-cell immunotherapy", "TREATMENT", 160, 212], ["efficacious treatments", "TREATMENT", 244, 266], ["anti-IL-6 monoclonal antibodies", "TREATMENT", 272, 303], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["However, since cytokines are a necessary feature of the antiviral immune responses, what are the consequences of inhibiting them with immunosuppressive treatments?CANCER IMMUNOLOGISTS COMBATING BIOLOGICAL MECHANISMS IN CORONAVIRUS DISEASE 2019Concerning cellular immunity, it is fundamental to know the role played by different cell populations in COVID-19.", [["cellular", "ANATOMY", 254, 262], ["cell", "ANATOMY", 328, 332], ["cellular", "CELL", 254, 262], ["cell populations", "CELL", 328, 344], ["COVID-19", "CELL", 348, 356], ["cytokines", "PROTEIN", 15, 24], ["cytokines", "PROBLEM", 15, 24], ["immunosuppressive treatments", "TREATMENT", 134, 162], ["COVID", "TEST", 348, 353], ["antiviral immune", "OBSERVATION", 56, 72], ["CORONAVIRUS DISEASE", "OBSERVATION", 219, 238], ["cellular immunity", "OBSERVATION", 254, 271]]], ["In other words, which cells are helpful and which are hurtful.", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27]]], ["Some evidence suggests that T cells, which usually represent a key component of the immune response against viruses, do not play a role in lung damage during COVID-19 infection, while stimulation of other cells in the lung microenvironment, such as macrophages, may make a difference.CANCER IMMUNOLOGISTS COMBATING BIOLOGICAL MECHANISMS IN CORONAVIRUS DISEASE 2019All these important questions, with relevant implications for treatment options, need answers that we are eager to find for the benefit of society.", [["T cells", "ANATOMY", 28, 35], ["lung", "ANATOMY", 139, 143], ["cells", "ANATOMY", 205, 210], ["lung", "ANATOMY", 218, 222], ["macrophages", "ANATOMY", 249, 260], ["lung damage", "DISEASE", 139, 150], ["infection", "DISEASE", 167, 176], ["T cells", "CELL", 28, 35], ["lung", "ORGAN", 139, 143], ["COVID-19", "ORGANISM", 158, 166], ["cells", "CELL", 205, 210], ["lung", "ORGAN", 218, 222], ["macrophages", "CELL", 249, 260], ["T cells", "CELL_TYPE", 28, 35], ["macrophages", "CELL_TYPE", 249, 260], ["T cells", "PROBLEM", 28, 35], ["viruses", "PROBLEM", 108, 115], ["lung damage", "PROBLEM", 139, 150], ["COVID-19 infection", "PROBLEM", 158, 176], ["treatment options", "TREATMENT", 426, 443], ["T cells", "OBSERVATION", 28, 35], ["lung", "ANATOMY", 139, 143], ["damage", "OBSERVATION", 144, 150], ["infection", "OBSERVATION", 167, 176], ["lung", "ANATOMY", 218, 222], ["CORONAVIRUS DISEASE", "OBSERVATION", 340, 359]]], ["In addition, an overwhelming amount of discordant or badly reported scientific results often cause great concern and alarm in the public opinion.", [["overwhelming", "OBSERVATION_MODIFIER", 16, 28], ["amount", "OBSERVATION_MODIFIER", 29, 35]]], ["In this context, we recently organized a website named InformaCOVID 1 , open to contributions from experts dealing with COVID-19-related topics in a popular style of writing.", [["InformaCOVID 1", "DNA", 55, 69]]], ["The site has had many visitors so far, and we hope it will remain an important instrument for accurate scientific information.CORONAVIRUS DISEASE 2019 IMPACT ON CANCER RESEARCH IN THE UNITED STATESThe rapid emergence of the COVID-19 pandemic has forced cancer research institutions worldwide to make decisions that prioritize the safety of their scientists and administrators and the need to continue ongoing experiments and meet timelines and deadlines.", [["cancer", "ANATOMY", 253, 259], ["cancer", "DISEASE", 253, 259], ["cancer", "CANCER", 253, 259], ["CORONAVIRUS DISEASE", "PROBLEM", 126, 145], ["the COVID", "TEST", 220, 229], ["ongoing experiments", "TREATMENT", 401, 420], ["CANCER", "OBSERVATION", 161, 167], ["rapid", "OBSERVATION_MODIFIER", 201, 206]]], ["In the United States, we have faced a whole spectrum of solutions ranging from a complete shutdown of any cancer research activity and lockdown of research labs to more compromising situations in which scientists are performing experiments, minimizing the amount of time they spend next to each other.", [["cancer", "ANATOMY", 106, 112], ["cancer", "DISEASE", 106, 112], ["cancer", "CANCER", 106, 112], ["a whole spectrum of solutions", "TREATMENT", 36, 65], ["research labs", "TEST", 147, 160], ["cancer", "OBSERVATION", 106, 112]]], ["This last goal is achieved by creating work shifts that limit the number of scientists present at the same time in the lab to a maximum of two (wearing face masks and gloves all the time and maintaining a 6-feet distance to each other), reducing the number of people working with cell cultures under the hood or in smaller rooms to one, not allowing in-person meetings with more than 10 people in general, and implementing a 6-feet social distancing practice even when 10 or fewer people are allowed to meet in person.", [["cell", "ANATOMY", 280, 284], ["people", "ORGANISM", 260, 266], ["cell cultures", "CELL", 280, 293], ["people", "ORGANISM", 481, 487], ["cell cultures", "CELL_LINE", 280, 293], ["people", "SPECIES", 260, 266], ["people", "SPECIES", 387, 393], ["people", "SPECIES", 481, 487], ["person", "SPECIES", 511, 517], ["face masks", "TREATMENT", 152, 162], ["gloves", "TREATMENT", 167, 173], ["cell cultures", "TEST", 280, 293]]], ["In vivo experiments have been quite impacted because of a reduction of personnel working on animal care during this period; given that animal experiments are usually quite expensive, complex, and long-lasting, principal investigators (whenever possible) are forced to postpone them until regular activities resume.CORONAVIRUS DISEASE 2019 IMPACT ON CANCER RESEARCH IN THE UNITED STATESThe National Institutes of Health (NIH) has been promptly responsive and has implemented a series of guidelines and initiatives to ensure that research continues.", [["animal care", "TREATMENT", 92, 103], ["CORONAVIRUS DISEASE", "PROBLEM", 314, 333], ["CANCER", "OBSERVATION", 349, 355]]], ["The NIH has created new funding opportunities through competing and administrative supplements to investigators with currently ongoing NIH support and in the creation of new awards (ongoing funding opportunities can be found at https://grants.nih.gov/ policy/natural-disasters/corona-virus.htm).", [["administrative supplements", "TREATMENT", 68, 94], ["ongoing NIH support", "TREATMENT", 127, 146], ["new", "OBSERVATION_MODIFIER", 20, 23], ["funding", "OBSERVATION", 24, 31]]], ["The National Cancer Institute (NCI) is participating in five out of the 45 NIH funding opportunities specific to COVID-19.", [["Cancer", "DISEASE", 13, 19], ["COVID-19", "DNA", 113, 121], ["COVID", "TEST", 113, 118], ["Cancer", "OBSERVATION", 13, 19]]], ["However, the rapid adaptation of the main scientific societies to web-based platforms has been extremely helpful in minimizing the impact of travel restrictions on the sharing of research findings, which remains essential for the scientific community.CONCLUDING REMARKSThe lessons we are learning during the response to the COVID-19 pandemic will likely accelerate the integration of digital technologies in the care of patients with cancer.", [["cancer", "ANATOMY", 434, 440], ["cancer", "DISEASE", 434, 440], ["patients", "ORGANISM", 420, 428], ["cancer", "CANCER", 434, 440], ["patients", "SPECIES", 420, 428], ["digital technologies", "TREATMENT", 384, 404], ["cancer", "PROBLEM", 434, 440], ["rapid", "OBSERVATION_MODIFIER", 13, 18], ["main", "OBSERVATION_MODIFIER", 37, 41], ["cancer", "OBSERVATION", 434, 440]]], ["Cancer centers worldwide have expanded their telemedicine capabilities very rapidly, and we anticipate an increasing use of telemedicine for the long-term follow-up of patients not on active therapies, for patients in remote locations, and for multidisciplinary case planning and tumor boards.CONCLUDING REMARKSAn organized triage and screening tests are essential for the safe management of patients with cancer during the ongoing COVID-19 pandemic.", [["Cancer", "ANATOMY", 0, 6], ["tumor", "ANATOMY", 280, 285], ["cancer", "ANATOMY", 406, 412], ["Cancer", "DISEASE", 0, 6], ["tumor", "DISEASE", 280, 285], ["cancer", "DISEASE", 406, 412], ["Cancer", "CANCER", 0, 6], ["patients", "ORGANISM", 168, 176], ["patients", "ORGANISM", 206, 214], ["tumor", "CANCER", 280, 285], ["patients", "ORGANISM", 392, 400], ["cancer", "CANCER", 406, 412], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 392, 400], ["telemedicine", "TREATMENT", 124, 136], ["active therapies", "TREATMENT", 184, 200], ["screening tests", "TEST", 335, 350], ["the safe management", "TREATMENT", 369, 388], ["cancer", "PROBLEM", 406, 412], ["the ongoing COVID", "TEST", 420, 437], ["pandemic", "PROBLEM", 441, 449], ["cancer", "OBSERVATION", 406, 412]]], ["Patients with cancer have shown an excellent adherence to the recommended preventive measures to reduce the risk of infections, and the SARS-CoV-2 positivity rate seen at a major cancer center is lower than the rate reported in the general population.", [["cancer", "ANATOMY", 14, 20], ["cancer", "ANATOMY", 179, 185], ["cancer", "DISEASE", 14, 20], ["infections", "DISEASE", 116, 126], ["SARS", "DISEASE", 136, 140], ["cancer", "DISEASE", 179, 185], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 14, 20], ["SARS-CoV-2", "ORGANISM", 136, 146], ["cancer", "CANCER", 179, 185], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 136, 144], ["cancer", "PROBLEM", 14, 20], ["preventive measures", "TREATMENT", 74, 93], ["infections", "PROBLEM", 116, 126], ["the SARS", "TEST", 132, 140], ["CoV", "TEST", 141, 144], ["positivity rate", "TEST", 147, 162], ["cancer", "OBSERVATION", 14, 20], ["excellent", "OBSERVATION_MODIFIER", 35, 44], ["adherence", "OBSERVATION", 45, 54], ["infections", "OBSERVATION", 116, 126], ["major", "OBSERVATION_MODIFIER", 173, 178], ["cancer", "OBSERVATION", 179, 185], ["lower", "OBSERVATION_MODIFIER", 196, 201]]], ["It is important to provide clear and validated information to patients with cancer and their families to optimize preventive strategies during the COVID-19 pandemic.CONCLUDING REMARKSConcerning research work, lockdown decisions aimed at prioritizing safety have seen a partial block of entry in research institutions with drastic reductions in wet lab experiments and preclinical animal model-based studies.", [["cancer", "ANATOMY", 76, 82], ["cancer", "DISEASE", 76, 82], ["patients", "ORGANISM", 62, 70], ["cancer", "CANCER", 76, 82], ["patients", "SPECIES", 62, 70], ["preventive strategies", "TREATMENT", 114, 135], ["the COVID", "TEST", 143, 152], ["pandemic", "PROBLEM", 156, 164], ["drastic reductions", "TREATMENT", 322, 340], ["preclinical animal model-based studies", "TEST", 368, 406]]], ["However, some institutions, such as the NIH, have been promptly responsive and implemented guidelines to allow for the continuation of research activities.", [["research activities", "TREATMENT", 135, 154]]], ["In addition, new funding opportunities have been created.", [["new", "OBSERVATION_MODIFIER", 13, 16], ["funding", "OBSERVATION", 17, 24]]], ["Finally, the flourishing of virtual meetings has provided opportunities for many scientists to interact with peers, discuss, and better organize their research, opportunities that should be kept after the pandemic.AUTHOR CONTRIBUTIONSAC and DT contributed to the conception of the work and final version approval.", [["DT", "PROBLEM", 241, 243]]], ["GC, MF, CB, LS, PD, and AF contributed to extensive literature search, manuscript drafting, and critical revision of the work.", [["PD", "DISEASE", 16, 18], ["AF", "DISEASE", 24, 26], ["GC", "TEST", 0, 2], ["CB", "TEST", 8, 10], ["PD", "PROBLEM", 16, 18], ["AF", "PROBLEM", 24, 26], ["CB", "ANATOMY", 8, 10], ["revision", "OBSERVATION", 105, 113]]], ["All authors contributed to the article and approved the submitted version.FUNDINGThis work was supported by SATIN-POR CAMPANIA FESR 2014/2020, to AC and PD.", [["PD", "DISEASE", 153, 155], ["PD", "TREATMENT", 153, 155]]]], "cde51fb9e3c69afff2f2c85dbe3a3ca165e7bab4": [["IntroductionThe use of a next-generation sequencing approaches in RNA sequencing has facilitated understanding and defi ning the expression profi les of cellular responses during pathogen infection.", [["cellular", "ANATOMY", 153, 161], ["pathogen infection", "DISEASE", 179, 197], ["cellular", "CELL", 153, 161], ["a next-generation sequencing approaches", "TREATMENT", 23, 62], ["pathogen infection", "PROBLEM", 179, 197], ["pathogen", "OBSERVATION_MODIFIER", 179, 187], ["infection", "OBSERVATION", 188, 197]]], ["This method has been proven to be helpful in explaining the pathogenesis of various viruses [ 1 , 2 ] , including Feline Immunodefi ciency Virus (FIV) [ 3 , 4 ] .", [["Feline Immunodefi ciency Virus", "DISEASE", 114, 144], ["Feline Immunodefi ciency Virus", "ORGANISM", 114, 144], ["FIV", "ORGANISM", 146, 149], ["Feline Immunodefi ciency Virus", "SPECIES", 114, 144], ["FIV", "SPECIES", 146, 149], ["various viruses", "PROBLEM", 76, 91], ["Feline Immunodefi ciency Virus", "TREATMENT", 114, 144]]], ["Furthermore, the increasing availability of complete genome sequences for a number of model organisms makes host transcriptome analysis a valuable tool for elucidating mechanisms of virus pathogenesis and host responses to virus infection.", [["infection", "DISEASE", 229, 238], ["genome sequences", "DNA", 53, 69], ["model organisms", "PROBLEM", 86, 101], ["virus pathogenesis", "PROBLEM", 182, 200], ["virus infection", "PROBLEM", 223, 238]]], ["Feline infectious peritonitis virus (FIPV) is thought to be the causative agent of feline infectious peritonitis (FIP).", [["Feline infectious peritonitis", "DISEASE", 0, 29], ["feline infectious peritonitis", "DISEASE", 83, 112], ["FIP", "DISEASE", 114, 117], ["Feline infectious peritonitis virus", "ORGANISM", 0, 35], ["FIPV", "ORGANISM", 37, 41], ["feline", "ORGANISM", 83, 89], ["Feline infectious peritonitis virus", "SPECIES", 0, 35], ["feline", "SPECIES", 83, 89], ["Feline infectious peritonitis virus", "SPECIES", 0, 35], ["FIPV", "SPECIES", 37, 41], ["Feline infectious peritonitis virus (FIPV", "PROBLEM", 0, 41], ["feline infectious peritonitis", "PROBLEM", 83, 112], ["infectious", "OBSERVATION_MODIFIER", 7, 17], ["peritonitis", "OBSERVATION", 18, 29], ["thought to be", "UNCERTAINTY", 46, 59], ["feline", "OBSERVATION_MODIFIER", 83, 89], ["infectious", "OBSERVATION_MODIFIER", 90, 100], ["peritonitis", "OBSERVATION", 101, 112]]], ["Understanding the molecular basis of FIPV pathogenesis will provide valuable information to devise effective treatments and formulate vaccines with higher effi cacy.", [["FIPV", "GENE_OR_GENE_PRODUCT", 37, 41], ["FIPV pathogenesis", "PROBLEM", 37, 54], ["effective treatments", "TREATMENT", 99, 119], ["formulate vaccines", "TREATMENT", 124, 142], ["FIPV", "OBSERVATION", 37, 41]]], ["Once established, focus can be directed at disrupting the virulent determinants or formulating new vaccine or even designing gene therapy treatment.", [["new vaccine", "TREATMENT", 95, 106], ["gene therapy treatment", "TREATMENT", 125, 147]]], ["Facilitating this, the complete 1.9X cat genome, using the Whole Genome Shotgun (WGS) approach, provides valuable information for bioinformatics analysis of feline host responses following pathogen infection.", [["pathogen infection", "DISEASE", 189, 207], ["feline", "ORGANISM", 157, 163], ["1.9X cat genome", "DNA", 32, 47], ["feline", "SPECIES", 157, 163], ["bioinformatics analysis", "TEST", 130, 153], ["pathogen infection", "PROBLEM", 189, 207], ["infection", "OBSERVATION", 198, 207]]], ["Moreover, the cat genome contigs were aligned, mapped, and annotated to NCBI annotated genome sequences of six index mammalian genomes (human, chimpanzee, mouse, rat, dog and cow) using MegaBLAST [ 5 ] .", [["cat", "ORGANISM", 14, 17], ["human", "ORGANISM", 136, 141], ["chimpanzee", "ORGANISM", 143, 153], ["mouse", "ORGANISM", 155, 160], ["rat", "ORGANISM", 162, 165], ["dog", "ORGANISM", 167, 170], ["cow", "ORGANISM", 175, 178], ["cat genome contigs", "DNA", 14, 32], ["NCBI annotated genome sequences", "DNA", 72, 103], ["index mammalian genomes", "DNA", 111, 134], ["human", "SPECIES", 136, 141], ["chimpanzee", "SPECIES", 143, 153], ["mouse", "SPECIES", 155, 160], ["rat", "SPECIES", 162, 165], ["dog", "SPECIES", 167, 170], ["cow", "SPECIES", 175, 178], ["human", "SPECIES", 136, 141], ["mouse", "SPECIES", 155, 160], ["rat", "SPECIES", 162, 165], ["dog", "SPECIES", 167, 170], ["cow", "SPECIES", 175, 178]]], ["In this chapter we describe a pipeline for transcriptome analysis using FIPV infection of feline cells in culture as an example.", [["cells", "ANATOMY", 97, 102], ["infection", "DISEASE", 77, 86], ["FIPV", "SIMPLE_CHEMICAL", 72, 76], ["feline", "ORGANISM", 90, 96], ["cells", "CELL", 97, 102], ["feline cells", "CELL_TYPE", 90, 102], ["FIPV", "SPECIES", 72, 76], ["transcriptome analysis", "TEST", 43, 65], ["FIPV infection of feline cells", "PROBLEM", 72, 102], ["culture", "TEST", 106, 113], ["feline cells", "OBSERVATION", 90, 102]]], ["Specifi cally, mRNA harvested from CRFK cells 3 h post infection with FIPV strain 79-1146 were sequenced using Illumina next-generation sequencing technology.", [["CRFK cells", "ANATOMY", 35, 45], ["infection", "DISEASE", 55, 64], ["CRFK cells", "CELL", 35, 45], ["mRNA", "RNA", 15, 19], ["CRFK cells", "CELL_LINE", 35, 45], ["FIPV strain 79-1146", "SPECIES", 70, 89], ["CRFK cells", "PROBLEM", 35, 45], ["infection", "PROBLEM", 55, 64], ["FIPV strain", "TEST", 70, 81], ["Illumina next-generation sequencing technology", "TREATMENT", 111, 157]]], ["The generated data was then analyzed using CLC bio Genomic Workbench, where the genes were compared to Felis catus 1.9X annotated shotgun reference genome.", [["shotgun reference genome", "DNA", 130, 154], ["Felis catus", "SPECIES", 103, 114]]], ["Kal's Z-test on expression proportions [ 6 ] was used to determine signifi cantly expressed genes.", [["signifi cantly expressed genes", "DNA", 67, 97], ["Kal", "TEST", 0, 3]]], ["Genes expressed with a False Discovery Rate (FDR) <0.05 and >1.99and <-1.99-fold change were considered for further analysis.", [["further analysis", "TEST", 108, 124]]], ["NanoDrop Nanophotometer or spectrophotometer.SensiFAST\u2122 SYBR No-ROX OneStep kit (Bioline).SensiFAST\u2122 SYBR No-ROX One8.", [["ROX", "CHEMICAL", 109, 112], ["SYBR No-ROX One8", "DNA", 101, 117], ["NanoDrop Nanophotometer", "TREATMENT", 0, 23], ["SensiFAST", "TEST", 45, 54], ["SensiFAST", "TEST", 90, 99]]], ["Primers specifi c for genes of interest and reference genes.", [["specifi c", "GENE_OR_GENE_PRODUCT", 8, 17], ["reference genes", "DNA", 44, 59]]], ["BD Vacutainer (BD) EDTA-K2 tubes.SensiFAST\u2122 SYBR No-ROX One10.", [["Vacutainer", "CHEMICAL", 3, 13], ["ROX", "CHEMICAL", 52, 55], ["EDTA", "CHEMICAL", 19, 23], ["ROX One10", "DNA", 52, 61], ["BD Vacutainer (BD) EDTA", "TREATMENT", 0, 23], ["K2 tubes", "TREATMENT", 24, 32], ["SensiFAST", "TEST", 33, 42], ["K2 tubes", "OBSERVATION", 24, 32]]], ["Ficoll-Paque Plus.MethodsTo take advantages of this technology, simultaneous analysis of virus-host interactions is investigated in one single experiment where both the transcription of viral genomes and host cell responses are scrutinized.", [["cell", "ANATOMY", 209, 213], ["host cell", "CELL", 204, 213], ["viral genomes", "DNA", 186, 199], ["this technology", "TREATMENT", 47, 62], ["simultaneous analysis", "TEST", 64, 85], ["virus", "PROBLEM", 89, 94], ["viral genomes", "PROBLEM", 186, 199], ["host cell responses", "TEST", 204, 223], ["viral genomes", "OBSERVATION", 186, 199], ["host cell", "OBSERVATION", 204, 213]]], ["Figure 1 illustrates the work fl ow for transcriptome analysis of this study.", [["transcriptome analysis", "TEST", 40, 62], ["this study", "TEST", 66, 76]]], ["Seed CRFK cells into 75 cm 2 fl asks and incubate at 37 \u00b0C with 5 % CO 2 until cells reach 60-70 % confl uency.Remove media and wash the cells with D-PBS.3.", [["Seed CRFK cells", "ANATOMY", 0, 15], ["cells", "ANATOMY", 79, 84], ["cells", "ANATOMY", 137, 142], ["CO", "CHEMICAL", 68, 70], ["Seed CRFK cells", "CELL", 0, 15], ["cells", "CELL", 79, 84], ["cells", "CELL", 137, 142], ["D-PBS", "SIMPLE_CHEMICAL", 148, 153], ["CRFK cells", "CELL_LINE", 5, 15], ["Seed CRFK cells", "TEST", 0, 15], ["cells", "TEST", 79, 84], ["media", "TREATMENT", 118, 123], ["D-PBS", "TREATMENT", 148, 153], ["75 cm", "OBSERVATION_MODIFIER", 21, 26]]], ["Infect the fl asks with virus at multiplicity of infection (MOI) 2 in 2 ml, or 2 ml D -PBS as a mock control, and incubate at 37 \u00b0C with 5 % CO 2 for 1 h to allow attachment.", [["infection", "DISEASE", 49, 58], ["CO 2", "CHEMICAL", 141, 145], ["virus", "PROBLEM", 24, 29], ["infection", "PROBLEM", 49, 58], ["a mock control", "TREATMENT", 94, 108], ["infection", "OBSERVATION", 49, 58]]], ["Perform inoculations in duplicates, one for RNA extraction and the other for CPE visualization.Remove media and wash the cells with D-PBS.4.", [["cells", "ANATOMY", 121, 126], ["cells", "CELL", 121, 126], ["D-PBS", "SIMPLE_CHEMICAL", 132, 137], ["RNA extraction", "TREATMENT", 44, 58], ["CPE visualization", "TEST", 77, 94], ["media", "TREATMENT", 102, 107], ["D-PBS", "TREATMENT", 132, 137]]], ["Add 10 ml of maintenance medium with 10 % FBS and incubate the fl asks for 3 h.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.6.", [["FBS", "ANATOMY", 42, 45], ["cells", "ANATOMY", 134, 139], ["FBS", "ORGANISM_SUBSTANCE", 42, 45], ["cells", "CELL", 134, 139], ["D -PBS", "SIMPLE_CHEMICAL", 145, 151], ["maintenance medium", "TREATMENT", 13, 31], ["10 % FBS", "TREATMENT", 37, 45], ["incubation", "TREATMENT", 96, 106], ["inoculum", "TREATMENT", 115, 123], ["D -PBS", "TREATMENT", 145, 151]]], ["Add 2 ml TrypLE and incubate for 1-2 min until cells detach.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.7.", [["cells", "ANATOMY", 47, 52], ["cells", "ANATOMY", 115, 120], ["cells", "CELL", 47, 52], ["cells", "CELL", 115, 120], ["D -PBS", "SIMPLE_CHEMICAL", 126, 132], ["incubation", "TREATMENT", 77, 87], ["inoculum", "TREATMENT", 96, 104], ["D -PBS", "TREATMENT", 126, 132]]], ["Transfer cells to a centrifuge tube and pellet the cells by centrifugation at 120 \u00d7 g for 5 min and discard supernatant.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.8.", [["cells", "ANATOMY", 9, 14], ["tube", "ANATOMY", 31, 35], ["cells", "ANATOMY", 51, 56], ["supernatant", "ANATOMY", 108, 119], ["cells", "ANATOMY", 175, 180], ["cells", "CELL", 9, 14], ["tube", "TISSUE", 31, 35], ["cells", "CELL", 51, 56], ["cells", "CELL", 175, 180], ["D -PBS", "SIMPLE_CHEMICAL", 186, 192], ["a centrifuge tube and pellet the cells", "TREATMENT", 18, 56], ["incubation", "TREATMENT", 137, 147], ["inoculum", "TREATMENT", 156, 164], ["D -PBS", "TREATMENT", 186, 192]]], ["Add 10 ml D -PBS and repeat centrifugation in order to remove every trace of medium and TrypLE, which could reduce RNA yield.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.9.", [["cells", "ANATOMY", 180, 185], ["TrypLE", "CHEMICAL", 88, 94], ["TrypLE", "SIMPLE_CHEMICAL", 88, 94], ["cells", "CELL", 180, 185], ["D -PBS", "SIMPLE_CHEMICAL", 191, 197], ["PBS", "TREATMENT", 13, 16], ["repeat centrifugation", "TREATMENT", 21, 42], ["incubation", "TREATMENT", 142, 152], ["inoculum", "TREATMENT", 161, 169], ["D -PBS", "TREATMENT", 191, 197]]], ["Discard the supernatants and store the cell pellets at \u221280 \u00b0C until RNA purifi cation.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.The RNeasy kit was used to extract and purify RNA samples in this study ( see Note 1 ) but other RNA extraction protocols may also be suitable.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.1.", [["supernatants", "ANATOMY", 12, 24], ["cell", "ANATOMY", 39, 43], ["cells", "ANATOMY", 141, 146], ["samples", "ANATOMY", 209, 216], ["cells", "ANATOMY", 357, 362], ["cell", "CELL", 39, 43], ["cation", "SIMPLE_CHEMICAL", 79, 85], ["cells", "CELL", 141, 146], ["D -PBS", "SIMPLE_CHEMICAL", 152, 158], ["cells", "CELL", 357, 362], ["D -PBS", "SIMPLE_CHEMICAL", 368, 374], ["the cell pellets", "TREATMENT", 35, 51], ["RNA purifi cation", "TREATMENT", 68, 85], ["incubation", "TREATMENT", 103, 113], ["inoculum", "TREATMENT", 122, 130], ["D -PBS", "TREATMENT", 152, 158], ["The RNeasy kit", "TREATMENT", 159, 173], ["RNA samples", "TEST", 205, 216], ["this study", "TEST", 220, 230], ["other RNA extraction protocols", "TREATMENT", 250, 280], ["incubation", "TREATMENT", 319, 329], ["inoculum", "TREATMENT", 338, 346], ["D -PBS", "TREATMENT", 368, 374]]], ["Spray all micropipettes, gloves, working area, and other things with RNase AWAY to remove any RNase and DNA contamination.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.2.", [["cells", "ANATOMY", 177, 182], ["RNase", "GENE_OR_GENE_PRODUCT", 69, 74], ["RNase", "GENE_OR_GENE_PRODUCT", 94, 99], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["cells", "CELL", 177, 182], ["D -PBS", "SIMPLE_CHEMICAL", 188, 194], ["RNase AWAY", "PROTEIN", 69, 79], ["RNase", "PROTEIN", 94, 99], ["Spray all micropipettes", "TREATMENT", 0, 23], ["gloves", "TREATMENT", 25, 31], ["RNase", "TREATMENT", 69, 74], ["any RNase", "PROBLEM", 90, 99], ["DNA contamination", "PROBLEM", 104, 121], ["incubation", "TREATMENT", 139, 149], ["inoculum", "TREATMENT", 158, 166], ["D -PBS", "TREATMENT", 188, 194]]], ["Extract RNA using RNeasy kit according to the manufacturer's instruction.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.3.", [["cells", "ANATOMY", 128, 133], ["cells", "CELL", 128, 133], ["D -PBS", "SIMPLE_CHEMICAL", 139, 145], ["RNeasy kit", "TREATMENT", 18, 28], ["incubation", "TREATMENT", 90, 100], ["inoculum", "TREATMENT", 109, 117], ["D -PBS", "TREATMENT", 139, 145]]], ["Aliquot the eluted RNAs (500 \u00b5l) into three different tubes to avoid repeated thawing and freezing of the sample which could affect the quality of the RNA.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.4.", [["sample", "ANATOMY", 106, 112], ["cells", "ANATOMY", 210, 215], ["cells", "CELL", 210, 215], ["D -PBS", "SIMPLE_CHEMICAL", 221, 227], ["RNA", "RNA", 151, 154], ["Aliquot the eluted RNAs", "TREATMENT", 0, 23], ["three different tubes", "TREATMENT", 38, 59], ["repeated thawing", "TREATMENT", 69, 85], ["freezing of the sample", "PROBLEM", 90, 112], ["incubation", "TREATMENT", 172, 182], ["inoculum", "TREATMENT", 191, 199], ["D -PBS", "TREATMENT", 221, 227]]], ["Use two tubes for quality control analysis with spectrophotometer and Illumina Agilent 2100 bio-analyzer and store the third one at \u221280 \u00b0C for sequencing.", [["two tubes", "TREATMENT", 4, 13], ["quality control analysis", "TEST", 18, 42], ["spectrophotometer", "TREATMENT", 48, 65], ["Illumina Agilent", "TREATMENT", 70, 86]]], ["Nano kit together with Agilent 2100 Bio-analyzer to conduct quality and quantity analysis to the extracted total RNA samples ( see Note 2 ).Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.4.", [["cells", "ANATOMY", 195, 200], ["cells", "CELL", 195, 200], ["D -PBS", "SIMPLE_CHEMICAL", 206, 212], ["Agilent 2100 Bio-analyzer", "TREATMENT", 23, 48], ["quantity analysis", "TEST", 72, 89], ["incubation", "TREATMENT", 157, 167], ["inoculum", "TREATMENT", 176, 184], ["D -PBS", "TREATMENT", 206, 212]]], ["Load and prime gel-dye mixtures, then load RNA 6000 Nano marker, ladder, and samples in the specifi ed manner.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.5.", [["samples", "ANATOMY", 77, 84], ["cells", "ANATOMY", 165, 170], ["cells", "CELL", 165, 170], ["D -PBS", "SIMPLE_CHEMICAL", 176, 182], ["Load and prime gel-dye mixtures", "TREATMENT", 0, 31], ["incubation", "TREATMENT", 127, 137], ["inoculum", "TREATMENT", 146, 154], ["D -PBS", "TREATMENT", 176, 182]]], ["Vortex the chip and insert in the Agilent 2100 Bio-analyzer machine.", [["Vortex the chip", "TREATMENT", 0, 15], ["the Agilent 2100 Bio-analyzer machine", "TREATMENT", 30, 67]]], ["Analyze the chips based on the method recommended by the manufacturer.", [["the chips", "TREATMENT", 8, 17], ["the method", "TREATMENT", 27, 37]]], ["Verify whether the run is successful and whether the sample is properly prepared and handled by means of properly pipetted into the wells ( see Note 3 ).Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.Perform the following steps using the reagents provided in the paired end sample preparation kit, according to manufacturer's instructions.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.1.", [["cells", "ANATOMY", 208, 213], ["cells", "ANATOMY", 420, 425], ["cells", "CELL", 208, 213], ["D -PBS", "SIMPLE_CHEMICAL", 219, 225], ["cells", "CELL", 420, 425], ["D -PBS", "SIMPLE_CHEMICAL", 431, 437], ["incubation", "TREATMENT", 170, 180], ["inoculum", "TREATMENT", 189, 197], ["D -PBS", "TREATMENT", 219, 225], ["the reagents", "TREATMENT", 260, 272], ["incubation", "TREATMENT", 382, 392], ["inoculum", "TREATMENT", 401, 409], ["D -PBS", "TREATMENT", 431, 437], ["successful", "OBSERVATION", 26, 36]]], ["Fragment genomic DNA into fragments of less than 800 bp.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.2.", [["fragments", "ANATOMY", 26, 35], ["cells", "ANATOMY", 111, 116], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["cells", "CELL", 111, 116], ["D -PBS", "SIMPLE_CHEMICAL", 122, 128], ["Fragment genomic DNA", "DNA", 0, 20], ["Fragment genomic DNA into fragments", "PROBLEM", 0, 35], ["bp", "TEST", 53, 55], ["incubation", "TREATMENT", 73, 83], ["inoculum", "TREATMENT", 92, 100], ["D -PBS", "TREATMENT", 122, 128], ["genomic DNA", "OBSERVATION", 9, 20], ["fragments", "OBSERVATION_MODIFIER", 26, 35], ["less", "OBSERVATION_MODIFIER", 39, 43]]], ["Perform end repair of DNA fragments to generate 5\u2032-phosphorylated blunt ends.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.3.", [["fragments", "ANATOMY", 26, 35], ["cells", "ANATOMY", 132, 137], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["cells", "CELL", 132, 137], ["D -PBS", "SIMPLE_CHEMICAL", 143, 149], ["DNA fragments", "DNA", 22, 35], ["5\u2032-phosphorylated blunt ends", "DNA", 48, 76], ["end repair", "TREATMENT", 8, 18], ["DNA fragments", "PROBLEM", 22, 35], ["incubation", "TREATMENT", 94, 104], ["inoculum", "TREATMENT", 113, 121], ["D -PBS", "TREATMENT", 143, 149], ["repair", "OBSERVATION", 12, 18], ["DNA fragments", "OBSERVATION", 22, 35]]], ["Add an \"A\" base to the 3\u2032 ends to make 3\u2032-dA overhang.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.4.", [["cells", "ANATOMY", 109, 114], ["3\u2032-dA", "CHEMICAL", 39, 44], ["3\u2032-dA", "SIMPLE_CHEMICAL", 39, 44], ["cells", "CELL", 109, 114], ["D -PBS", "SIMPLE_CHEMICAL", 120, 126], ["3\u2032 ends", "DNA", 23, 30], ["incubation", "TREATMENT", 71, 81], ["inoculum", "TREATMENT", 90, 98], ["D -PBS", "TREATMENT", 120, 126]]], ["Ligate adapters to the ends of the DNA fragments.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.5.", [["fragments", "ANATOMY", 39, 48], ["cells", "ANATOMY", 104, 109], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["cells", "CELL", 104, 109], ["D -PBS", "SIMPLE_CHEMICAL", 115, 121], ["DNA fragments", "DNA", 35, 48], ["Ligate adapters", "TREATMENT", 0, 15], ["the DNA fragments", "PROBLEM", 31, 48], ["incubation", "TREATMENT", 66, 76], ["inoculum", "TREATMENT", 85, 93], ["D -PBS", "TREATMENT", 115, 121], ["DNA fragments", "OBSERVATION", 35, 48]]], ["Purify ligation products by removing un-ligated adapters.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.6.", [["cells", "ANATOMY", 112, 117], ["cells", "CELL", 112, 117], ["D -PBS", "SIMPLE_CHEMICAL", 123, 129], ["Purify ligation products", "TREATMENT", 0, 24], ["un-ligated adapters", "TREATMENT", 37, 56], ["incubation", "TREATMENT", 74, 84], ["inoculum", "TREATMENT", 93, 101], ["D -PBS", "TREATMENT", 123, 129], ["ligation", "OBSERVATION", 7, 15]]], ["Enrich the Adapter-Modifi ed DNA Fragments by PCR.Following 3 h of incubation, remove inoculum, wash the cells with D -PBS.7.", [["cells", "ANATOMY", 105, 110], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["cells", "CELL", 105, 110], ["D -PBS", "SIMPLE_CHEMICAL", 116, 122], ["Adapter-Modifi ed DNA Fragments", "DNA", 11, 42], ["the Adapter", "TREATMENT", 7, 18], ["Modifi ed DNA Fragments", "TREATMENT", 19, 42], ["incubation", "TREATMENT", 67, 77], ["inoculum", "TREATMENT", 86, 94], ["D -PBS", "TREATMENT", 116, 122]]], ["Obtain the Genomic DNA library.CLC Bio Genomics Workbench (GWB) Software Analysis1.", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["Genomic DNA library", "DNA", 11, 30]]], ["Once imported, subject the raw data to sequence reads trimming by quality trimming, ambiguity trimming and adapter trimming with the settings as in Fig. 2 .", [["ambiguity trimming and adapter trimming", "TREATMENT", 84, 123], ["the settings", "TREATMENT", 129, 141]]], ["BLAST the list of genes that were upregulated and downregulated, using the built-in BLAST program in the CLC bio GWB.CLC Bio Genomics Workbench (GWB) Software Analysis3.", [["CLC bio GWB", "DNA", 105, 116]]], ["Based on the BLAST result, select homologous sequence with the lowest e-value, highest score and lowest percentage of gaps to the query sequence as the gene identity.CLC Bio Genomics Workbench (GWB) Software Analysis4.", [["select homologous sequence", "TEST", 27, 53], ["the lowest e-value", "TEST", 59, 77]]], ["Briefl y, opt blastn: DNA sequence and database program and references mRNA sequences (refseq_rna) or nucleotide collection (nr) database for analysis.", [["nucleotide", "CHEMICAL", 102, 112], ["nucleotide", "CHEMICAL", 102, 112], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["DNA sequence", "DNA", 22, 34], ["references mRNA sequences", "DNA", 60, 85], ["refseq_rna", "DNA", 87, 97], ["DNA sequence", "TEST", 22, 34], ["database program", "TEST", 39, 55], ["mRNA sequences", "TEST", 71, 85], ["nucleotide collection", "TEST", 102, 123], ["analysis", "TEST", 142, 150]]], ["In silico analysis which is also a part of bioinformatics analysis is able to analyze the interactions of different genes by integrating data available on bioinformatics databases ( see Note 7 ).", [["silico analysis", "TEST", 3, 18], ["bioinformatics analysis", "TEST", 43, 66], ["bioinformatics databases", "TEST", 155, 179]]], ["One cycle for the dissociation curve for all reactions is added and melting curve analysis is performed.", [["the dissociation curve", "TEST", 14, 36], ["all reactions", "PROBLEM", 41, 54], ["melting curve analysis", "TEST", 68, 90]]], ["The fi rst feature of a successful total RNA run is that the electropherogram must contain three peaks where one peak represents marker peak while the others two are 18S and 28S ribosomal peaks.", [["18S", "GENE_OR_GENE_PRODUCT", 166, 169], ["28S", "CELLULAR_COMPONENT", 174, 177], ["ribosomal", "CELLULAR_COMPONENT", 178, 187], ["a successful total RNA", "TREATMENT", 22, 44], ["the electropherogram", "TEST", 57, 77], ["28S ribosomal peaks", "PROBLEM", 174, 193], ["marker peak", "OBSERVATION", 129, 140], ["ribosomal peaks", "OBSERVATION", 178, 193]]], ["Absence of one or both of the ribosomal peaks indicates poor sample preparation or poor sample pipetting technique.", [["ribosomal", "ANATOMY", 30, 39], ["sample", "ANATOMY", 61, 67], ["sample", "ANATOMY", 88, 94], ["ribosomal", "CELLULAR_COMPONENT", 30, 39], ["the ribosomal peaks", "PROBLEM", 26, 45], ["poor sample pipetting technique", "TREATMENT", 83, 114], ["ribosomal peaks", "OBSERVATION", 30, 45], ["poor sample", "OBSERVATION_MODIFIER", 56, 67]]], ["The second feature of a successful run is a complete ladder electropherogram.", [["a complete ladder electropherogram", "TREATMENT", 42, 76]]], ["A complete ladder electropherogram must feature one marker peak and six RNA peaks where all seven peaks are well resolved.Real-Time RT-qPCR Analysis of FIPV Infected CRFK Cells4.", [["CRFK Cells4", "CELL", 166, 177], ["FIPV", "PROTEIN", 152, 156], ["CRFK Cells4", "PROTEIN", 166, 177], ["FIPV", "SPECIES", 152, 156], ["A complete ladder electropherogram", "TEST", 0, 34], ["six RNA peaks", "TEST", 68, 81], ["FIPV", "PROBLEM", 152, 156], ["RNA peaks", "OBSERVATION", 72, 81], ["seven", "OBSERVATION_MODIFIER", 92, 97], ["peaks", "OBSERVATION_MODIFIER", 98, 103], ["resolved", "OBSERVATION_MODIFIER", 113, 121], ["FIPV Infected", "OBSERVATION", 152, 165]]], ["Adapters used by common high-throughput sequencing vendors such as Illumina and SOLiD were predefi ned and are available by the software.", [["Illumina and SOLiD", "TREATMENT", 67, 85]]], ["Removing the adapters will increase the specifi city of the raw sequence reducing false match.Real-Time RT-qPCR Analysis of FIPV Infected CRFK Cells5.", [["FIPV", "PROTEIN", 124, 128], ["CRFK Cells5", "PROTEIN", 138, 149], ["FIPV", "SPECIES", 124, 128], ["the adapters", "TREATMENT", 9, 21], ["FIPV", "PROBLEM", 124, 128], ["false match", "OBSERVATION", 82, 93], ["FIPV", "OBSERVATION", 124, 128], ["Infected CRFK", "OBSERVATION", 129, 142]]], ["Perform expression analysis based on the method described by Mortazavi et al. in 2008 [ 7 ] and CLC bio manual, CLC bio tutorials and recommendations from CLC bio support services.Real-Time RT-qPCR Analysis of FIPV Infected CRFK Cells6.", [["CRFK Cells6", "CELL", 224, 235], ["FIPV", "PROTEIN", 210, 214], ["CRFK Cells6", "PROTEIN", 224, 235], ["FIPV", "SPECIES", 210, 214], ["expression analysis", "TEST", 8, 27], ["the method", "TREATMENT", 37, 47], ["FIPV Infected CRFK Cells6", "PROBLEM", 210, 235], ["FIPV Infected", "OBSERVATION", 210, 223]]], ["In short, high quality trim value allowed low quality base or base with low Phred quality score to be included in the sequence.", [["short", "OBSERVATION_MODIFIER", 3, 8], ["base", "ANATOMY_MODIFIER", 62, 66]]], ["The ambiguity trimming trims the sequence ends based on the presence of ambiguous nucleotides usually denoted as N making the sequence more specifi c.Real-Time RT-qPCR Analysis of FIPV Infected CRFK Cells7.", [["nucleotides", "CHEMICAL", 82, 93], ["CRFK Cells7", "CELL", 194, 205], ["FIPV", "PROTEIN", 180, 184], ["CRFK Cells7", "PROTEIN", 194, 205], ["FIPV", "SPECIES", 180, 184], ["The ambiguity trimming trims the sequence ends", "TREATMENT", 0, 46], ["ambiguous nucleotides", "PROBLEM", 72, 93], ["the sequence", "TEST", 122, 134], ["FIPV Infected CRFK Cells7", "PROBLEM", 180, 205], ["FIPV Infected", "OBSERVATION", 180, 193]]], ["Other Bioinformatics analysis : A gene in eukaryotic organism is commonly regulated by other genes and proteins in its system.", [["A", "GENE_OR_GENE_PRODUCT", 32, 33], ["A gene in eukaryotic organism", "PROBLEM", 32, 61]]], ["The interactions among genes expressed and between gene expressed and other genes can be elucidated by means of computer or in silico analysis.", [["silico analysis", "TEST", 127, 142]]], ["In silico analysis, a part of bioinformatics analysis, able to do this by integrating data with available data on bioinformatics databases.", [["silico analysis", "TEST", 3, 18], ["bioinformatics analysis", "TEST", 30, 53], ["bioinformatics databases", "TEST", 114, 138]]], ["The main objective of in silico analysis is gene ontology which is defi ned as the process of elucidating associated pathways, molecular function, biological process, cellular components and protein products of a gene [ 8 ] .Real-Time RT-qPCR Analysis of FIPV Infected CRFK CellsThe bioinformatics database used to analyze gene identity and gene interaction is Protein Analysis Through Evolutionary Relationships Classifi cation System or in short known as PANTHER ( http://www.pantherdb.org/ ).", [["cellular", "ANATOMY", 167, 175], ["Cells", "ANATOMY", 274, 279], ["cellular", "CELL", 167, 175], ["CRFK Cells", "CELL", 269, 279], ["protein products", "PROTEIN", 191, 207], ["CRFK Cells", "CELL_LINE", 269, 279], ["FIPV", "SPECIES", 255, 259], ["silico analysis", "TEST", 25, 40], ["FIPV Infected CRFK Cells", "PROBLEM", 255, 279], ["The bioinformatics database", "TEST", 279, 306], ["Protein Analysis", "TEST", 361, 377], ["main", "OBSERVATION_MODIFIER", 4, 8], ["FIPV Infected", "OBSERVATION", 255, 268], ["CRFK Cells", "OBSERVATION", 269, 279]]], ["It is a unique resource that classifi es genes by their functions, using published scientifi c experimental evidence and evolutionary relationships to predict function even in the absence of direct experimental evidence and is a part of the Gene Ontology Reference Genome Project ( http://www.geneontology.org/ GO.refgenome.shtml#curation ).Real-Time RT-qPCR Analysis of FIPV Infected CRFK CellsPANTHER provides tools for gene expression analysis for data interpretation ( http://www.pantherdb.org/tools/ genexAnalysis.jsp ).", [["FIPV", "DNA", 371, 375], ["CRFK CellsPANTHER", "DNA", 385, 402], ["FIPV", "SPECIES", 371, 375], ["FIPV", "PROBLEM", 371, 375], ["gene expression analysis", "TEST", 422, 446], ["data interpretation", "TEST", 451, 470]]], ["Multiple gene lists will be mapped to PANTHER molecular function, biological process, and cellular", [["cellular", "ANATOMY", 90, 98], ["cellular", "CELL", 90, 98]]]], "PMC7399997": [["IntroductionFunctional decline is one of the greatest threats to independence in older adults and leads to varying disability in performing activities of daily living (ADL) [9].", [["disability", "DISEASE", 115, 125]]], ["There are three categories of disability-mild (1\u20132 ADLs), moderate (3\u20134 ADLs), and severe (5\u20136 ADLs)-that correspond to the progressive inability to perform various ADLs [10].", [["mild (1\u20132 ADLs)", "PROBLEM", 41, 56], ["severe (5\u20136 ADLs)", "PROBLEM", 83, 100], ["the progressive inability", "PROBLEM", 120, 145], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["moderate", "OBSERVATION_MODIFIER", 58, 66], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["progressive", "OBSERVATION_MODIFIER", 124, 135]]], ["Cognitive decline, though distinct, is related to physical decline by hastening the latter.", [["Cognitive decline", "DISEASE", 0, 17], ["Cognitive decline", "PROBLEM", 0, 17], ["physical decline", "PROBLEM", 50, 66]]], ["For example, individuals with dementia have a higher likelihood of disability [9].", [["dementia", "DISEASE", 30, 38], ["disability", "DISEASE", 67, 77], ["dementia", "PROBLEM", 30, 38]]], ["Increasing deficits result in higher health care utilization and expenditure.", [["Increasing deficits", "DISEASE", 0, 19], ["Increasing deficits", "PROBLEM", 0, 19], ["deficits", "OBSERVATION", 11, 19], ["higher", "OBSERVATION_MODIFIER", 30, 36]]], ["Functional decline is the key determinant for subsidies.", [["Functional decline", "PROBLEM", 0, 18]]], ["To align with the Sustainable Development Goals (SDGs) in establishing the economic inclusion of persons with disabilities, Singapore introduced a new Home Caregiving Grant (HCG) in 2019.", [["persons", "ORGANISM", 97, 104], ["persons", "SPECIES", 97, 104]]], ["It took into account the caregivers, regardless of age, responsible for caring for a person with a permanent moderate disability, by providing a SGD 200 monthly grant to partially offset the cost of hiring a foreign domestic worker [11].Functional and Social Drivers of Demand for LTC Services ::: 1.", [["disability", "DISEASE", 118, 128], ["person", "SPECIES", 85, 91]]], ["IntroductionBeyond functional drivers, there are social drivers of demand for LTC services.", [["LTC services", "TREATMENT", 78, 90]]], ["The World Health Organization (WHO) identified social isolation\u2019s association with an increased risk of institutionalization.", [["social isolation", "TREATMENT", 47, 63], ["increased", "OBSERVATION_MODIFIER", 86, 95]]], ["Specifically, disabled elders who live alone tend to require increased need in paid care services compared to those who live with children or a spouse [13].", [["children", "ORGANISM", 130, 138], ["children", "SPECIES", 130, 138]]], ["Several studies have converged on the negative effects of living alone, and there is emerging evidence that living with company is a better alternative [14].", [["Several studies", "TEST", 0, 15]]], ["Against this background, we ordered living arrangements, with increasing efficacy, through the following: (1) living alone; (2) living with spouse; (3) living with others; (4) living with children or grandchildren, predicated on the following evidence.Functional and Social Drivers of Demand for LTC Services ::: 1.", [["children", "ORGANISM", 188, 196], ["children", "SPECIES", 188, 196]]], ["IntroductionNumerous studies proposed that living alone tends to be the least efficacious: social isolation is linked to decreased happiness and increased depression [15].", [["depression", "DISEASE", 155, 165], ["IntroductionNumerous studies", "TEST", 0, 28], ["decreased happiness", "PROBLEM", 121, 140], ["increased depression", "PROBLEM", 145, 165]]], ["Across ethnicity and gender, the number of older adults living alone has increased, and the highest prevalence of social isolation is found in the UK and Finland [12,16].", [["increased", "OBSERVATION_MODIFIER", 73, 82], ["social isolation", "OBSERVATION", 114, 130]]], ["On the other hand, living with a spouse achieves reciprocal support, provides emotional succor, and long-term mutual commitment to interests and values [17].", [["reciprocal support", "TREATMENT", 49, 67]]], ["In addition, elders who live with others displayed better health outcomes because of the benefits from social support.", [["social support", "TREATMENT", 103, 117]]], ["There is substantial evidence to suggest that social relationships, exemplified by living with others, are linked to lower mortality risk and increase mental wellness [18].", [["increase mental wellness", "PROBLEM", 142, 166], ["substantial evidence to suggest", "UNCERTAINTY", 9, 40]]], ["Specifically, living with children/grandchildren achieves the most optimal mental and physical health outcomes.", [["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34]]], ["Against this background, living arrangements can be ranked based on efficacy to an elder\u2019s well-being, with social isolation (living alone) as the least efficacious to living with children/grandchildren as the most efficacious.Functional and Social Drivers of Demand for LTC Services ::: 1.", [["children", "ORGANISM", 180, 188], ["children", "SPECIES", 180, 188]]], ["IntroductionOn a separate note, while previous studies have explored the differences in living arrangements across west and east, no known studies have investigated how ethnic diversity within eastern cultures influence living arrangements [3].", [["previous studies", "TEST", 38, 54], ["known studies", "TEST", 133, 146]]], ["In addition to other contributions, our study closes this gap by analyzing how living arrangements differ across Asian ethnicities: Chinese, Malays and Indians.Dataset and Analytic Strategy ::: 2.", [["our study", "TEST", 36, 45]]], ["Materials and MethodsThe primary dataset is the Retirement and Health Study (RHS), Singapore\u2019s first and largest nationally representative longitudinal study of noninstitutionalized older adults spanning the age range 45\u201385 with over 15,000 respondents.", [["Methods", "TREATMENT", 14, 21]]], ["Conducted through a face-to-face interview, participants underwent extensive assessments of health, savings, and expenditure by trained interviewers.", [["participants", "SPECIES", 44, 56]]], ["Given the multiethnic and multilingual nature of the older Singaporeans, the interviews were conducted in the language and/or dialect that each participant was most conversant.", [["participant", "SPECIES", 144, 155]]], ["Informed consent was sought by the participant or on behalf of their respective legally acceptable representative (LAR) when the participant was bounded with some form of disability (i.e., physical, mental, and cognitive).Dataset and Analytic Strategy ::: 2.", [["disability", "DISEASE", 171, 181], ["participant", "SPECIES", 35, 46], ["participant", "SPECIES", 129, 140]]], ["Materials and MethodsEstablished procedures were used to distil the projections of disability and living arrangements:Disability prevalence for 2010 and 2014 were taken from nationally representative surveys: Social Isolation, Health & Lifestyles study (SIHS) and RHS, respectively.To derive the age-specific proportion of seniors by living arrangements in 2034, the cohort of residents aged 45 and over in 2014 was used to form the senior cohort in 2034.", [["disability", "DISEASE", 83, 93], ["MethodsEstablished procedures", "TREATMENT", 14, 43]]], ["ResultsAmong seniors aged 65 and above, comparing 2010 with 2014, moderate and severe disability increased while mild disability decreased.", [["disability", "DISEASE", 86, 96], ["disability", "DISEASE", 118, 128], ["moderate and severe disability", "PROBLEM", 66, 96], ["mild disability", "PROBLEM", 113, 128], ["moderate", "OBSERVATION_MODIFIER", 66, 74], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["disability", "OBSERVATION", 86, 96], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["mild", "OBSERVATION_MODIFIER", 113, 117], ["disability", "OBSERVATION_MODIFIER", 118, 128], ["decreased", "OBSERVATION_MODIFIER", 129, 138]]], ["Specifically, moderate disability prevalence inched from 6.09% to 6.64%; severe disability increased from 2.41% to 3.33%; mild disability decreased from 13.12% to 9.63% in Table 2.3.1.", [["disability", "DISEASE", 23, 33], ["disability", "DISEASE", 80, 90], ["disability", "DISEASE", 127, 137], ["moderate disability prevalence", "PROBLEM", 14, 44], ["severe disability", "PROBLEM", 73, 90], ["mild disability", "PROBLEM", 122, 137], ["moderate", "OBSERVATION_MODIFIER", 14, 22], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["disability", "OBSERVATION_MODIFIER", 80, 90], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["mild", "OBSERVATION_MODIFIER", 122, 126], ["disability", "OBSERVATION_MODIFIER", 127, 137], ["decreased", "OBSERVATION_MODIFIER", 138, 147]]], ["ResultsBy applying the disability prevalence in Table 2 to the population figures from the Department of Statistics (DOS) for residents aged 45 years and older, we obtained the projected disability level estimates from 2020 to 2060.", [["disability", "DISEASE", 23, 33]]], ["Between 2014 and 2030, we expect the number of seniors with at least mild disability (\u22651 ADL) to increase by 2.4 times from 42,000 to 100,000.", [["disability", "DISEASE", 74, 84], ["mild disability", "PROBLEM", 69, 84]]], ["Within this group, we expect the number of seniors with moderate to severe disability (\u22653 ADLs) to increase by 1.4 times from 29,000 to 69,000 during the same period in Figure 1.3.2.", [["disability", "DISEASE", 75, 85], ["moderate to severe disability", "PROBLEM", 56, 85]]], ["ResultsElders who live alone are more likely to be institutionalized, resulting in higher demand for LTC services.", [["LTC services", "TREATMENT", 101, 113]]], ["ResultsResults show interesting ethnic differences (Table 3): Malay elders are 2.6 times less likely than Chinese to live alone, after controlling for their marital status, age, and housing type (a proxy for socioeconomic status) in an ordered logit model.", [["an ordered logit model", "TREATMENT", 233, 255]]], ["Multinomial logit models corroborated these findings: minority ethnic groups evidenced a decreased chance of social isolation.", [["Multinomial logit models", "TEST", 0, 24], ["minority ethnic groups", "PROBLEM", 54, 76], ["social isolation", "TREATMENT", 109, 125], ["decreased", "OBSERVATION_MODIFIER", 89, 98], ["social isolation", "OBSERVATION", 109, 125]]], ["We obtained the predicted living arrangements for this cohort, controlling for covariates.", [["this cohort", "TREATMENT", 50, 61]]], ["Thereafter, we scaled up the figures to take into account the seniors that would be staying in nursing homes assuming that the institutionalized rates remain at 2014 levels.", [["the institutionalized rates", "TEST", 123, 150]]], ["Overall, the number of socially isolated seniors are projected to increase four times over 40 years.", [["number", "OBSERVATION_MODIFIER", 13, 19], ["socially", "OBSERVATION_MODIFIER", 23, 31], ["isolated", "OBSERVATION_MODIFIER", 32, 40], ["seniors", "OBSERVATION", 41, 48]]], ["This is plausible given that there is a higher proportion of singles and married seniors without children among younger cohorts compared to older cohorts in Figure 3.4.", [["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105]]], ["This is a useful tool for a rapidly aging society to right-size demand for LTC services in the coming decades.", [["LTC services", "TREATMENT", 75, 87], ["right", "ANATOMY_MODIFIER", 53, 58], ["size", "OBSERVATION_MODIFIER", 59, 63]]], ["To this end, we projected the 40-year prevalence of disability and social isolation as functional and social drivers of LTC demand, respectively.4.", [["disability", "DISEASE", 52, 62], ["social isolation", "TREATMENT", 67, 83]]], ["Models of living arrangements found interesting ethnic differences: Malay seniors are 2.6 times less likely to be socially isolated compared to their Chinese counterparts, controlling for marital status, age, and housing type.", [["2.6 times", "OBSERVATION_MODIFIER", 86, 95]]], ["These projections indicate the scale of demand for LTC services and the increasing burden on caregivers and community resources.", [["LTC services", "TREATMENT", 51, 63]]], ["Demand for LTC services is becoming more heterogeneous beyond nursing homes [21].", [["LTC services", "TREATMENT", 11, 23], ["heterogeneous", "OBSERVATION_MODIFIER", 41, 54]]], ["These findings contribute to a more granular and realistic calibration of LTC demand and adds to the growing literature on the impact of an aging population from North Africa, Australia, and the UK [2,3,6].4.", [["a more granular and realistic calibration of LTC demand", "PROBLEM", 29, 84], ["more", "OBSERVATION_MODIFIER", 31, 35], ["granular", "OBSERVATION_MODIFIER", 36, 44], ["LTC demand", "OBSERVATION", 74, 84], ["growing", "OBSERVATION_MODIFIER", 101, 108], ["North", "OBSERVATION_MODIFIER", 162, 167], ["Africa", "OBSERVATION_MODIFIER", 168, 174]]], ["This was given national prominence when Singapore\u2019s Minister for Finance spoke extensively about CNS during his 2018 annual budget speech in Parliament [24].", [["CNS", "ANATOMY", 97, 100], ["CNS", "ANATOMICAL_SYSTEM", 97, 100]]], ["Spearheaded by the Ministry of Health (MOH) and its Agency for Integrated Care (AIC), the CNS uses different stakeholders in the community-voluntary welfare organizations, grassroots organizations, regional health systems, and government agencies-to jointly engage and support our seniors.", [["Integrated Care (AIC)", "TREATMENT", 63, 84], ["CNS", "ANATOMY", 90, 93]]], ["CNS has successfully activated more than 70 Residents\u2019 Committees (RCs) in conducting regular preventive health and active aging activities for more than 70,000 seniors.", [["CNS", "ANATOMY", 0, 3], ["CNS", "ANATOMICAL_SYSTEM", 0, 3]]], ["CNS has also matched more than 600 seniors to befrienders and assisted about 800 seniors with complex health and social needs.", [["CNS", "ANATOMY", 0, 3], ["CNS", "ANATOMICAL_SYSTEM", 0, 3]]], ["Importantly, our projections provide insights into how much and how fast to scale CNS.4.", [["CNS", "ANATOMY", 82, 85], ["CNS", "ANATOMICAL_SYSTEM", 82, 85]]], ["This is a promising model for aging-in-place, especially in the empowerment of older adults when developing intervention strategies or programs, and they serve as catalysts to promote social inclusion.4.", [["intervention strategies", "TREATMENT", 108, 131]]], ["Beyond projections, simulations can also be done to shed light on how policy changes could affect disability prevalence and acute care [27].", [["disability", "DISEASE", 98, 108]]], ["Future studies could also explore the impact of ageism on disability projections as ageism has increased over time [28], and across countries [29,30], as cultural factors impact a variety of outcomes [31,32].", [["ageism", "DISEASE", 48, 54], ["disability", "DISEASE", 58, 68], ["ageism", "DISEASE", 84, 90], ["Future studies", "TEST", 0, 14], ["increased", "OBSERVATION_MODIFIER", 95, 104]]], ["Future studies should attempt to model the impact of Covid-19 on LTC demand.5.", [["Future studies", "TEST", 0, 14], ["Covid", "TEST", 53, 58], ["LTC demand", "TREATMENT", 65, 75]]], ["ConclusionsIn sum, this is one of the first known studies to project disability prevalence and social isolation.", [["disability", "DISEASE", 69, 79], ["social isolation", "TREATMENT", 95, 111]]], ["This is useful for policy makers to right-size the demand for LTC services and chart a long-term strategy to manage a rapidly aging population.", [["LTC services", "TREATMENT", 62, 74], ["a long-term strategy", "TREATMENT", 85, 105], ["a rapidly aging population", "PROBLEM", 116, 142]]], ["Of broader significance, this study highlighted the importance of social isolation in projecting the demand for LTC services.", [["this study", "TEST", 25, 35], ["social isolation", "TREATMENT", 66, 82], ["LTC services", "TREATMENT", 112, 124]]]], "00707fbc1093276237c6f9896f0737df58425bb2": [["ns, non-significant (two-tailed unpaired t-test with Bonferroni correction comparing wild type to each mutantMathematical assessment of stop codon background noiseThe overall NGS error frequency in the context of our work, is not of interest per se; rather, only the fraction of errors that cause stop codons, since only those errors could affect our results.", [["ns", "TREATMENT", 0, 2], ["tailed unpaired t-test", "TREATMENT", 25, 47], ["Bonferroni correction", "TREATMENT", 53, 74], ["Mathematical assessment", "TEST", 109, 132], ["stop codon background noise", "PROBLEM", 136, 163], ["stop codons", "PROBLEM", 297, 308], ["non-significant", "OBSERVATION_MODIFIER", 4, 19], ["NGS error", "OBSERVATION", 175, 184]]], ["The question we ask here is whether more of fewer Stop mutations are observed at all of the altered Ser/Leu sites combined, rather than at individual sites.", [["Ser", "CHEMICAL", 100, 103], ["Leu", "CHEMICAL", 104, 107], ["Leu sites", "AMINO_ACID", 104, 113], ["Ser", "PROTEIN", 100, 103], ["fewer Stop mutations", "PROBLEM", 44, 64], ["the altered Ser/Leu sites", "PROBLEM", 88, 113], ["Leu sites", "OBSERVATION", 104, 113]]], ["This increases our sample size by approximately 100-fold, thereby further increasing our statistical power.", [["sample", "OBSERVATION_MODIFIER", 19, 25], ["size", "OBSERVATION_MODIFIER", 26, 30], ["increasing", "OBSERVATION_MODIFIER", 74, 84]]], ["To model the frequency of 'false' stop codons due to sequencing error, we use a Poisson background noise model (a standard for estimating independent rare errors under minimal additional structural assumptions, which has already been used to model NGS error rates in the context of minority variant discovery) 1,2 .", [["'false' stop codons", "PROBLEM", 26, 45], ["a Poisson background noise model", "TREATMENT", 78, 110], ["minimal additional structural assumptions", "TREATMENT", 168, 209]]], ["Since sequencing errors are nucleotide-context dependent 3 , and the number of stop codons that can be reached by a single mutation is different for different 1-to-stop codons, we model , the number of observed stop codons for sample at site , as an observation of the random variable:Mathematical assessment of stop codon background noisewhere is the total number of reads for the same sample and site, is the probability of observing an erroneous stop codon given the nucleotide context , is the true stop codon frequency for sample at site ; and the sequencing errors in different reads are assumed to be independent.", [["nucleotide", "CHEMICAL", 28, 38], ["nucleotide", "CHEMICAL", 28, 38], ["nucleotide", "CHEMICAL", 470, 480], ["stop codons", "RNA", 79, 90], ["1-to-stop codons", "DNA", 159, 175], ["sequencing errors", "PROBLEM", 6, 23], ["nucleotide", "TEST", 28, 38], ["a single mutation", "PROBLEM", 114, 131], ["Mathematical assessment", "TEST", 285, 308], ["an erroneous stop codon", "PROBLEM", 436, 459], ["sample at site", "PROBLEM", 528, 542], ["the sequencing errors", "PROBLEM", 549, 570]]], ["The Poisson approximation is very good since is large and + is small.", [["very", "OBSERVATION_MODIFIER", 29, 33], ["good", "OBSERVATION_MODIFIER", 34, 38], ["large", "OBSERVATION_MODIFIER", 48, 53], ["+", "OBSERVATION", 58, 59], ["small", "OBSERVATION_MODIFIER", 63, 68]]], ["Both the influence of nucleotide context and the number of different stop codons reachable within one mutation are captured in the parameter.Mathematical assessment of stop codon background noiseLet \u2236= ( + ) and ( ), the probability mass function of the Poisson distribution with rate .", [["nucleotide", "CHEMICAL", 22, 32], ["nucleotide", "CHEMICAL", 22, 32], ["nucleotide context", "TREATMENT", 22, 40], ["different stop codons", "TREATMENT", 59, 80], ["Mathematical assessment", "TEST", 141, 164], ["stop codon background noiseLet", "TEST", 168, 198], ["mass", "OBSERVATION", 233, 237]]], ["The log-likelihood isMathematical assessment of stop codon background noiseHence, maximizing is equivalent to maximizing each term separately, and the ML estimate for the Poisson distribution is given by \u0302= .", [["Mathematical assessment", "TEST", 21, 44]]], ["Reparameterizing in and , it follows that the ML estimate is achieved for any \u0302\u2208 [0, min , / ], with \u0302 = / \u2212\u0302, since \u2265 0 and \u2265 0 for all , .Mathematical assessment of stop codon background noiseThe log likelihood test statistic The model was thus applied to 5 (96-well plates each) sequencing runs, for a total of 420 samples.", [["samples", "ANATOMY", 318, 325], ["Mathematical assessment", "TEST", 140, 163], ["stop codon background noise", "PROBLEM", 167, 194], ["The log likelihood test", "TEST", 194, 217], ["sequencing runs", "TEST", 282, 297]]], ["Only samples from the same run are compared, to ignore noise due to batch effect.", [["samples", "ANATOMY", 5, 12], ["batch effect", "PROBLEM", 68, 80]]], ["Each codon site that had a 1-to-Stop codon in the wild type genome (and thus the identical codon, in the identical context, in the 1to-Stop construct) was considered.", [["codon site", "DNA", 5, 15], ["1-to-Stop codon", "DNA", 27, 42], ["wild type genome", "DNA", 50, 66], ["1to-Stop construct", "DNA", 131, 149], ["Each codon site", "PROBLEM", 0, 15]]], ["The nucleotide contexts coincide with the 1-to-Stop codons (UUA, UUG, UCA and UCG), since a mutation that produces a stop codon must change the middle nucleotide in the codon.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 151, 161], ["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 151, 161], ["1-to-Stop codons", "DNA", 42, 58], ["UUA", "DNA", 60, 63], ["UUG", "DNA", 65, 68], ["UCA", "DNA", 70, 73], ["UCG", "DNA", 78, 81], ["stop codon", "DNA", 117, 127], ["UUA", "TEST", 60, 63], ["UCG", "TEST", 78, 81], ["a mutation", "PROBLEM", 90, 100], ["a stop codon", "PROBLEM", 115, 127], ["middle", "OBSERVATION_MODIFIER", 144, 150]]], ["To produce a single confidence interval for the stop codon error rate for each sequencing run, the confidence intervals for the different nucleotide contexts, UUA , UUG , UCA and UCG , were averaged with weights proportional to the number of codon sites for each context.", [["nucleotide", "CHEMICAL", 138, 148], ["nucleotide", "CHEMICAL", 138, 148], ["UUA", "DNA", 159, 162], ["UUG", "DNA", 165, 168], ["UCA", "DNA", 171, 174], ["codon sites", "DNA", 242, 253], ["the different nucleotide contexts", "PROBLEM", 124, 157], ["UUA", "TEST", 159, 162], ["UUG", "TEST", 165, 168], ["UCG", "TEST", 179, 182], ["codon sites", "TREATMENT", 242, 253], ["codon sites", "OBSERVATION", 242, 253]]], ["Thus, considering the 1-to-Stop codon sites, if the sequencing error rates were at the upper endpoints of the 95% confidence intervals, the contribution of sequencing errors to the stop codon frequency as it was computed (sum over all Leu/Ser) would be ~10 \u22126 \u00d7 100 = 10 \u22124 for the 1-to-Stop virus, which is still more than 10 times below the observed frequencies.SequencingSupplementary References", [["Leu", "CHEMICAL", 235, 238], ["Ser", "CHEMICAL", 239, 242], ["1-to-Stop codon sites", "DNA", 22, 43], ["the sequencing error rates", "TEST", 48, 74], ["sequencing errors", "PROBLEM", 156, 173], ["the stop codon frequency", "PROBLEM", 177, 201], ["all Leu/Ser)", "TEST", 231, 243], ["Stop virus", "PROBLEM", 287, 297]]]]}